Trichotin Hair Regenesis

Technical Information

Proprietary Name and Dosage Form
Trichotin Hair Regenesis
517mg Caplet

Scheduling Status
S0

Pharmacological Classification
Category D Medicine.

Ingredients
Vitamin B12, Zepufa-N3, Magnesium, Vitamin B1, Sarsaparilla, Inositol, L-Cysteine, Saw Palmetto, Vitamin B6, Zinc, Biotin, Kelp, Pyridoxine, Vitamin A, Vitamin B2, Choline, Silica, Vitamin B5, Folic Acid, Copper, MSM (Methyl Sulfonyl Methane), Amino-acid blend, Nettle root extract, Vitamin C, Vitamin E, Co-enzyme Q10, Chromium Polinicotinate, Pygeum extract, PABA, Glycine, Oat straw.

NO ARTIFICIAL FLAVOURANTS
NO ARTIFICIAL COLOURANTS
NO PRESERVATIVES

Dosage and Directions for use
Take one caplet daily before breakfast.

Contra-indications
If you suffer from a chronic medical condition consult your healthcare practitioner before using this product.

Warnings
The loss of 50 to 100 hairs per day, constitutes normal hair loss. If you are losing larger amounts of hair, contact your physician to exclude a medical cause.

Precautions
Use only as directed.
Keep out of reach of children.
Consult a medical practitioner prior to use.

Interaction
Use this product under the supervision of your healthcare practitioner if you are using chronic prescription medication. Discontinue using this product at least 2 weeks prior to any surgical procedure.

Pregnancy and Lactation
Pregnant and breastfeeding women should avoid using this product.

Side Effects and Special Precautions
Discontinue the use of this product where there is sensitivity towards any of the ingredients. This product contains Iron and Iodine.

Known Symptoms of Overdose and Treatment
No known symptoms.

Identification
Coated Oval, Mint Green caplet.

Presentation
Printed carton containing printed glass bottle with 30 caplets.

Storage Instructions
Store below 25 degrees Celsius.
Protect from light and moisture.

Date of Publication of this Package Information
 August 2014

Nappi Code
715586-001

Ingredients

Primary Benefits
Minimizing Hair Loss
1. Nettle Root Extract
2. Saw Palmetto
3. Oat straw
4. Pygeum
5. Biotin
6. Choline
7. Vitamin B6
8. Calcium

Hair Growth
9. Kelp
10. Pyridoxine
11. Glycine
12. L-Cysteine
13. Silica
14. Vitamin A
15. Vitamin B2
16. Vitamin B6
17. Folic Acid
18. Copper
19. Inositol
20. Iron

Healthy Hair
21. Vitamin B12
22. Zepufa N3
23 Magnesium AAC
24. Vitamin B1
25. Sarsaparilla

Strength
26. MSM (Methyl Sulfonyl Methane)
27. Vitamin B1

Anti-ageing
28. Co-enzyme Q10
29. Vitamin E
30. Chromium Polinicotinate

Secondary Benefits
Hair Protection
31. Vitamin C

Anti-greying
32. PABA (Para-Amino Benzoic Acid)

Healthy skin
33. Zinc
34. Vitamin B3

Research

A single follicle grows approximately .35 millimetres per day. The normal cycle of growth of each follicle consists alternatively of rebuilding and tearing down of the structure. After a period of rest the follicle is built anew from raw materials, each hair follicle replicating this process as it grows longer and stronger. It is important to emphasize that the metabolic requirements of the hair follicle must be met at this time or else adequate and optimal hair growth will not occur.

This requires that certain vitamins and minerals be present in adequate quantities or else there will be non-existent or defective hair growth.

Good nutrition and a diet adequate in multi nutrients are required to encourage healthy hair and skin. High quality vitamins, herbals and minerals also prevent or minimise hair loss and thinning. Our modern lifestyle and a typical diet is invariably low in multi nutrients, leading to vitamin deficiency and hormonal imbalance both of which are prominent causes of hair loss.

Vitamin A
The body reacts negatively to Vitamin A deficiency by slowing down regrowth of hair and nails causing the scalp to become keratinised. Keratin, an insoluble protein, releases compounds which are irritating to the scalp and prevent hair growth. In addition, Vitamin A acts as an antioxidant protecting the body against free radical damage. It is also beneficial to the skin as it is required for the maintenance and repair of epithelial tissue.

Kelp
Kelp contains 30 minerals including iodine which is essential for the treatment of symptoms associated with an underactive thyroid, such as hair loss and obesity. Its ability to stimulate metabolism is useful in weight management. Treatment with Kelp reverses conditions caused by a thyroid hormone deficiency including hair loss.

Saw Palmetto Extract
Saw Palmetto minimises hereditary male pattern hair loss. It is able to block dihydrotestosterone (DHT) from binding to hair follicles. DHT results from the increased breakdown of testosterone. Saw palmetto basically “short-circuits” the production of DHT which is responsible for the occurrence of male pattern baldness and prostate inflammation.

Pygeum 
Trichotin formula strategically combines Pygeum with Saw palmetto for the treatment of hair loss. Pygeum is able to lower DHT and luteinizing hormone (LH) production which are responsible for inflammation of hair follicles – a prevalent cause of hair loss in both men and women.

Nettle
Trichotin’s superior quality grade of Nettle binds to receptors on hair follicles preventing DHT from doing so. This averts the onset of hair loss. Nettle also increases the amount of free circulating testosterone in the body by preventing its break down to DHT. Research proves that if Nettle stores are replenished in hair loss patients, they are more likely to reduce hair shedding and restore regrowth.

Sarsaparilla
Sarsaparilla stimulates hormone production in the body and has been widely used to induce hair growth.

Oat Straw
Oat straw is able to free testosterone by preventing it binding to other sites or hormones in the body. It is thus an important ingredient in Fusion Labs armamentarium to prevent hair loss and stimulate new growth.

Oat straw also regulates the production of LH in the body. The Trichotin formula utilizes this function in conjunction with silica to remedy hair loss.

Vitamin E
Vitamin E encourages healthy hair growth by increasing the oxygen supply to the body and thereby improving scalp circulation. It is also known to combat dandruff and prevent hair loss.
Vitamin E is also an important antioxidant aiding in the utilisation of vitamin A, a process which allows cells to replicate at a more rapid rate. Inadequate vitamin E is a contributing factor in premature ageing and a compromised immune system.

Vitamin C 
Vitamin C is a well-recognised antioxidant and is required for at least 300 metabolic functions, the result of which is to support healthy hair growth. Vitamin C improves scalp circulation thereby stimulating hair follicles by increasing its oxygen supply. It is therefore recommended in a prudent diet for combating hair loss.

Vitamin C encourages growth of the protein chains in collagen, which is the main ingredient in all-fibrous tissue. As an antioxidant Vitamin C neutralises heavy metals in the body rendering them harmless thus slowing down the ageing process. Vitamin C also helps combat infection, boosts immune function and promotes healing of wounds.

Vitamin A, C, and E act synergistically to protect the body from free radical damage and thus promote peak health.

Vitamin B1 (Thiamine)
Thiamine protects the body from the degenerative effects of ageing, stress, alcohol, smoking and pollutants.
As a protein builder and by enhancing circulation, follicle stimulation and transport of nutrients to the scalp, it stimulates hair growth, encourages hair shine, increases volume and good texture.
Strategically combining it with folic acid induces hair re-growth. Thiamine is also important for brain function and relieving depression.

Vitamin B2 (Riboflavin)
Riboflavin is required by every cell of your body on a daily basis. Structuring it with Vitamin A helps to promote the repair of epithelial tissue and stimulate hair growth. Riboflavin facilitates oxygen delivery to the body’s tissues and is included in the Trichotin formula to increase iron absorption.

Vitamin B3 (Niacin) 
Niacin supports healthy hair by improving digestion and absorption of amino acids. It stimulates circulation promoting a healthier scalp and also plays an important role in maintaining the health of the nervous system.

Vitamin B6 (Pyrodoxine HCl)
Vitamin B6 is involved in more bodily functions than any other single nutrient to promote both physical and mental health. Vitamin B6 is important for a healthy scalp and consistent hair growth. It regulates sodium and potassium levels and is also required for the production of RNA and DNA which contain genetic information for normal cellular growth.

Folic Acid 
Folic acid is considered “brain food”, and needed for energy production. It is also required for promoting cell exfoliation. Augmented levels are imperative for periods of rapid growth.
Folic acid is a coenzyme for DNA and RNA production, and is therefore important for healthy hair cell development. Trichotin’s formula incorporates folic acid with Vitamin B12 and Vitamin C since this configuration works best for hair follicle reconstruction. Once this is achieved healthy hair and skin are maintained.

Vitamin B12 
Vitamin B12 is essential for red blood cell formation, tissue, cellular repair and cell longevity – thus serving to sustain a healthy scalp.
The Trichotin formula uses Vitamin B12 together with iron to support the haemopoetic system improves circulation and oxygen supply to the scalp.
Trichotin encourages Vitamin B6, B12 and folic acid to work synergistically to reduce homocysteine levels in the body, high levels of which together with cholesterol are known to cause vascular damage.

Biotin
Various research programs concluded that when individuals were fed a diet low in biotin or inositol, they lose substantial amounts of hair. Minute doses of Biotin daily can prevent hair loss.
Biotin improves cell growth and is included in Trichotin to complement Zepufa. It is required for essential fatty acid production and has been used in this formula for the benefits listed below:

1. Helps improve hair quality.
2. Prevents thinning and splitting of hair
3. Minimizes hair greying.
4. Appears to metabolise fatty acids
5. Enhances the utilization of B complex vitamins.

On its own Biotin prevents seborrheic dermatitis, or cradle cap. It also functions to keep hair, skin, bone marrow, and glands growing and functioning optimally.

Magnesium
Magnesium increases the activity of energy producing enzymes in the body. It enhances calcium absorption and regulates the pH (acidity level) in the body. Research concluded that individuals who were fed a diet deficient in Magnesium suffer hair loss in “bunches”.

This nutrient deficiency was found to be reversible with supplementation – resulting in the generous restoration of hair.

Iron
Medically Iron deficiency is probably the most common known cause of hair loss. It is vital for the manufacturing of cells which oxygenate all tissues including hair, nails and skin. Cell growth and energy production are thus stimulated.

In pre and peri-menopausal women hair loss is not only hormonal, but also due to nutrient deficiency, with depleted iron stores being the most important factor. It could also be a possible trigger for telogen effluvium which causes much hair shedding. When hair loss is subtle, occurring over many months or even years, iron supplementation is critical.
Trichotin also utilizes iron as a contributor to energy. If the ingredients for energy production are not continuously replenished, then iron stores will be depleted, resulting in hair cell degradation.
One method of maximally utilizing iron in the body is to stimulate the liver to mobilise ferritin. As circulating levels of ferritin decline, stores are depleted to provide support for more essential functions. The loss of this ferritin from the hair follicle can lead to the development of vellus, non-pigmented fine hairs – a condition indicative of early iron deficiency. The presence of vellus hairs is seen in androgenic alopecia. Once iron levels are restored hair growth returns to normal.
Optimal hair growth cannot be sustained with low iron stores. Treatment for hair loss is enhanced when iron deficiency, with or without obvious anaemia, is corrected. Iron-deficiency is so important that it is imperative in hair loss screening.

Zinc 
Severe zinc deficiency has been shown to produce baldness and negative scalp conditions. These are reversed when zinc levels are restored to normal.
Trichotin incorporates Zinc because it:

1. Minimises hair loss.
2. Stimulates hair growth.
3. Prevents acne.
4. Is required for skin healing.
5. Is required for protein synthesis and collagen formation.
6. Acts as a powerful antioxidant
7. Protects against free radical damage.
8. Increases the absorption of Vitamin A.

Amino Acids
If essential amino acids are deficient hair fibres become weak, break, fall out, and fail to regenerate normally. Trichotin has included these in its formula because they also form the structural components of chromosomes.

PABA (Para-Amino Benzoic Acid)
PABA contains sun screening properties – a function which is utilized in sunscreen preparations. It is well known for its ability to protect the skin from the harmful effects of sun rays
In Trichotin PABA is used to assist the breakdown of amino acids and promotes its optimal utilization.
Its benefits include hair shine and “body” as well as skin clarity. It is used in the Trichotin formula because synergistically with folic acid it acts as a powerful anti-greying and hair-colour restoring agent.
A deficiency of PABA (Para-amino benzoic acid) causes:

1. extreme fatigue
2. eczema
3. irritability
4. depression
5. nervousness
6. constipation
7. headaches
8. digestive disorders
9. premature greying of hair

Choline 
Choline containing supplements are prescribed to balding patients. This ingredient shows significant benefits in hair loss. Choline enhances brain function, improves memory and concentration.

Inositol 
Inositol is a cell membrane stabilizer and an anti-oxidant which has protective effects on hair follicles by safeguarding them from membrane damage caused by oxidized cholesterol in the scalp.
Inositol is fundamental for growth, shine and improved hair quality. It strengthens hair structure allowing it to grow thicker and more vibrant. Inositol is said to have a calming effect on the body and also plays a role in lowering raised cholesterol levels.
Functioning synergistically with Choline, Inositol is responsible for the formation of lecithin which stimulates hair growth.

L-Cysteine 
Cysteine is the chief protein component of hair and the largest single element and constituting about 10-14%. It is therefore a vital ingredient. Cysteine is a sulphur containing amino acid and is essential for the formation of new cells and detoxification of the skin. It also increases collagen production resulting in greater skin clarity and better texture.

L-Glycine 
L-Glycine is an amino acid found in the protein of all life forms. It is a major constituent of proteins, and promotes repair of damaged cells. It is also used in the assembly of RNA and DNA. Large concentrations are found in the skin and scalp connective tissue.

Co Enzyme Q10
Co Enzyme Q 10 is a powerful antioxidant. It stimulates circulation thus fulfilling an important role in oxygenation and energy production. It is best recognised for its “anti-aging properties”. It is used in this formula to maintain the integrity of cell membranes.
Research has proved that its usage is incumbent on any individual using chronic medication. Co Enzyme Q 10 is an important ingredient for senior citizens whose circulation is compromised. Many people who supplement with Co Enzyme Q 10 daily report thicker stronger hair.
Prior to undergoing surgery and chemotherapy, patients should supplement with Co- Enzyme Q 10 to minimize hair loss and maintain existing hair.

Zepufa 
Fatty acids are utilized in numerous processes in the body including hair growth. An Omega 3 and 6 deficiency is characterized by hair loss, eczema and a less effectively functioning immune system.

EFA’s are essential to the body and required for healthy hair and skin structure. For thinning of hair, health care practitioners highly recommend EFA supplementation. In Trichotin it has been used to feed hair roots – “fertilizer”. Essential fatty acids also improve hair texture and prevent dry, brittle hair by balancing its moisture content and keeping hair well hydrated,

Increasing EFA’s in an individual’s diet results in hair improvement, noticeable in about six to eight weeks.

Methyl Sulfonyl Methane (MSM)
MSM is a naturally occurring, organic sulphur compound which helps to nourish collagen in the hair, skin and nails. For this reason it is referred to by many as “the beauty mineral”. It also aids the detoxification process by scavenging for free radicals. MSM aids the liver in its production of Choline and controls acidity in the stomach – coating the intestinal tract causing parasites to lose their ability to adhere. MSM can jump-start hair growth in persons with sulphur deficiencies which may be causing thinning hair of hair loss.

Silica
A consistent supply of Silica is imperative for the integrity of hair, skin and nails. Lustreless hair and brittle nails are treated with silica to help rejuvenate hair follicles and rebuild connective tissue. Silica also increases the production of collagen whereby skin and nail condition is greatly enhanced.

 

References:

598                 Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of Prostata. Ann Intern Med 1997;127:169-70. View abstract.

764                 Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urol 1998;51:1003-7. View abstract.

2732               Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9. View abstract.

2735               Marks LS, Tyler VE. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology 1999;53:457-61. View abstract.

2736               USRF Research. Clinical effects of saw palmetto extract in men with symptomatic BPH webpage: www.usrf.org/spepapers.html (Accessed 23 June 2004).

3484               Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38. View abstract.

4239               Ondrizek RR, Chan PJ, Patton WC, King A. Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet 1999;16:87-91. View abstract.

4240               Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999;71:517-22. View abstract.

5093               Marks L, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-6. View abstract.

5094               Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000;163:1408-12. View abstract.

5095               Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999;38:208-15. View abstract.

5548               DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91. View abstract.

6424               Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40. View abstract.

6484               Small EJ, Frohlich MW, Bok R, et al.Prospective trial of the herbal supplement, PC-SPES, in patients with pregressive prostate cancer. J Clin Oncol 2000;18:3595-603. View abstract.

6750               Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984;18:461-2. View abstract.

6751               Braeckman J. The extract of serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994;55:776-85.

6752               Reece-Smith H, Memon A, Smart CJ, Dewbury K. The value of permixon in benign prostatic hypertrophy. Br J Urol 1986;58:36-40. View abstract.

6762               Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;(2):CD001423. View abstract.

6763               Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000;86:439-42. View abstract.

6764               Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-9. View abstract.

6765               Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83. View abstract.

6766               Di Silverio F, D’Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14. View abstract.

6769               Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 2000;28:201-9. View abstract.

6770               Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of serenoa repens (permixon®) on the prostate. J Urol 2000;164:876-81. View abstract.

6771               Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-52. View abstract.

6772               Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 1999;16:231-41. View abstract.

6773               Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5 alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999;40:232-41. View abstract.

6775               Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97-103. View abstract.

6776               Adriazola-Semino M, Lozano-Ortega JL, Garcia-Cobo E, et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens]. Arch Esp Urol 1992; 45:211-3. View abstract.

6777               Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990;66:639-41. View abstract.

6778               Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders Clin Drug Invest 1995; 9:291-7.

6779               Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997;57:299-304. View abstract.

6780               Gutierrez M, Garcia de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996;27:171-6. View abstract.

8330               Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 1993;25:565-9. View abstract.

8659               Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001;250:167-9. View abstract.

8901               Glemain P, Coulange C, Grapin FN, Muszynski RC. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. [Abstract]. J Urol 2001;167:374.

8902               Goldmann WH, Sharma AL, Currier SJ, et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 2001;25:1117-24. View abstract.

11026            Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005;11:433-9. View abstract.

11224            Vela Navarrete R, Garcia Cardoso JV, Barat A, et al. BPH and Inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003;44:549-55.. View abstract.

11225            Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003;74:536-42. View abstract.

11241            Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 2001; 33: 217-25. View abstract.

11243            Debruyne F, Koch G, Boyle P, et al. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. Eur Urol 2002;41:497-506. View abstract.

11314            Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267-70.. View abstract.

11354            Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004;171:284-8. . View abstract.

13712            Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40. . View abstract.

14274            Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66. View abstract.

14275            Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(3):CD001423. View abstract.

14457            Jibrin I, Erinle A, Saidi A, Aliyu ZY. Saw palmetto-induced pancreatitis. South Med J 2006;99:611-2. View abstract.

15217            Bonnar-Pizzorno RM, Littman AJ, Kestin M, White E. Saw palmetto supplement use and prostate cancer risk. Nutr Cancer 2006;55:21-7. View abstract.

15550            Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002;8:143-52. View abstract.

15551            Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000;86:439-42. View abstract.

17202            Tuncel A, Ener K, Han O, et al. Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. Scand J Urol Nephrol 2009;43:377-82. View abstract.

17304            Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009;(2):CD001423. View abstract.

17305            Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195-200. View abstract.

17306            Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008;16:147-54. View abstract.

17307            Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms–a placebo-controlled, double-blind, multicenter trial. World J Urol 2005;23:139-46. View abstract.

17308            Habib FK, Ross M, Ho CK, et al. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190-4. View abstract.

17684            Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344-51. View abstract.

18215            Suter A, Saller R, Riedi E, Heinrich M. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Results from a pilot trial. Phytother Res 2012 Apr 23. doi: 10.1002/ptr.4696. View abstract.

35871            Ashar, B. H., Rice, T. N., and Sisson, S. D. Medical residents’ knowledge of dietary supplements. South.Med J 2008;101(10):996-1000. View abstract.

48603            Izzo, A. A. and Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69(13):1777-1798. View abstract.

50920            Pavone, C., Abbadessa, D., Tarantino, M. L., Oxenius, I., Lagana, A., Lupo, A., and Rinella, M. [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. Urologia. 2010;77(1):43-51. View abstract.

54714            Thangapazham, R. L., Gaddipati, J. P., Rajeshkumar, N. V., Sharma, A., Singh, A. K., Ives, J. A., Maheshwari, R. K., and Jonas, W. B. Homeopathic medicines do not alter growth and gene expression in prostate and breast cancer cells in vitro. Integr.Cancer Ther 2006;5(4):356-361. View abstract.

54715            MacLaughlin, B. W., Gutsmuths, B., Pretner, E., Jonas, W. B., Ives, J., Kulawardane, D. V., and Amri, H. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr.Cancer Ther 2006;5(4):362-372. View abstract.

60442            Morgia, G., Mucciardi, G., Gali, A., Madonia, M., Marchese, F., Di, Benedetto A., Romano, G., Bonvissuto, G., Castelli, T., Macchione, L., and Magno, C. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol.Int. 2010;84(4):400-406. View abstract.

70221            Hutchison, A., Farmer, R., Verhamme, K., Berges, R., and Navarrete, R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007;51(1):207-215. View abstract.

70223            Dedhia, R. C. and McVary, K. T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J.Urol. 2008;179(6):2119-2125. View abstract.

70232            Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabriel, M., Pierre-Malice, M., and Gibelin, B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51. View abstract.

73309            Bauer, H. W., Casarosa, C., Cosci, M., Fratta, M., and Blessmann, G. [Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study]. MMW.Fortschr.Med 6-24-1999;141(25):62. View abstract.

73310            Goepel, M., Dinh, L., Mitchell, A., Schafers, R. F., Rubben, H., and Michel, M. C. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? Prostate 2-15-2001;46(3):226-232. View abstract.

73311            Medvedev, A. A., Siniakova, L. A., and Zaitsev, A. V. [Prostaplant treatment of benign prostatic hyperplasia]. Urologiia 2000;(4):13-15. View abstract.

73312            Ishii, K., Usui, S., Sugimura, Y., Yamamoto, H., Yoshikawa, K., and Hiran, K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001;24(2):188-190. View abstract.

73313            Iguchi, K., Okumura, N., Usui, S., Sajiki, H., Hirota, K., and Hirano, K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47(1):59-65. View abstract.

73314            Marks, L. S., Hess, D. L., Dorey, F. J., Luz, Macairan M., Cruz Santos, P. B., and Tyler, V. E. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57(5):999-1005. View abstract.

73315            Gerber, G. S., Kuznetsov, D., Johnson, B. C., and Burstein, J. D. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58(6):960-964. View abstract.

73316            Anonymous. Effectiveness of lipidosterol extract Serenoa repens (Permixon) in patients with prostatic hyperplasia. Urologiia. 2002;(1):23-25. View abstract.

73317            Debruyne, F., Koch, G., Boyle, P., Da Silva, F. C., Gillenwater, J. G., Hamdy, F. C., Perrin, P., Teillac, P., Vela-Navarrete, R., and Raynaud, J. P. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. Prog.Urol. 2002;12(3):384-392. View abstract.

73318            Glemain, P., Coulange, C., Billebaud, T., Gattegno, B., Muszynski, R., and Loeb, G. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Prog.Urol. 2002;12(3):395-403. View abstract.

73319            Sinclair, R. D., Mallari, R. S., and Tate, B. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. Australas.J Dermatol. 2002;43(4):311-312. View abstract.

73320            Al Shukri, S. H., Deschaseaux, P., Kuzmin, I. V., and Amdiy, R. R. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic.Dis. 2000;3(3):195-199. View abstract.

73321            Giannakopoulos, X., Baltogiannis, D., Giannakis, D., Tasos, A., Sofikitis, N., Charalabopoulos, K., and Evangelou, A. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv.Ther 2002;19(6):285-296. View abstract.

73322            Pytel, Y. A., Vinarov, A., Lopatkin, N., Sivkov, A., Gorilovsky, L., and Raynaud, J. P. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv.Ther 2002;19(6):297-306. View abstract.

73323            Pecoraro, S., Annecchiarico, A., Gambardella, M. C., and Sepe, G. [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]. Minerva Urol.Nefrol. 2004;56(1):73-78. View abstract.

73324            Debruyne, F., Boyle, P., Calais, da Silva, Gillenwater, J. G., Hamdy, F. C., Perrin, P., Teillac, P., Vela-Navarrete, R., Raynaud, J. P., and Schulman, C. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients–PERMAL study subset analysis]. Prog.Urol. 2004;14(3):326-331. View abstract.

73325            Vela-Navarrete, R., Escribano-Burgos, M., Farre, A. L., Garcia-Cardoso, J., Manzarbeitia, F., and Carrasco, C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol. 2005;173(2):507-510. View abstract.

73326            Djavan, B., Fong, Y. K., Chaudry, A., Reissigl, A., Anagnostou, T., Bagheri, F., Waldert, M., Fajkovic, H., Marihart, S., Harik, M., Spaller, S., and Remzi, M. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol. 2005;23(4):253-256. View abstract.

73327            Chan, J. M., Elkin, E. P., Silva, S. J., Broering, J. M., Latini, D. M., and Carroll, P. R. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology 2005;66(6):1223-1228. View abstract.

73328            Breu, W., Hagenlocher, M., Redl, K., Tittel, G., Stadler, F., and Wagner, H. [Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism]. Arzneimittelforschung 1992;42(4):547-551. View abstract.

73329            Aliaev, IuG, Vinarov, A. Z., Lokshin, K. L., and Spivak, L. G. [Efficiency and safety of prostamol-Uno in patients with chronic abacterial prostatitis]. Urologiia. 2006;(1):47-50. View abstract.

73330            Engelmann, U., Walther, C., Bondarenko, B., Funk, P., and Schlafke, S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-229. View abstract.

73331            Webber, R. Benign prostatic hyperplasia. Clin Evid. 2005;(14):1076-1091. View abstract.

73332            Casner, P. R. Saw palmetto for benign prostatic hyperplasia. N Engl.J Med 5-4-2006;354(18):1950-1951. View abstract.

73333            Dimitrakov, J. D. Saw palmetto for benign prostatic hyperplasia. N Engl.J Med 5-4-2006;354(18):1950-1951. View abstract.

73334            Lopatkin, N. A., Sivkov, A. V., Medvedev, A. A., Walter, K., Schlefke, S., Avdeichuk, IuI, Golubev, G. V., Mel’nik, K. P., Elenberger, N. A., and Engelman, U. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]. Urologiia. 2006;(2):12, 14-12, 19. View abstract.

73335            Singh, Y. N., Devkota, A. K., Sneeden, D. C., Singh, K. K., and Halaweish, F. Hepatotoxicity potential of saw palmetto (Serenoa repens) in rats. Phytomedicine 2007;14(2-3):204-208. View abstract.

73336            Avins, A. L. and Bent, S. Saw palmetto and lower urinary tract symptoms: what is the latest evidence? Curr Urol Rep. 2006;7(4):260-265. View abstract.

73337            Hizli, F. and Uygur, M. C. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int.Urol.Nephrol. 2007;39(3):879-886. View abstract.

73338            Magri, V., Trinchieri, A., Pozzi, G., Restelli, A., Garlaschi, M. C., Torresani, E., Zirpoli, P., Marras, E., and Perletti, G. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob.Agents 2007;29(5):549-556. View abstract.

73339            Hostanska, K., Suter, A., Melzer, J., and Saller, R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res 2007;27(2):873-881. View abstract.

73340            Yeu, E. and Grostern, R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract.Surg 2007;33(5):927-928. View abstract.

73341            Groom, S. N., Johns, T., and Oldfield, P. R. The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation. J Med Food 2007;10(1):73-79. View abstract.

73342            Magri, V., Trinchieri, A., Montanari, E., Del Nero, A., Mangiarotti, B., Zirpoli, P., de Eguileor, M., Marras, E., Ceriani, I., Vral, A., and Perletti, G. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. Arch Ital Urol Androl 2007;79(2):84-92. View abstract.

73343            Shi, R., Xie, Q., Gang, X., Lun, J., Cheng, L., Pantuck, A., and Rao, J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J.Urol. 2008;179(2):610-615. View abstract.

73344            Magri, V., Trinchieri, A., Perletti, G., and Marras, E. Activity of Serenoa repens, lycopene and selenium on prostatic disease: evidences and hypotheses. Arch.Ital.Urol.Androl 2008;80(2):65-78. View abstract.

73345            Carballido, J., Ruiz-Cerda, J. L., Unda, M., Baena, V., Campoy, P., Manasanch, J., and Slof, J. [Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequently used in its treatment]. Actas Urol.Esp. 2008;32(9):916-925. View abstract.

73346            Cai, T., Mazzoli, S., Bechi, A., Addonisio, P., Mondaini, N., Pagliai, R. C., and Bartoletti, R. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int.J Antimicrob.Agents 2009;33(6):549-553. View abstract.

73347            Neff, K. D., Sandoval, H. P., Fernandez de Castro, L. E., Nowacki, A. S., Vroman, D. T., and Solomon, K. D. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009;116(4):658-663. View abstract.

73348            Agbabiaka, T. B., Pittler, M. H., Wider, B., and Ernst, E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009;32(8):637-647. View abstract.

73349            Villanueva, S. and Gonzalez, J. Coagulopathy induced by saw palmetto: a case report. Bol.Asoc.Med.P.R. 2009;101(3):48-50. View abstract.

73350            Wargo, K. A., Allman, E., and Ibrahim, F. A possible case of saw palmetto-induced pancreatitis. South.Med.J. 2010;103(7):683-685. View abstract.

73351            Lapi, F., Gallo, E., Giocaliere, E., Vietri, M., Baronti, R., Pieraccini, G., Tafi, A., Menniti-Ippolito, F., Mugelli, A., Firenzuoli, F., and Vannacci, A. Acute liver damage due to Serenoa repens: a case report. Br.J.Clin.Pharmacol. 2010;69(5):558-560. View abstract.

73352            Timmermans, L. M. and Timmermans, L. G., Jr. [Determination of the activity of extracts of Echinaceae and Sabal in the treatment of idiopathic megabladder in women]. Acta Urol Belg. 1990;58(2):43-59. View abstract.

73353            Anceschi, R., Bisi, M., Ghidini, N., Ferrari, G., and Ferrari, P. Serenoa repens (Permixon(R)) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia. Minerva Urol.Nefrol. 2010;62(3):219-223. View abstract.

73354            Mantovani, F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol.Nefrol. 2010;62(4):335-340. View abstract.

73355            Kul’chavenia, E. V., Breusov, A. A., Brizhatiuk, E. V., and Kholtobin, D. P. [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]. Urologiia. 2010;(6):55-58. View abstract.

73356            Lee, J. Y., Foster, H. E., Jr., McVary, K. T., Meleth, S., Stavris, K., Downey, J., and Kusek, J. W. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. J.Altern.Complement Med. 2011;17(5):469-472. View abstract.

73357            MacDonald, R., Tacklind, J. W., Rutks, I., and Wilt, T. J. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU.Int. 2012;109(12):1756-1761. View abstract.

73358            Hanaka, M., Yoshii, C., Yatera, K., Ito, C., Chojin, Y., Nagata, S., Yamasaki, K., Nishida, C., Kawanami, T., Kawanami, Y., Ishimoto, H., and Mukae, H. [A case of rhabdomyolysis caused by saw palmetto of healthy foods]. J.UOEH. 6-1-2012;34(2):193-199. View abstract.

73359            Scaglione, F., Lucini, V., Pannacci, M., Dugnani, S., and Leone, C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur.Rev.Med.Pharmacol.Sci. 2012;16(5):569-574. View abstract.

73360            Giulianelli, R., Pecoraro, S., Sepe, G., Leonardi, R., Gentile, B. C., Albanesi, L., Brunori, S., Mavilla, L., Pisanti, F., Giannella, R., Morello, P., Tuzzolo, D., Coscione, M., Galasso, F., D’Angelo, T., Ferravante, P., Morelli, E., and Miragliuolo, A. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation. Arch.Ital.Urol.Androl 2012;84(2):94-98. View abstract.

73361            Miroddi, M., Carni, A., Mannucci, C., Moleti, M., Navarra, M., and Calapai, G. Hot flashes in a young girl: a wake-up call concerning Serenoa repens use in children. Pediatrics 2012;130(5):e1374-e1376. View abstract.

73362            Bertaccini, A., Giampaoli, M., Cividini, R., Gattoni, G. L., Sanseverino, R., Realfonso, T., Napodano, G., Fandella, A., Guidoni, E., Prezioso, D., Galasso, R., Cicalese, C., Scattoni, V., Armenio, A., Conti, G., Corinti, M., Spasciani, R., Liguori, G., Lampropoulou, N., and Martorana, G. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project. Arch.Ital.Urol.Androl 2012;84(3):117-122. View abstract.

73363            Tasca, A., Barulli, M., Cavazzana, A., Zattoni, F., Artibani, W., and Pagano, F. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo]. Minerva Urol.Nefrol. 1985;37(1):87-91. View abstract.

73364            Casarosa, C., Cosci, di Coscio, and Fratta, M. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther 1988;10(5):585-588. View abstract.

73365            Hiermann, A. [The contents of sabal fruits and testing of their anti-inflammatory effect]. Arch Pharm (Weinheim) 1989;322(2):111-114. View abstract.

73366            Elghamry, M. I. and Hansel, R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens Small), a new estrogenic plant. Experientia 8-15-1969;25(8):828-829. View abstract.

73367            Champault, G., Bonnard, A. M., Cauquil, J., and Patel, J. C. [Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients]. Ann Urol (Paris) 1984;18(6):407-410. View abstract.

73368            Schneider, H. J., Honold, E., and Masuhr, T. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices]. Fortschr Med 1-30-1995;113(3):37-40. View abstract.

73369            Iehle, C., Delos, S., Guirou, O., Tate, R., Raynaud, J. P., and Martin, P. M. Human prostatic steroid 5 alpha-reductase isoforms–a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54(5-6):273-279. View abstract.

73370            Vahlensieck, W., Jr., Volp, A., Lubos, W., and Kuntze, M. [Benign prostatic hyperplasia–treatment with sabal fruit extract. A treatment study of 1,334 patients]. Fortschr Med 6-30-1993;111(18):323-326. View abstract.

73371            Weisser, H., Tunn, S., Behnke, B., and Krieg, M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28(5):300-306. View abstract.

73372            Ravenna, L., Di Silverio, F., Russo, M. A., Salvatori, L., Morgante, E., Morrone, S., Cardillo, M. R., Russo, A., Frati, L., Gulino, A., and Petrangeli, E. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996;29(4):219-230. View abstract.

73373            Buck, A. C. Phytotherapy for the prostate. Br J Urol 1996;78(3):325-336. View abstract.

73374            Plosker, G. L. and Brogden, R. N. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9(5):379-395. View abstract.

73375            Flamm, J., Kiesswetter, H., and Englisch, M. [An urodynamic study of patients with benign prostatic hypertrophy treated conservatively with phytotherapy or testosterone (author’s transl)]. Wien.Klin.Wochenschr. 9-28-1979;91(18):622-627. View abstract.

73376            Paubert-Braquet, M., Richardson, F. O., Servent-Saez, N., Gordon, W. C., Monge, M. C., Bazan, N. G., Authie, D., and Braquet, P. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone- induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34(3-4):171-179. View abstract.

73377            Kondas, J., Philipp, V., and Dioszeghy, G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol.Nephrol. 1996;28(6):767-772. View abstract.

73378            Paubert-Braquet, M., Cousse, H., Raynaud, J. P., Mencia-Huerta, J. M., and Braquet, P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33(3):340-347. View abstract.

73379            Mohanty NK, Jha RJ, and Dutt C. Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic grade I to grade II benign prostatic hyperplasia (BPH). Indian J Urol 1999;16(1):26-31.

73380            Cukier J, Ducassou J, Le Guillou M, and et al. Permixon versus placebo; resultats d’une etude multicentrique. C R Ther Pharmacol Clin 1985;4(25):15-21.

73381            Sokeland J and Albrecht J. Kombination aus Sabal und Urticaextrakt vs. finasterid bei BPH (Stad I bis II nach Alken). Urologe 1997;36 (4):327-333.

73382            Reece Smith H, Memon A, Smart C, and et al. The value of Permixon in benign prostatic hypertrophy. Brit J Urol 1986;58(1):36-40.

73383            Bach D and Ebeling L. Long-term drug treatment of benign prostatic hyperplasia–results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomed 1996;3:105-111.

73384            Braeckman J, Denis L, de Leval J, and et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997;9:247-259.

73385            Braeckman J, Bruhwyler J, Vandekerckhove K, and et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytother Res 1997;11:558-563.

73386            Glemain, C. Coulange F. N. Grapin et al. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. J Urol, 2002;167 (suppl 4)(Abstract 1486):374.

73387            Roveda S and Colombo P. Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160mg or rectal capsules 640mg. Arch Med Interna 1994;46(2):61-75.

73388            Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Current Therapeutic Research 1994;55(7):776-785.

73389            Descotes J, Rambeaud J, Deschaseaux P, and et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;9(5):291-297.

73390            Paubert-Braquet M, Raynaud JP, and Braquet PG. Permixon [lipid sterolic extract of

73391            Vacherot F, Azzouz M, Gil-Diez-De-Medina S, and et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSEr, Permixon) in benign prostatic hyperplasia. Prostate 2000;45(3):259-266.

73392            Van Coppenolle F, Le Bourhis X, Carpentier F, and et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000;43(1):49-58.

73393            Briley M, Carilla E, and Fauran F. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in the rat prostate. Br J Pharmacol 1983;79:327P.

73394            Stenger A, Rarayre JP, and Carilla E. Etude pharmacologizue et biochimique de l’extrait hexanique de Serenoa repens B. Gaz Med Fr 1982;89:2041-2048.

73395            Sultan C, Terraza A, Carilla E, and et al. Anti-androgenic effects of Permixon: In vitro studies. In: Di Silverio F and Steg A. New Trends in BPH Etiopathogenesis. Rome: Acta Medica;1988.

73396            Mitropoulos D, Kiroudi A, Mitsogiannis I, and et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cells accumulation and glandular epithelium trophism in the rat prostate. J Urol 1999;161(4S):362.

73397            Bayne C, Donnelly F, Ross M, and et al. Serenoa repens (Permixon): a 5 alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999;40(4):232-241.

73398            Di Silverio F, Sciarra A, D’Eramo G, and et al. Zonal distribution of androgens and epidermal growth factor (EGF) in human BPH tissue: responsiveness to flutamide, finasteride, and Serenoa repens administration. Brit J Urol 1997;80(Suppl 2):214.

73399            Di Silverio F, Monti S, Sciarra A, and et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37(2):77-83.

73400            Epstein J, Partin A, Simon I, and et al. Prostate tissue effects of saw palmetto extract in men with symptomatic BPH. J Urol 1999;161(4S):362.

73401            De Bernardi VM, Tripodi AS, Contos S, and et al. Serenoa repens capsules: a bioequivalence study. ACTA TOXICOL THER 1994;15(1):21-39.

73402            Sosnowska J, Balslev H. American palm ethnomedicine: a meta-analysis. J Ethnobiol Ethnomed. 2009;24(5):43.

73403            Boccafoschi C, Annoscia S. Confronto fra estratto di Serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50:1257-1268.

73404            Braeckman J. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research. 1997;9:247-259.

73405            Cukier J, Ducassou J Le Guillou M Leriche A Lobel B Toubol J. [Permixon versus placebo; resultats d’une étude multicentrique]. Comptes Rendus deTherapeutique et de Pharmacologie Clinique. 1985;4:15-21.

73406            Descotes JL, Rambeaud JJ Deschaseaux P Faure G. Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation. 1995;5:291-297.

73407            Emili E, Lo Cigno M Petrone U. [Risultati clinici su un nuovo farmaco nella terapia dell’ipertofia della prostata (Permixon)]. Urologia. 1983;50:1042-1048.

73408            Gabric V, Miskic H. [Behandlung des benignen prostata-adenoms und der chronischen prostatatitis]. Therapiewoche. 1987;37:1775-1788.

73409            Lobelenz J. [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). klinische prufung im stadium I und II]. Therapeutikon. 1992;6(1-2):34-37.

73410            Mandressi S, Tarallo U Maggioni A Tombolini P Rocco F Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon) compared to that of the extract of Pygeum africanum and a placebo. Urologia. 1983;50(4):752-758.

73411            Mattei FM, Capone M Acconcia A. [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie. 1990;2:346-350.

73412            Metzker H, Kieser M Holscher U. [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B. 1996;36(4):292-300.

73413            Pannunzio E, D’Ascenzo R, Giardinetti F, and et al. Serenoa repens vs. gestonorone caproato nel trattamento dell’ipertrofia prostatica benigna. Studio randomizzato. Urologia 1986;53(5):696-705.

73414            Semino A, Ortega L, Cobo G, and et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens.]. Archivos Espanoles de Urologia 1992;45(3):211-213.

73415            Authie D and Cauquil J. Appreciation de l’efficacite de permixon en pratique quotidienne. [Appreciation of the in practice daily effectiveness of permixon]. C R Ther Pharmacol Clin 1987;5(56):4-13.

73416            Boccafoschi C and Annoscia S. Confronto fra estratto di Serenoa repens e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50(6):1257-1268.

73417            Emili E, Lo Cigno M, and Petrone U. Risultati clinici su un nuovo farmaco nella terapia dell’ipertrofia della prostata (Permixon). Urologia 1983;50(5):1042-1048.

73418            Foroutan F. Wirksamkeit und vertraglichkeit von permixon bei einem grosseren patientenkollektiv (592 patienten) unter praxisbedingungen. J Urol Urogynakol 1997;2:17-21.

73419            Mandressi A, Tarallo U, Maggioni A, and et al. Terapia medica dell’adenoma prostatico: confronto della efficacia del’estratto di serenoa repens (Permixon) versus l’estratto di pigeum africanum e placebo. Valutazione in doppio cieco. Urologia 1983;50(4):752-757.

73420            Gabric V and Miskic H. Behandlung des benignen Prostataadenoms und der chronischen Prostatitis. Placebokontrollierte randomisierte doppelblindstudie mit Prostagutt. Therapiewoche 1987;37:1775-1788.

73421            Löbelenz J. Extractum Sabal fructus bei benigner Prostatahyperplasie (BPH): Klinische Prüfung im Stadium I und II. Therapeutikon 1992;6(1-2):34, 37.

73422            Mattei FM, Capone M, and Acconcia A. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urol Nephrol 1990;2(5):346-350.

73423            Metzker H, Kieser M, and Hölscher U. Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH). Urologe 1996;36(4):292-300.

73424            Mandressi A. Treatment of uncomplicated benign prostatic hypertrophy (BPH) by an extract of Serenoa repens: clinical results. J Endocrinol Invest 1987;10 (suppl 2):49.

73425            Comar OB and Di Rienzo A. Mepartricina versus Serenoa repens: studio sperimentale doppio cieco su 20 casi di iperplasia prostatica benigna. Riv Ital Biol Med 1986;6(2):122-125.

73426            Savel’eva KV, Kachanova MV Pavlov VN Kazikhinurov RA Frolov MY Mukhin AB Udut VV Yurmazov ZA Dugina YL Sergeeva SA Epshtein OI. Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia. Bull Exp Biol Med. 2009;148(2):305-307.

73427            Tosto A, Rovereto B, Paoletti MC, and et al. Study of Serenoa repens in treatment of functional secondary adenoma of the prostate: consideration of 20 cases. Urologia 1985;52:536-542.

73428            Ziegler H and Holscher U. Efficacy of saw palmetto fruit special extract WS1473 in patients with Alken stage I-II benign prostatic hyperplasia–open multicentre study. Jatros Uro 1998;14(3):34-43.

73429            Paoletti PP, Francalanci R, Tenti S, and et al. Medical treatment of prostatic hypertrophy. Experience with Serenoa repens extract. Urologia 1986;53:182-187.

73430            Greca P and Volip R. Experience with a new drug in the medical treatment of prostatic adenoma. Urologia 1985;52:532-535.

73431            Carreras JO. Novel treatment with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy. Archiv Esp de Urolog 1987;40:310-313.

73432            Cirillo-Marucco E, Pagliarulo A, Tritto G, and et al. L’estratto di Serenoa repens (Permixon) nel trattamento precoce dell’ipertrofia prostatica . Urologia 1983;50(6):1269-1277.

73433            Breza, J., Kliment, J., Valansky, L., and et al. Prostamol Uno (Alcohol extract of the fruits of

73434            Redecker KD. [Sabal extract WS 1473 in benign prostatic hyperplasia]. Extracta Urologica 1998;21(3):23-25.

73435            Morganti P, Fabrizi G, James B, and et al. Effect of gelatin-cystine and Serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol 1998;16:57-64.

 

1                      Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.

2                      Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.

4                      Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.

5                      Foster S, Tyler VE. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.

6                      The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.

7                      Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician’s Guide to Herbal Medicine. Terry C. Telger, transl. 3rd ed. Berlin, GER: Springer, 1998.

8                      Wichtl MW. Herbal Drugs and Phytopharmaceuticals. Ed. N.M. Bisset. Stuttgart: Medpharm GmbH Scientific Publishers, 1994.

11                    Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.

19                    Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.

483                 Anon. Quercetin. Alt Med Rev 1998;3:140-3.

5093               Marks L, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-6. View abstract.

6500               Mills S, Bone K. Principles and Practice of Phytotherapy. London: Churchill Livingstone, 2000.

6774               Sokeland J, Albrecht J. [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]. Urologe A 1997;36:327-33. View abstract.

7035               Mittman P. Randomized, double-blind study of freeze-dried Urtica dioica in the treatment of allergic rhinitis. Planta Med 1990;56:44-7. View abstract.

11227            Konrad L, Muller HH, Lenz C, et al. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med 2000;66:44-7. View abstract.

11228            Schottner M, Gansser D, Spiteller G, et al. Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG). Planta Med 1997;63:529-32. View abstract.

11229            Lichius JJ, Muth C. The inhibiting effects of Urtica dioica root extracts on experimentally induced prostatic hyperplasia in the mouse. Planta Med 1997;63:307-10. . View abstract.

11230            Vontobel HP, Herzog R, Rutishauser G, Kres H. [Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia]. (Abstract). Urologe A 1985;24:49-51. View abstract.

11234            Kassen A, Berges R, Senge T, et al. Effect of beta-sitosterol on transforming growth factor-beta-1 expression and translocation protein kinase C alpha in human prostate stromal cells in vitro. Eur Urol 2000;37:735-41. . View abstract.

11759            Cabeza M, Bratoeff E, Heuze I, et al. Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate. Proc West Pharmacol Soc 2003;46:153-5.

12490            Randall C, Randall H, Dobbs F, et al. Randomized controlled trial of nettle sting for treatment of base-of-thumb pain. J R Soc Med 2000;93:305-9. View abstract.

15195            Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms–a placebo-controlled, double-blind, multicenter trial. World J Urol 2005;23:139-46. View abstract.

15196            Durak I, Biri H, Devrim E, et al. Aqueous extract of Urtica dioica makes significant inhibition on adenosine deaminase activity in prostate tissue from patients with prostate cancer. Cancer Biol Ther 2004;3:855-7. View abstract.

15197            Caliskaner Z, Karaayvaz M, Ozturk S. Misuse of a herb: stinging nettle (Urtica urens) induced severe tongue oedema. Complement Ther Med 2004;12:57-8. View abstract.

15551            Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000;86:439-42. View abstract.

17307            Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms–a placebo-controlled, double-blind, multicenter trial. World J Urol 2005;23:139-46. View abstract.

18923            Dar SA, Ganai FA, Yousuf AR, et al. Pharmacological and toxicological evaluation of Urtica dioica. Pharm Biol 2013;51:170-80. View abstract.

31002            Baykul, T., Alanoglu, E. G., and Kocer, G. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience. J Contemp Dent Pract 2010;11(1):E088-E094. View abstract.

31003            Purnak, T., Ozaslan, E., Beyazit, Y., and Haznedaroglu, I. C. Upper gastrointestinal bleeding in a patient with defective hemostasis successfully treated with ankaferd blood stopper. Phytother.Res. 2011;25(2):312-313. View abstract.

31004            Beyazit, Y., Kurt, M., Kekilli, M., Goker, H., and Haznedaroglu, I. C. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern.Med.Rev. 2010;15(4):329-336. View abstract.

35893            Buettner, C., Mukamal, K. J., Gardiner, P., Davis, R. B., Phillips, R. S., and Mittleman, M. A. Herbal supplement use and blood lead levels of United States adults. J.Gen.Intern.Med. 2009;24(11):1175-1182. View abstract.

37425            Swanston-Flatt, S. K., Day, C., Flatt, P. R., Gould, B. J., and Bailey, C. J. Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetes Res 1989;10(2):69-73. View abstract.

39801            Luczaj, L. and Szymanski, W. M. Wild vascular plants gathered for consumption in the Polish countryside: a review. J.Ethnobiol.Ethnomed. 2007;3:17. View abstract.

50920            Pavone, C., Abbadessa, D., Tarantino, M. L., Oxenius, I., Lagana, A., Lupo, A., and Rinella, M. [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. Urologia. 2010;77(1):43-51. View abstract.

70230            Krzeski, T., Kazon, M., Borkowski, A., Witeska, A., and Kuczera, J. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. Clin Ther 1993;15(6):1011-1020. View abstract.

70232            Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabriel, M., Pierre-Malice, M., and Gibelin, B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51. View abstract.

73334            Lopatkin, N. A., Sivkov, A. V., Medvedev, A. A., Walter, K., Schlefke, S., Avdeichuk, IuI, Golubev, G. V., Mel’nik, K. P., Elenberger, N. A., and Engelman, U. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]. Urologiia. 2006;(2):12, 14-12, 19. View abstract.

73346            Cai, T., Mazzoli, S., Bechi, A., Addonisio, P., Mondaini, N., Pagliai, R. C., and Bartoletti, R. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int.J Antimicrob.Agents 2009;33(6):549-553. View abstract.

76398            Lichius, J. J., Lenz, C., Lindemann, P., Muller, H. H., Aumuller, G., and Konrad, L. Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP). Pharmazie 1999;54(10):768-771. View abstract.

76399            Randall, C., Meethan, K., Randall, H., and Dobbs, F. Nettle sting of Urtica dioica for joint pain–an exploratory study of this complementary therapy. Complement Ther Med 1999;7(3):126-131. View abstract.

76400            Klingelhoefer, S., Obertreis, B., Quast, S., and Behnke, B. Antirheumatic effect of IDS 23, a stinging nettle leaf extract, on in vitro expression of T helper cytokines. J Rheumatol. 1999;26(12):2517-2522. View abstract.

76401            Taskila, K., Saarinen, J. V., Harvima, I. T., and Harvima, R. J. Histamine and LTC4 in stinging nettle-induced urticaria. Allergy 2000;55(7):680-681. View abstract.

76402            Tahri, A., Yamani, S., Legssyer, A., Aziz, M., Mekhfi, H., Bnouham, M., and Ziyyat, A. Acute diuretic, natriuretic and hypotensive effects of a continuous perfusion of aqueous extract of Urtica dioica in the rat. J Ethnopharmacol 2000;73(1-2):95-100. View abstract.

76403            Koch, E. Extracts from Fruits of Saw Palmetto (Sabal serrulata) and Roots of Stinging Nettle (Urtica dioica): Viable Alternatives in the Medical Treatment of Benign Prostatic Hyperplasia and Associated Lower Urinary Tracts Symptoms. Planta Med 2001;67(6):489-500. View abstract.

76404            Balzarini, J., Neyts, J., Schols, D., Hosoya, M., Van Damme, E., Peumans, W., and De Clercq, E. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 1992;18(2):191-207. View abstract.

76405            Schneider, T. and Rubben, H. [Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months]. Urologe A 2004;43(3):302-306. View abstract.

76406            Safarinejad, M. R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J.Herb.Pharmacother. 2005;5(4):1-11. View abstract.

76407            Chrubasik, J. E., Roufogalis, B. D., Wagner, H., and Chrubasik, S. A. A comprehensive review on nettle effect and efficacy profiles, Part I: herba urticae. Phytomedicine. 2007;14(6):423-435. View abstract.

76408            Chrubasik, J. E., Roufogalis, B. D., Wagner, H., and Chrubasik, S. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7-8):568-579. View abstract.

76409            Lopatkin, N., Sivkov, A., Schlafke, S., Funk, P., Medvedev, A., and Engelmann, U. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms–long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int.Urol.Nephrol. 2007;39(4):1137-1146. View abstract.

76410            Sahin, M., Yilmaz, H., Gursoy, A., Demirel, A. N., Tutuncu, N. B., and Guvener, N. D. Gynaecomastia in a man and hyperoestrogenism in a woman due to ingestion of nettle (Urtica dioica). N.Z.Med.J. 2007;120(1265):U2803. View abstract.

76411            Francois, K. O., Auwerx, J., Schols, D., and Balzarini, J. Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development. Mol.Pharmacol. 2008;74(2):330-337. View abstract.

76412            Randall, C., Dickens, A., White, A., Sanders, H., Fox, M., and Campbell, J. Nettle sting for chronic knee pain: a randomised controlled pilot study. Complement Ther.Med. 2008;16(2):66-72. View abstract.

76413            Edgcumbe, D. P. and McAuley, D. Hypoglycaemia related to ingestion of a herbal remedy. Eur.J.Emerg.Med. 2008;15(4):236-237. View abstract.

76414            Rayburn, K., Fleischbein, E., Song, J., Allen, B., Kundert, M., Leiter, C., and Bush, T. Stinging nettle cream for osteoarthritis. Altern.Ther.Health Med. 2009;15(4):60-61. View abstract.

76415            Jacquet, A., Girodet, P. O., Pariente, A., Forest, K., Mallet, L., and Moore, N. Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial. Arthritis Res.Ther. 2009;11(6):R192. View abstract.

76416            Christensen, R. and Bliddal, H. Is Phytalgic(R) a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment. Arthritis Res.Ther. 2010;12(1):105. View abstract.

76417            Oliver, F., Amon, E. U., Breathnach, A., Francis, D. M., Sarathchandra, P., Black, A. K., and Greaves, M. W. Contact urticaria due to the common stinging nettle (Urtica dioica)– histological, ultrastructural and pharmacological studies. Clin Exp Dermatol. 1991;16(1):1-7. View abstract.

76418            Bercovich, E. and Saccomanni, M. Analysis of the results obtained with a new phytotherapeutic association for LUTS versus control. [corrected]. Urologia. 2010;77(3):180-186. View abstract.

76419            Uslu, S., Bulbul, A., Diler, B., Bas, E. K., and Nuhoglu, A. Urticaria due to Urtica dioica in a neonate. Eur.J.Pediatr. 2011;170(3):401-403. View abstract.

76420            Czarnetzki, B. M., Thiele, T., and Rosenbach, T. Immunoreactive leukotrienes in nettle plants (Urtica urens). Int Arch Allergy Appl.Immunol. 1990;91(1):43-46. View abstract.

76421            Huber, R., Bross, F., Schempp, C., and Grundemann, C. Arnica and stinging nettle for treating burns – a self-experiment. Complement Ther.Med. 2011;19(5):276-280. View abstract.

76422            Namazi, N., Esfanjani, A. T., Heshmati, J., and Bahrami, A. The effect of hydro alcoholic Nettle (Urtica dioica) extracts on insulin sensitivity and some inflammatory indicators in patients with type 2 diabetes: a randomized double-blind control trial. Pak.J.Biol.Sci. 8-1-2011;14(15):775-779. View abstract.

76423            Paydary, K., Emamzadeh-Fard, S., Khorram Khorshid, H. R., Kamali, K., SeyedAlinaghi, S., and Mohraz, M. Safety and efficacy of Setarud (IMOD TM ) among people living with HIV/AIDS: a review. Recent Pat Antiinfect.Drug Discov. 2012;7(1):66-72. View abstract.

76424            Namazi, N., Tarighat, A., and Bahrami, A. The effect of hydro alcoholic nettle (Urtica dioica) extract on oxidative stress in patients with type 2 diabetes: a randomized double-blind clinical trial. Pak.J.Biol.Sci. 1-15-2012;15(2):98-102. View abstract.

76425            Konieczynski, P. and Wesolowski, M. Water-extractable magnesium, manganese and copper in leaves and herbs of medicinal plants. Acta Pol.Pharm. 2012;69(1):33-39. View abstract.

76426            Maar, K. [Regression of the symptoms of prostatic adenomas. Results of 6 months’ conservative treatment using ERU capsules]. Fortschr.Med 1-10-1987;105(1):18-20. View abstract.

76427            Romics, I. Observations with Bazoton in the management of prostatic hyperplasia. Int Urol Nephrol 1987;19(3):293-297. View abstract.

76428            Kulze, A. and Greaves, M. Contact urticaria caused by stinging nettles. Br.J Dermatol. 1988;119(2):269-270. View abstract.

76429            Barlow, R. B. and Dixon, R. O. Choline acetyltransferase in the nettle Urtica dioica L. Biochem J 1973;132(1):15-18. View abstract.

76430            Hallwachs, O. [Urination disorders caused by prostatic hyperplasia. Effect of Bazoton, Harzol and Prosta-capsules]. MMW.Munch.Med Wochenschr. 10-30-1981;123(44):1675-1676. View abstract.

76431            Schmidt, K. [Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate hyperplasia]. Fortschr Med 4-21-1983;101(15):713-716. View abstract.

76432            Ziegler, H. [Fluorescence microscopic studies of prostate cells treated with Extract. radicis urticae]. Fortschr Med 12-1-1983;101(45):2112-2114. View abstract.

76433            Stahl, H. P. [Therapy of prostatic nycturia with standardized extractum radix urticae]. ZFA.(Stuttgart.) 1-31-1984;60(3):128-132. View abstract.

76434            Hirano, T., Homma, M., and Oka, K. Effects of stinging nettle root extracts and their steroidal components on the Na+,K(+)-ATPase of the benign prostatic hyperplasia. Planta Med 1994;60(1):30-33. View abstract.

76435            Hryb, D. J., Khan, M. S., Romas, N. A., and Rosner, W. The effect of extracts of the roots of the stinging nettle (Urtica dioica) on the interaction of SHBG with its receptor on human prostatic membranes. Planta Med 1995;61(1):31-32. View abstract.

76436            Randall, C. F. Stinging nettles for osteoarthritis pain of the hip. Br.J Gen.Pract. 1994;44(388):533-534. View abstract.

76437            Obertreis, B., Ruttkowski, T., Teucher, T., Behnke, B., and Schmitz, H. Ex-vivo in-vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha and interleukin-1 beta secretion in human whole blood by extractum urticae dioicae foliorum. Arzneimittelforschung 1996;46(4):389-394. View abstract.

76438            Obertreis, B., Giller, K., Teucher, T., Behnke, B., and Schmitz, H. [Anti-inflammatory effect of Urtica dioica folia extract in comparison to caffeic malic acid]. Arzneimittelforschung. 1996;46(1):52-56. View abstract.

76439            Hill, N., Stam, C., and van Haselen, R. A. The efficacy of Prrrikweg gel in the treatment of insect bites: a double-blind, placebo-controlled clinical trial. Pharm World Sci 1996;18(1):35-41. View abstract.

76440            Basaran, A. A., Yu, T. W., Plewa, M. J., and Anderson, D. An investigation of some Turkish herbal medicines in Salmonella typhimurium and in the COMET assay in human lymphocytes. Teratog.Carcinog.Mutagen. 1996;16(2):125-138. View abstract.

76441            Teucher, T., Obertreis, B., Ruttkowski, T., and Schmitz, H. [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. Arzneimittelforschung. 1996;46(9):906-910. View abstract.

76442            Barsom, S. and Bettermann, A. A. [Prostatic adenoma. The conservative therapy with urtica extract]. ZFA.(Stuttgart.) 11-30-1979;55(33):1947-1950. View abstract.

76443            Van der Weijden, G. A., Timmer, C. J., Timmerman, M. F., Reijerse, E., Mantel, M. S., and van, der, V. The effect of herbal extracts in an experimental mouthrinse on established plaque and gingivitis. J Clin Periodontol. 1998;25(5):399-403. View abstract.

76444            Riehemann, K., Behnke, B., and Schulze-Osthoff, K. Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kB. FEBS Lett 1-8-1999;442(1):89-94. View abstract.

76445            Broncano FJ. Estudio de efecto sobre musculatura lisa uterina de distintos preparados de las hojas de Urtica dioica L. An R Acad Farm 1987;53:69-76.

76446            Van Parijs J, Broekaert WF, and Peumans WJ. Urtica dioica agglutinin: a plant lectin with antifungal properties. Archives Internationales de Physiologie et de Biochimie 1988;96(1):31.

76447            Bombardelli E and Morazzoni P. Urtica dioica L. Fitoterapia 1997;68(5):387-402.

76448            Patten G. Medicinal plant review: Urtica. Aust J Med Herbalism 1993;5(1):5-13.

76449            Bauer HW, Sudhoff F, and Dressler S. Endocrine parameters during treatment of benign prostatic hyperplasia with ERU. Klin Exp Urol 1988;19:44-49.

76450            Dathe G and Schmid H. [Phytotherapy of the benign prostatic hyperplasia (BPH). Double-blind study with an extract of Radicus Urticae (ERU)]. Urologe B 1987;27:223-226.

76451            Djulepa J. [A two year study of prostatic syndrome: the results of a conservative treatment with Bazoton®]. Kanoldt Arzneimittel 1982;34(63):2199-2205.

76452            Engelmann U, Boos G, and Kres H. [Therapy of benign prostatic hyperplasia with Bazoton liquidum]. Urologe B 1996;36:287-291.

76453            Fischer M and Wilbert D. [Efficacy testing of a phytopharmacon in the treatment of benign prostate hyperplasia (BPH)]. In: Rutishauser G. Benigne Prostatahyperplasie. Munchen: Zuckerscherdt;1992.

76454            Ziegler H. Cytomorphological study of benign prostatic hyperplasia under treatment with extract. Radicis urticae (ERU) – preliminary results. Fortschr Med 1982;100(39):1832-1834.

76455            Chrubasik S, Enderlein W, Bauer R, and Grabner W. Evidence for antirheumatic effectiveness of Herba Urticae dioicae in acute arthritis: A pilot study. Phytomedicine 1997;4(2):105-108.

76456            Baraibar CB, Broncano FJ, Lazaro-Carrasco MJ, and et al. [Toxicity study of Urtica dioica L. nettle’s] . Anales de Bromatologia 1983;35(1):99-104.

76457            Schneider H, Honold E, and Masuhr T. Treatment of benign prostatic hyperplasia with a combination plant preparation. Results of an observational study of sabal extract WS 1473 and Urtica extract WS 1031 in the offices of urologists. Fortschr Med 1995;113(3):37-40.

76458            Sonnenschein R. [Efficacy testing of a prostatetropic phytopharmacon for benign prstate hyperpasia and prostatis]. Urologe [B] 1987;27:232-237.

76459            Ramos RR, Alarcon-Aguilar F, Lara-Lemus A, and et al. Hypoglycemic effect of plants used in Mexico as antidiabetics. Archives of Medical Research 1992;23(1):59-64.

76460            Goetz P. [Treatment of benign prostate hyperplasia with nettle roots]. Zeitschrift für Phytotherapie 1989;10:175-178.

76461            Hartmann RW, Mark M, and Soldati F. Inhibition of a 5 a-reductase and aromatase by PHL-00801 (Prostatonin®), a combination of PY102 (Pygeum africanum) and UR 102 (Urtica dioica) extracts. Phytomedicine 1996;3(2):121-128.

76462            Awang DV. Saw palmetto, African prune and stinging nettle for benign prostatic hyperplasia (BPH). Can Pharm J 1997;37-40, 43, 44, 62.

76463            Chaurasia N and Wichtl M. Sterols and steryl glycosides from Urtica dioica. Journal of Natural Products 1987;50(5):881-885.

76464            Wagner H, Willer F, Samtleben R, and et al. Search for the antiprostatic principle of stinging nettle (Urtica dioica) roots. Phytomedicine 1994;1:213-224.

76465            Gansser D and Spiteller G. Aromatase inhibitors from Urtica dioica roots. Planta Medica 1995;61:138-140.

76466            Kraus R, Spiteller G, and Bartsch W. [(10E,12Z)-9-Hydroxy-10,12-octadecadienoic acid, an aromatase inhibitor from roots of Urtica dioica]. Liebigs Ann Chem 1991;335-339.

76467            Wagner H, Geiger WN, Boos G, and et al. Studies on the binding of Urtica dioica agglutinin (UDA) and other lectins in an in vitro epidermal growth factor receptor test. Phytomedicine 1995;4:287-290.

76468            Koch E. Pharmacology and modes of action of extracts of palmetto fruit (sabal fructus), stinging nettle roots (urticae radix) and pumpkin seed (cucurbitae peponis semen) in the treatment of benign prostatic hyperplasia. In: Loew D and Rietbrock N. Phytopharm Forsch Klin Anwend. Darmstadt: Verlag Dietrich Steinkopf;1995.

76469            Scapanini U and Friesen A. Urtica-dioica-Extrakt und Folgesubstanzen im Tierversuch. Experimental protocol. 1-13.

455                 Nagao T, Ibayashi S, Fujii K, et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995;346:1104-5. View abstract.

456                 Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999;16:312-8. View abstract.

457                 Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994;15:s273-80. View abstract.

492                 Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999;9:315-8. View abstract.

512                 Robbers JE, Tyler VE. Tyler’s Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: The Haworth Herbal Press, 1999.

1357               Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington’s disease. Mov Disord 1996;11:321-3. View abstract.

2107               Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. Molec Aspects Med 1994;15:S241-8. View abstract.

2108               Watts TLP. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? Br Dent J 1995;178:209-13. View abstract.

2109               Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997;161:379-84. View abstract.

2110               Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? Int J Sport Nutr 1997;7:197-206. View abstract.

2121               Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247-51. View abstract.

2122               Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;S265-72. View abstract.

2123               Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991;176:786-91. View abstract.

2124               Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 1988;153:888-96. View abstract.

2125               Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41:584-8. View abstract.

2126               Andersen CB, Henriksen JE, Hother-Nielsen O, et al. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 1997;18 Suppl:S307-9. View abstract.

2127               Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta 1995;1271:281-6. View abstract.

2128               Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3. View abstract.

2134               Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608. View abstract.

2135               Lewin A, Lavon H. The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med 1997;18 Suppl:S213-9. View abstract.

3365               Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999;13:203-8. View abstract.

3366               Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-5. View abstract.

3367               Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6. View abstract.

3368               Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XV. Inhibition of coenzyme Q10 enzymes by clinically used adrenergic blockers of B-receptors. Res Commun Chem Pathol Pharmacol 1977;17:157-64. View abstract.

3369               Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10 enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975;12:533-40. View abstract.

3370               Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharm 2000;25:28-41.

3653               Bertelli A, Ronca G. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action. Int J Tissue React 1990;12:183-6. View abstract.

3993               Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-7. View abstract.

3995               Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-8. View abstract.

4404               Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4. View abstract.

4405               Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-44. View abstract.

4406               Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9. View abstract.

4407               De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA Reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7. View abstract.

4408               Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15:187-93. View abstract.

4409               Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7. View abstract.

4410               Hanaki Y, Sugiyama S, Ozawa T, et al. Coenzyme Q10 and coronary artery disease. Clin Investig 1993;71:112-5. View abstract.

4846               Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506-9. View abstract.

5090               Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40. View abstract.

5158               Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279-84. View abstract.

5159               Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 1998;43:505-6. View abstract.

5248               Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992;56:95-9. View abstract.

6037               Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52. View abstract.

6038               Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33. View abstract.

6047               Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:521-3. View abstract.

6048               Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7. View abstract.

6199               Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160:3226-7. View abstract.

6407               Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term, multicenter, randomized study. Clin Investig 1993;71:S134-6. View abstract.

6408               Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Card Fail 1995;1:101-7. View abstract.

6409               Baggio E, Gandini R, Plauncher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15 Suppl:S287-94. View abstract.

6410               Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 2nd ed. New York: Churchill Livingston, 1999.

7000               Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608. View abstract.

7722               Elsayed NM, Bendich A. Dietary antioxidants: potential effects on oxidative products in cigarette smoke. Nutr Res 2001;21:551-67.

8135               Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41. View abstract.

8159               Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-5. View abstract.

8160               Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-43. View abstract.

8161               Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-6. View abstract.

8162               Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-8. View abstract.

8163               Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-8. View abstract.

8907               Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001;94:1112-7. View abstract.

8908               Lonnrot K, Porsti I, Alho H, et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998;124:1500-6. View abstract.

8909               Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18:S159-68. View abstract.

8910               Mortensen SA. Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. JACC 2000;36:304-5. View abstract.

8911               Bonetti A, Solito F, Carmosino G, et al. Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects. J Sports Med Phys Fitness 2000;40:51-7. View abstract.

8912               Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-55. View abstract.

8913               Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8. View abstract.

8914               de Rijke YB, Bredie SJ, Demacker PN, et al. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:127-33. View abstract.

8915               Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001;142:E2. View abstract.

8916               Iwamoto Y, Nakamura R, Folkers K, Morrison RF. Study of periodontal disease and coenzyme Q. Res Commun Chem Pathol Pharmacol 1975;11:265-71. View abstract.

8917               Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975;12:111-23. View abstract.

8918               Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1976;14:715-9. View abstract.

8938               Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50. View abstract.

8939               Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-5. View abstract.

8940               The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001;57:397-404. View abstract.

8941               Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 2002;22:1592-9.. View abstract.

8958               Pepping J. Coenzyme Q10. Am J Health-Syst Pharm 1999;56:519-21. View abstract.

8959               Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: Yamamura Y, Folkers K, Ito Y (eds). Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier/North-Holland Biomedical Press 1980;2:139-54.

9603               Bertelli A, Cerrati A, Giovannini L, et al. Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol. Drugs Exp Clin Res 1993;19:65-8.. View abstract.

9890               Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-42.. View abstract.

10152            Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003;246:75-82. View abstract.

11031            Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997;18 Suppl:S145-51. View abstract.

11048            Porterfield LM. Why did the response to warfarin change? RN 2000;63:107. View abstract.

11049            Joshi SS, Sawant SV, Shedge A, Halpner AD. Comparative bioavailability of two novel coenzyme Q10 preparations in humans. Int J Clin Pharmacol Ther 2003;41:42-8. View abstract.

11050            Berbel-Garcia A, Barbera-Farre JR, Etessam JP, ET AL. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004;27:187-91. View abstract.

11416            Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. J Inherit Metab Dis 2001;24:28-34. View abstract.

11421            Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36:73-82. . View abstract.

11427            Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm 1998;54:301-10. View abstract.

11872            Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-5. View abstract.

11873            FDA. List of Orphan Designations and Approvals. http://www.fda.gov/orphan/DESIGNAT/list.htm (Accessed 19 June 2004).

11877            Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-79. View abstract.

11892            Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99. View abstract.

11893            American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003;9:417-70. View abstract.

11894            Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21:797-806. View abstract.

11895            Ishii N, Senoo-Matsuda N, Miyake K, et al. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004;125:41-6. View abstract.

11896            Lee CK, Pugh TD, Klopp RG, et al. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. Free Radic Biol Med 2004;36:1043-57. View abstract.

11897            Welch KM. Current opinions in headache pathogenesis: introduction and synthesis. Curr Opin Neurol 1998;11:193-7. View abstract.

11898            Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. View abstract.

11899            Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91. View abstract.

11900            Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3. View abstract.

11902            Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996;37:229-35. View abstract.

11903            Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994;58:1427-32. View abstract.

11904            Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg 1996;61:829-33. View abstract.

11905            Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-6. View abstract.

12099            Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-92.. View abstract.

12169            Balercia G, Mosca F, Mantero F, et al. Coenzyme Q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004;81:93-8. View abstract.

12170            Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004;27:295–9. View abstract.

12199            Elshershari H, Ozer S, Ozkutlu S, Ozme S. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Int J Cardiol 2003;88:101-2. View abstract.

13223            Soongswang J, Sangtawesin C, Durongpisitkul K, et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol 2005;26:361-6. View abstract.

14412            Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000;302:1-9. View abstract.

14413            Zhou Q, Chowbay B. Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet 2002;27:185-92. View abstract.

15115            Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006;29:703-12. View abstract.

15255            The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8. View abstract.

15256            Hershey AD, Powers SW, Vockell AB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent Migraine. Headache 2007;47:73-80. View abstract.

15395            Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64:938-44. View abstract.

16008            Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12. View abstract.

16009            Marcoff L, Thompson, PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7. View abstract.

17201            Teran E, Hernandez I, Nieto B, et al. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 2009;105:43-5. View abstract.

17413            Safarinejad MR. Efficacy of coenzyme Q-10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182:237-48. View abstract.

17650            Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994;15 Suppl:s257-63. View abstract.

17651            Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. In: Folkers KA, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5. Amsterdam: Elsevier Science Publications, 1986:337-43.

17702            Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension (review). Cochrane Database Syst Rev 2009;(4):CD007435. View abstract.

17703            Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010;10:10. View abstract.

17704            Lee YJ, Cho WJ, Kim JK, Lee DC. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011;14:386-90. View abstract.

17705            Cordero MD, Moreno-Fernandez AM, deMiguel M, et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem 2009;42:732-5. View abstract.

17716            Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30:195-9. View abstract.

19206            Galasko D. R., Peskind E., Clark C. M., Quinn J. F., Ringman J. M., Jicha G. A., Cotman C., Cottrell B., Montine T. J., Thomas R. G., Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69(7):836-841. View abstract.

21651            Leong J. Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ 2010;19(10):584-591. View abstract.

30889            Palacka, P., Kucharska, J., Murin, J., Dostalova, K., Okkelova, A., Cizova, M., Waczulikova, I., Moricova, S., and Gvozdjakova, A. Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl.Lek.Listy 2010;111(4):205-211. View abstract.

30915            Pfeffer, G., Majamaa, K., Turnbull, D. M., Thorburn, D., and Chinnery, P. F. Treatment for mitochondrial disorders. Cochrane Database.Syst.Rev. 2012;4:CD004426. View abstract.

34283            Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv.Ther 2011;28(12):1105-1113. View abstract.

37528            Schiapparelli, P., Allais, G., Castagnoli, Gabellari, I, Rolando, S., Terzi, M. G., and Benedetto, C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol.Sci. 2010;31 Suppl 1:S137-S139. View abstract.

37534            Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806. View abstract.

42069            Nahas, R. Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review. Can.Fam.Physician 2008;54(11):1529-1533. View abstract.

43894            Abe, K., Matsuo, Y., Kadekawa, J., Inoue, S., and Yanagihara, T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol.Sci. 1-1-1999;162(1):65-68. View abstract.

43895            Barbiroli, B., Iotti, S., Cortelli, P., Martinelli, P., Lodi, R., Carelli, V., and Montagna, P. Low brain intracellular free magnesium in mitochondrial cytopathies. J Cereb.Blood Flow Metab 1999;19(5):528-532. View abstract.

43896            Nielsen, A. N., Mizuno, M., Ratkevicius, A., Mohr, T., Rohde, M., Mortensen, S. A., and Quistorff, B. No effect of antioxidant supplementation in triathletes on maximal oxygen uptake, 31P-NMRS detected muscle energy metabolism and muscle fatigue. Int J Sports Med 1999;20(3):154-158. View abstract.

43897            Blatt, T., Mundt, C., Mummert, C., Maksiuk, T., Wolber, R., Keyhani, R., Schreiner, V., Hoppe, U., Schachtschabel, D. O., and Stab, F. [Modulation of oxidative stresses in human aging skin]. Z.Gerontol.Geriatr. 1999;32(2):83-88. View abstract.

43898            Zhou, M., Zhi, Q., Tang, Y., Yu, D., and Han, J. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J Cardiovasc.Surg.(Torino) 1999;40(3):355-361. View abstract.

43899            Lopez-Lluch, G., Barroso, M. P., Martin, S. F., Fernandez-Ayala, D. J., Gomez-Diaz, C., Villalba, J. M., and Navas, P. Role of plasma membrane coenzyme Q on the regulation of apoptosis. Biofactors 1999;9(2-4):171-177. View abstract.

43900            Tomasetti, M., Alleva, R., Solenghi, M. D., and Littarru, G. P. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999;9(2-4):231-240. View abstract.

43901            Barbiroli, B., Iotti, S., and Lodi, R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 1999;9(2-4):253-260. View abstract.

43902            Shults, C. W., Haas, R. H., and Beal, M. F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors 1999;9(2-4):267-272. View abstract.

43903            Langsjoen, P. H. and Langsjoen, A. M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999;9(2-4):273-284. View abstract.

43904            Munkholm, H., Hansen, H. H., and Rasmussen, K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2-4):285-289. View abstract.

43905            Sacher, H. L., Sacher, M. L., Landau, S. W., Kersten, R., Dooley, F., Sacher, A., Sacher, M., Dietrick, K., and Ichkhan, K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther 1997;4(2-3):66-72. View abstract.

43906            Kogan, A. K., Syrkin, A. L., Drinitsina, S. V., and Kokanova, I. V. [The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort]. Patol.Fiziol.Eksp.Ter. 1999;4(4):16-19. View abstract.

43907            Portakal, O. and Inal-Erden, M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. Clin Biochem 1999;32(6):461-466. View abstract.

43908            Kaikkonen, J., Nyyssonen, K., Tomasi, A., Iannone, A., Tuomainen, T. P., Porkkala-Sarataho, E., and Salonen, J. T. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic.Res 2000;33(3):329-340. View abstract.

43909            Sinatra, S. T. Coenzyme Q10 and congestive heart failure. Ann.Intern.Med 11-7-2000;133(9):745-746. View abstract.

43910            Gottlieb, S. S., Khatta, M., and Fisher, M. L. Coenzyme Q10 and Congestive Heart Failure. Ann.Intern.Med 11-7-2000;133(9):745-746. View abstract.

43911            Del Mar, C. B., Glasziou, P. P., Spinks, A. B., and Sanders, S. L. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 4-16-2001;174(8):421. View abstract.

43912            Lodi, R., Hart, P. E., Rajagopalan, B., Taylor, D. J., Crilley, J. G., Bradley, J. L., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann.Neurol. 2001;49(5):590-596. View abstract.

43913            Gazdikova, K., Gvozdjakova, A., Kucharska, J., Spustova, V., Braunova, Z., and Dzurik, R. [Effect of coenzyme Q10 in patients with kidney diseases]. Cas.Lek.Cesk. 5-24-2001;140(10):307-310. View abstract.

43914            Strong, M. J. and Pattee, G. L. Creatine and coenzyme Q10 in the treatment of ALS. Amyotroph.Lateral.Scler.Other Motor Neuron Disord 2000;1(suppl 4):17-20. View abstract.

43915            Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol.Pharmacol 1975;11(2):273-288. View abstract.

43916            Watson, P. S., Scalia, G. M., Gaibraith, A. J., Burstow, D. J., Aroney, C. N., and Bett, J. H. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448. View abstract.

43917            Vitetta, L., Sali, A., and Reavley, N. J. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448. View abstract.

43918            Gutzmann, H., Kuhl, K. P., Hadler, D., and Rapp, M. A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35(1):12-18. View abstract.

43919            Miquel, J. Can antioxidant diet supplementation protect against age-related mitochondrial damage? Ann N Y.Acad Sci 2002;959:508-516. View abstract.

43920            Rosenfeldt, F. L., Pepe, S., Linnane, A., Nagley, P., Rowland, M., Ou, R., Marasco, S., and Lyon, W. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. Biogerontology. 2002;3(1-2):37-40. View abstract.

43921            Linnane, A. W., Kopsidas, G., Zhang, C., Yarovaya, N., Kovalenko, S., Papakostopoulos, P., Eastwood, H., Graves, S., and Richardson, M. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic.Res 2002;36(4):445-453. View abstract.

43922            Jeejeebhoy, F., Keith, M., Freeman, M., Barr, A., McCall, M., Kurian, R., Mazer, D., and Errett, L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 2002;143(6):1092-1100. View abstract.

43923            Kurowska, E. M., Dresser, G., Deutsch, L., Bassoo, E., and Freeman, D. J. Relative bioavailability and antioxidant potential of two coenzyme q10 preparations. Ann.Nutr.Metab 2003;47(1):16-21. View abstract.

43924            Muller, T., Buttner, T., Gholipour, A. F., and Kuhn, W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci.Lett. 5-8-2003;341(3):201-204. View abstract.

43925            Singh, R. B., Kartikey, K., Charu, A. S., Niaz, M. A., and Schaffer, S. Effect of taurine and coenzyme Q10 in patients with acute myocardial infarction. Adv.Exp.Med.Biol. 2003;526:41-48. View abstract.

43926            Beyer, R. E. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 1992;70(6):390-403. View abstract.

43927            Snider, I. P., Bazzarre, T. L., Murdoch, S. D., and Goldfarb, A. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int J Sport Nutr 1992;2(3):272-286. View abstract.

43928            Disdier, P., Harle, J. R., Figarella-Branger, D., Cherif, A. A., Desnuelle, C., and Weiller, P. J. [Ptosis and asthenia manifesting a mitochondrial myopathy]. Rev Med Interne 1992;13(5):381-383. View abstract.

43929            Hanisch, F. and Zierz, S. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. Eur.J Med.Res 11-12-2003;8(11):485-491. View abstract.

43930            Shults, C. W. Treatments of Parkinson disease: circa 2003. Arch.Neurol. 2003;60(12):1680-1684. View abstract.

43931            Migliore, L., Molinu, S., Naccarati, A., Mancuso, M., Rocchi, A., and Siciliano, G. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004;19(1):43-49. View abstract.

43932            Rosenfeldt, F., Hilton, D., Pepe, S., and Krum, H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18(1-4):91-100. View abstract.

43933            Shults, C. W., Flint, Beal M., Song, D., and Fontaine, D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp.Neurol. 2004;188(2):491-494. View abstract.

43934            Aure, K., Benoist, J. F., Ogier, de Baulny, Romero, N. B., Rigal, O., and Lombes, A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 8-24-2004;63(4):727-729. View abstract.

43935            Damian, M. S., Ellenberg, D., Gildemeister, R., Lauermann, J., Simonis, G., Sauter, W., and Georgi, C. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 11-9-2004;110(19):3011-3016. View abstract.

43936            Silver, M. A., Langsjoen, P. H., Szabo, S., Patil, H., and Zelinger, A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 11-15-2004;94(10):1306-1310. View abstract.

43937            Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., Esmore, D., Davis, B., Pick, A., Rabinov, M., Smith, J., Nagley, P., and Pepe, S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac.Cardiovasc.Surg. 2005;129(1):25-32. View abstract.

43938            van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev 2005;(1):CD003917. View abstract.

43939            Carli, F., Chiellini, E. E., Bellich, B., Macchiavelli, S., and Cadelli, G. Ubidecarenone nanoemulsified composite systems. Int J Pharm 3-3-2005;291(1-2):113-118. View abstract.

43940            Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., and Rotrosen, J. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:43-57. View abstract.

43941            Forgionne, G. A. Bovine cartilage, coenzyme Q10, and wheat grass therapy for primary peritoneal cancer. J Altern.Complement Med 2005;11(1):161-165. View abstract.

43942            Hoenjet, K. M., Dagnelie, P. C., Delaere, K. P., Wijckmans, N. E., Zambon, J. V., and Oosterhof, G. O. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005;47(4):433-439. View abstract.

43943            Hart, P. E., Lodi, R., Rajagopalan, B., Bradley, J. L., Crilley, J. G., Turner, C., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch.Neurol. 2005;62(4):621-626. View abstract.

43944            Bentler, S. E., Hartz, A. J., and Kuhn, E. M. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry 2005;66(5):625-632. View abstract.

43945            Cicero, A. F., Derosa, G., Miconi, A., Laghi, L., Nascetti, S., and Gaddi, A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 2005;59(6):312-317. View abstract.

43946            Feher, J., Kovacs, B., Kovacs, I., Schveoller, M., Papale, A., and Balacco, Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005;219(3):154-166. View abstract.

43947            Maeda, K., Tatsumi, M., Tahara, M., Murata, Y., Kawai, H., and Yasuda, H. [A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone]. Rinsho Shinkeigaku 2005;45(6):416-421. View abstract.

43948            Mancini, A., Milardi, D., Conte, G., Festa, R., De Marinis, L., and Littarru, G. P. Seminal antioxidants in humans: preoperative and postoperative evaluation of coenzyme Q10 in varicocele patients. Horm.Metab Res 2005;37(7):428-432. View abstract.

43949            Witte, K. K., Nikitin, N. P., Parker, A. C., von Haehling, S., Volk, H. D., Anker, S. D., Clark, A. L., and Cleland, J. G. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005;26(21):2238-2244. View abstract.

43950            Salviati, L., Sacconi, S., Murer, L., Zacchello, G., Franceschini, L., Laverda, A. M., Basso, G., Quinzii, C., Angelini, C., Hirano, M., Naini, A. B., Navas, P., DiMauro, S., and Montini, G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 8-23-2005;65(4):606-608. View abstract.

43951            Zaffanello, M. and Zamboni, G. Therapeutic approach in a case of Pearson’s syndrome. Minerva Pediatr 2005;57(3):143-146. View abstract.

43952            Ullmann, U., Metzner, J., Schulz, C., Perkins, J., and Leuenberger, B. A new Coenzyme Q10 tablet-grade formulation (all-Q) is bioequivalent to Q-Gel and both have better bioavailability properties than Q-SorB. J Med.Food 2005;8(3):397-399. View abstract.

43953            Zhou, S., Zhang, Y., Davie, A., Marshall-Gradisnik, S., Hu, H., Wang, J., and Brushett, D. Muscle and plasma coenzyme Q10 concentration, aerobic power and exercise economy of healthy men in response to four weeks of supplementation. J Sports Med Phys.Fitness 2005;45(3):337-346. View abstract.

43954            Salles, J. E., Moises, V. A., Almeida, D. R., Chacra, A. R., and Moises, R. S. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 2006;72(1):100-103. View abstract.

43955            Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O’Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O’Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B., and Cudkowicz, M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 12-13-2005;65(11):1834-1836. View abstract.

43956            Mohr, D., Bowry, V. W., and Stocker, R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 6-26-1992;1126(3):247-254. View abstract.

43957            Horvath, R., Schneiderat, P., Schoser, B. G., Gempel, K., Neuen-Jacob, E., Ploger, H., Muller-Hocker, J., Pongratz, D. E., Naini, A., DiMauro, S., and Lochmuller, H. Coenzyme Q10 deficiency and isolated myopathy. Neurology 1-24-2006;66(2):253-255. View abstract.

43958            Chinnery, P., Majamaa, K., Turnbull, D., and Thorburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst.Rev. 2006;(1):CD004426. View abstract.

43959            Rusciani, L., Proietti, I., Rusciani, A., Paradisi, A., Sbordoni, G., Alfano, C., Panunzi, S., De Gaetano, A., and Lippa, S. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54(2):234-241. View abstract.

43960            Tawankanjanachot, I., Channarong, N. S., and Phanthumchinda, K. Auditory symptoms: a critical clue for diagnosis of MELAS. J Med Assoc Thai. 2005;88(11):1715-1720. View abstract.

43961            Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A., Arbing, R., Battista, V., Zhou, X., Mitsumoto, H., Levin, B., and Thompson, J. L. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 3-14-2006;66(5):660-663. View abstract.

43962            Artuch, R., Brea-Calvo, G., Briones, P., Aracil, A., Galvan, M., Espinos, C., Corral, J., Volpini, V., Ribes, A., Andreu, A. L., Palau, F., Sanchez-Alcazar, J. A., Navas, P., and Pineda, M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol.Sci 7-15-2006;246(1-2):153-158. View abstract.

43963            Hirano, M., Quinzii, C. M., and DiMauro, S. Restoring balance to ataxia with coenzyme Q10 deficiency. J Neurol.Sci 7-15-2006;246(1-2):11-12. View abstract.

43964            Miles, M. V., Patterson, B. J., Schapiro, M. B., Hickey, F. J., Chalfonte-Evans, M., Horn, P. S., and Hotze, S. L. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr Neurol. 2006;35(1):30-37. View abstract.

43965            Belaia, O. L., Kalmykova, V. I., Ivanova, L. A., and Kochergina, L. G. [Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia]. Klin Med (Mosk) 2006;84(5):59-62. View abstract.

43966            Islam, J., Uretsky, B. F., and Sierpina, V. S. Heart failure improvement with CoQ10, Hawthorn, and magnesium in a patient scheduled for cardiac resynchronization-defibrillator therapy: a case study. Explore.(NY) 2006;2(4):339-341. View abstract.

43967            Belardinelli, R., Mucaj, A., Lacalaprice, F., Solenghi, M., Principi, F., Tiano, L., and Littarru, G. P. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005;25(1-4):137-145. View abstract.

43968            Singh, R. B., Niaz, M. A., Kumar, A., Sindberg, C. D., Moesgaard, S., and Littarru, G. P. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors 2005;25(1-4):219-224. View abstract.

43969            Gvozdjakova, A., Kucharska, J., Bartkovjakova, M., Gazdikova, K., and Gazdik, F. E. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25(1-4):235-240. View abstract.

43970            Kang, H. C., Kim, H. D., Lee, Y. M., and Han, S. H. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr.Neurol. 2006;35(2):158-161. View abstract.

43971            Belardinelli, R., Mucaj, A., Lacalaprice, F., Solenghi, M., Seddaiu, G., Principi, F., Tiano, L., and Littarru, G. P. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006;27(22):2675-2681. View abstract.

43972            Ramelli, G. P., Gallati, S., Weis, J., Krahenbuhl, S., and Burgunder, J. M. Point mutation tRNA(Ser(UCN)) in a child with hearing loss and myoclonus epilepsy. J Child Neurol. 2006;21(3):253-255. View abstract.

43973            Sander, S., Coleman, C. I., Patel, A. A., Kluger, J., and White, C. M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12(6):464-472. View abstract.

43974            Donovan, L. E. and Severin, N. E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol.Metab 2006;91(12):4737-4742. View abstract.

43975            Galili, N., Sechman, E. V., Cerny, J., Mehdi, M., Mumtaz, M., Westervelt, P., Maguire, J., and Raza, A. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. Leuk.Res 2007;31(1):19-26. View abstract.

43976            Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., and Tarnopolsky, M. A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235-242. View abstract.

43977            Letsas, K. P., Efremidis, M., Pappas, L. K., Gavrielatos, G., Sideris, A., and Charitos, C. Pathophysiology and management of syncope in Kearns-Sayre syndrome. Am Heart Hosp.J 2006;4(4):301-302. View abstract.

43978            Nishino, M., Usami, M., Sugimura, S., and Yoshizaki, S. [Case of drug-induced pneumonitis associated with a dietary supplement containing CoQ10]. Nihon Kokyuki.Gakkai Zasshi 2006;44(10):766-770. View abstract.

43979            Schulz, C., Obermuller-Jevic, U. C., Hasselwander, O., Bernhardt, J., and Biesalski, H. K. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Int J Food Sci Nutr 2006;57(7-8):546-555. View abstract.

43980            Lopez, L. C., Schuelke, M., Quinzii, C. M., Kanki, T., Rodenburg, R. J., Naini, A., DiMauro, S., and Hirano, M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum.Genet. 2006;79(6):1125-1129. View abstract.

43981            Khan, M., Gross, J., Haupt, H., Jainz, A., Niklowitz, P., Scherer, H., Schmidt, F. P., Klapp, B. F., Reisshauer, A., and Mazurek, B. A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol.Head Neck Surg 2007;136(1):72-77. View abstract.

43982            Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J. Y., and Watts, G. F. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum.Hypertens. 2007;21(4):297-306. View abstract.

43983            Folkers, K., Langsjoen, P., and Langsjoen, P. H. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys.Res Commun. 1-15-1992;182(1):247-253. View abstract.

43984            Shah, S. A., Sander, S., Cios, D., Lipeika, J., Kluger, J., and White, C. M. Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial. Ann Pharmacother 2007;41(3):420-425. View abstract.

43985            Geng, A., Li, B., and Guo, Y. Effects of dietary L-carnitine and coenzyme Q10 at different supplemental ages on growth performance and some immune response in ascites-susceptible broilers. Arch.Anim Nutr. 2007;61(1):50-60. View abstract.

43986            Keith, M., Mazer, C. D., Mikhail, P., Jeejeebhoy, F., Briet, F., and Errett, L. Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation. Nutr Metab Cardiovasc.Dis. 2008;18(2):105-111. View abstract.

43987            Niklowitz, P., Sonnenschein, A., Janetzky, B., Andler, W., and Menke, T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci 2007;3(4):257-262. View abstract.

43988            Rusciani, L., Proietti, I., Paradisi, A., Rusciani, A., Guerriero, G., Mammone, A., De Gaetano, A., and Lippa, S. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res 2007;17(3):177-183. View abstract.

43989            Storch, A. [Coenzyme Q10 in Parkinson’s disease. Symptomatic or neuroprotective effects?]. Nervenarzt 2007;78(12):1378-1382. View abstract.

43990            Papas, K. A., Sontag, M. K., Pardee, C., Sokol, R. J., Sagel, S. D., Accurso, F. J., and Wagener, J. S. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst.Fibros. 2008;7(1):60-67. View abstract.

43991            Tiano, L., Belardinelli, R., Carnevali, P., Principi, F., Seddaiu, G., and Littarru, G. P. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur.Heart J 2007;28(18):2249-2255. View abstract.

43992            Yuvaraj, S., Premkumar, V. G., Vijayasarathy, K., Gangadaran, S. G., and Sachdanandam, P. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin. Cancer Chemother.Pharmacol 2008;61(6):933-941. View abstract.

43993            Tsujita, Y., Kunitomo, T., Fujii, M., Furukawa, S., Otsuki, H., Fujino, K., Hamamoto, T., Tabata, T., Matsumura, K., Sasaki, T., Saotome, T., Kawai, H., Matsumoto, T., Maeda, K., Horie, M., and Eguchi, Y. A surviving case of mitochondrial cardiomyopathy diagnosed from the symptoms of multiple organ dysfunction syndrome. Int J Cardiol. 8-1-2008;128(1):e43-e45. View abstract.

43994            Satta, A., Grandi, M., Landoni, C. V., Migliori, G. B., Spanevello, A., Vocaturo, G., and Neri, M. Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. Clin Ther. 1991;13(6):754-757. View abstract.

43995            Tekle, M., Turunen, M., Dallner, G., Chojnacki, T., and Swiezewska, E. Investigation of coenzyme Q biosynthesis in human fibroblast and HepG2 cells. J Biochem Biophys Methods 4-24-2008;70(6):909-917. View abstract.

43996            Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol.Sci 4-15-2008;267(1-2):66-69. View abstract.

43997            Myers, L., Farmer, J. M., Wilson, R. B., Friedman, L., Tsou, A., Perlman, S. L., Subramony, S. H., Gomez, C. M., Ashizawa, T., Wilmot, G. R., Mathews, K. D., Balcer, L. J., and Lynch, D. R. Antioxidant use in Friedreich ataxia. J Neurol.Sci 4-15-2008;267(1-2):174-176. View abstract.

43998            Schallreuter, K. U., Rokos, H., Chavan, B., Gillbro, J. M., Cemeli, E., Zothner, C., Anderson, D., and Wood, J. M. Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells. Free Radic.Biol Med 2-15-2008;44(4):538-546. View abstract.

43999            Lu, C., Zhang, D., Whiteman, M., and Armstrong, J. S. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid.Redox.Signal. 2008;10(3):651-660. View abstract.

44000            Mizushina, Y., Takeuchi, T., Takakusagi, Y., Yonezawa, Y., Mizuno, T., Yanagi, K., Imamoto, N., Sugawara, F., Sakaguchi, K., Yoshida, H., and Fujita, M. Coenzyme Q10 as a potent compound that inhibits Cdt1-geminin interaction. Biochim.Biophys.Acta 2008;1780(2):203-213. View abstract.

44001            Lim, S. C., Lekshminarayanan, R., Goh, S. K., Ong, Y. Y., Subramaniam, T., Sum, C. F., Ong, C. N., and Lee, B. L. The effect of coenzyme Q10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus. Atherosclerosis 2008;196(2):966-969. View abstract.

44002            Yang, X., Yang, Y., Li, G., Wang, J., and Yang, E. S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol.Neurosci. 2008;34(2):165-171. View abstract.

44003            Pineda, M., Arpa, J., Montero, R., Aracil, A., Dominguez, F., Galvan, M., Mas, A., Martorell, L., Sierra, C., Brandi, N., Garcia-Arumi, E., Rissech, M., Velasco, D., Costa, J. A., and Artuch, R. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr.Neurol. 2008;12(6):470-475. View abstract.

44004            Senes, M., Erbay, A. R., Yilmaz, F. M., Topkaya, B. C., Zengi, O., Dogan, M., and Yucel, D. Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy. Clin Chem.Lab Med 2008;46(3):382-386. View abstract.

44005            Eiholzer, U., Meinhardt, U., Rousson, V., Petrovic, N., Schlumpf, M., and l’Allemand, D. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet.A 4-1-2008;146(7):873-880. View abstract.

44006            Mizuno, K., Tanaka, M., Nozaki, S., Mizuma, H., Ataka, S., Tahara, T., Sugino, T., Shirai, T., Kajimoto, Y., Kuratsune, H., Kajimoto, O., and Watanabe, Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008;24(4):293-299. View abstract.

44007            Kon, M., Tanabe, K., Akimoto, T., Kimura, F., Tanimura, Y., Shimizu, K., Okamoto, T., and Kono, I. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr 2008;100(4):903-909. View abstract.

44008            Miles, M. V., Miles, L., Tang, P. H., Horn, P. S., Steele, P. E., Degrauw, A. J., Wong, B. L., and Bove, K. E. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion. 2008;8(2):170-180. View abstract.

44009            Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic.Res 2008;42(3):221-225. View abstract.

44010            Bentinger, M., Tekle, M., Brismar, K., Chojnacki, T., Swiezewska, E., and Dallner, G. Polyisoprenoid epoxides stimulate the biosynthesis of coenzyme Q and inhibit cholesterol synthesis. J Biol.Chem 5-23-2008;283(21):14645-14653. View abstract.

44011            Montero, R., Sanchez-Alcazar, J. A., Briones, P., Hernandez, A. R., Cordero, M. D., Trevisson, E., Salviati, L., Pineda, M., Garcia-Cazorla, A., Navas, P., and Artuch, R. Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes. Clin Biochem. 2008;41(9):697-700. View abstract.

44012            LeWitt, P. A. and Taylor, D. C. Protection against Parkinson’s disease progression: clinical experience. Neurotherapeutics. 2008;5(2):210-225. View abstract.

44013            Balercia, G., Buldreghini, E., Vignini, A., Tiano, L., Paggi, F., Amoroso, S., Ricciardo-Lamonica, G., Boscaro, M., Lenzi, A., and Littarru, G. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil.Steril. 2009;91(5):1785-1792. View abstract.

44014            Menke, T. [Coenzyme q10 in childhood: detection methods, reference values and disease-related changes in the coenzyme q10 status]. Georgian.Med News 2008;(156):24-32. View abstract.

44015            Premkumar, V. G., Yuvaraj, S., Sathish, S., Shanthi, P., and Sachdanandam, P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul.Pharmacol. 2008;48(4-6):191-201. View abstract.

44016            van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2008;(2):CD003917. View abstract.

44017            Santa-Mara, I., Santpere, G., MacDonald, M. J., Gomez de, Barreda E., Hernandez, F., Moreno, F. J., Ferrer, I., and Avila, J. Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. J Neuropathol.Exp.Neurol. 2008;67(5):428-434. View abstract.

44018            Braun, B., Clarkson, P. M., Freedson, P. S., and Kohl, R. L. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. Int J Sport Nutr. 1991;1(4):353-365. View abstract.

44019            Voronkova, K. V. and Meleshkov, M. N. [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. Zh.Nevrol.Psikhiatr.Im S.S.Korsakova 2008;108(4):27-32. View abstract.

44020            Stamelou, M., Reuss, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade-Brittinger, C., Oertel, W. H., and Hoglinger, G. U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 5-15-2008;23(7):942-949. View abstract.

44021            Pepe, S., Leong, J. Y., Van der Merwe, J., Marasco, S. F., Hadj, A., Lymbury, R., Perkins, A., and Rosenfeldt, F. L. Targeting oxidative stress in surgery: effects of ageing and therapy. Exp.Gerontol. 2008;43(7):653-657. View abstract.

44022            Casarin, A., Jimenez-Ortega, J. C., Trevisson, E., Pertegato, V., Doimo, M., Ferrero-Gomez, M. L., Abbadi, S., Artuch, R., Quinzii, C., Hirano, M., Basso, G., Ocana, C. S., Navas, P., and Salviati, L. Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. Biochem.Biophys.Res Commun. 7-18-2008;372(1):35-39. View abstract.

44023            Chew, G. T., Watts, G. F., Davis, T. M., Stuckey, B. G., Beilin, L. J., Thompson, P. L., Burke, V., and Currie, P. J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31(8):1502-1509. View abstract.

44024            Harinstein, M. E., Berliner, J. I., Shah, S. J., Taegtmeyer, H., and Gheorghiade, M. Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients. Am J Ther 2008;15(3):206-213. View abstract.

44025            Gille, L., Rosenau, T., Kozlov, A. V., and Gregor, W. Ubiquinone and tocopherol: dissimilar siblings. Biochem.Pharmacol 8-1-2008;76(3):289-302. View abstract.

44026            Gruber, J., Schaffer, S., and Halliwell, B. The mitochondrial free radical theory of ageing–where do we stand? Front Biosci 2008;13:6554-6579. View abstract.

44027            Sakata, T., Furuya, R., Shimazu, T., Odamaki, M., Ohkawa, S., and Kumagai, H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4):371-378. View abstract.

44028            Ravina, B., Romer, M., Constantinescu, R., Biglan, K., Brocht, A., Kieburtz, K., Shoulson, I., and McDermott, M. P. The relationship between CAG repeat length and clinical progression in Huntington’s disease. Mov Disord. 7-15-2008;23(9):1223-1227. View abstract.

44029            Laguna, T. A., Sontag, M. K., Osberg, I., Wagener, J. S., Accurso, F. J., and Sokol, R. J. Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis. J Pediatr 2008;153(3):402-407. View abstract.

44030            Lekli, I., Das, S., Das, S., Mukherjee, S., Bak, I., Juhasz, B., Bagchi, D., Trimurtulu, G., Krishnaraju, A. V., Sengupta, K., Tosaki, A., and Das, D. K. Coenzyme Q9 provides cardioprotection after converting into coenzyme Q10. J Agric.Food Chem. 7-9-2008;56(13):5331-5337. View abstract.

44031            Sunamori, M., Tanaka, H., Maruyama, T., Sultan, I., Sakamoto, T., and Suzuki, A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc.Drugs Ther 1991;5 Suppl 2:297-300. View abstract.

44032            Belanger, M. C., Mirault, M. E., Dewailly, E., Berthiaume, L., and Julien, P. Environmental contaminants and redox status of coenzyme Q10 and vitamin E in Inuit from Nunavik. Metabolism 2008;57(7):927-933. View abstract.

44033            Wadsworth, T. L., Bishop, J. A., Pappu, A. S., Woltjer, R. L., and Quinn, J. F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer’s disease. J Alzheimers.Dis 2008;14(2):225-234. View abstract.

44034            Montini, G., Malaventura, C., and Salviati, L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N.Engl.J Med 6-26-2008;358(26):2849-2850. View abstract.

44035            Schmitz-Hubsch, T. and Klockgether, T. An update on inherited ataxias. Curr Neurol.Neurosci.Rep. 2008;8(4):310-319. View abstract.

44036            Jimenez-Caballero, P. E., Mollejo-Villanueva, M., and Alvarez-Tejerina, A. [Mitochondrial encephalopathy due to complex I deficiency. Brain tissue biopsy findings and clinical course following pharmacological]. Rev.Neurol. 7-1-2008;47(1):27-30. View abstract.

44037            Zmitek, J., Smidovnik, A., Fir, M., Prosek, M., Zmitek, K., Walczak, J., and Pravst, I. Relative bioavailability of two forms of a novel water-soluble coenzyme Q10. Ann Nutr Metab 2008;52(4):281-287. View abstract.

44038            Tarnopolsky, M. A. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv.Drug Deliv.Rev. 2008;60(13-14):1561-1567. View abstract.

44039            Miles, M. V., Tang, P. H., Miles, L., Steele, P. E., Moye, M. J., and Horn, P. S. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets. Biomed.Chromatogr. 2008;22(12):1403-1408. View abstract.

44040            Tauler, P., Ferrer, M. D., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. Supplementation with an antioxidant cocktail containing coenzyme Q prevents plasma oxidative damage induced by soccer. Eur J Appl.Physiol 2008;104(5):777-785. View abstract.

44041            Menke, T., Niklowitz, P., Wiesel, T., and Andler, W. Antioxidant level and redox status of coenzyme Q10 in the plasma and blood cells of children with diabetes mellitus type 1. Pediatr Diabetes 2008;9(6):540-545. View abstract.

44042            Keogh, A., Fenton, S., Leslie, C., Aboyoun, C., Macdonald, P., Zhao, Y. C., Bailey, M., and Rosenfeldt, F. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12(3):135-141. View abstract.

44043            Hatanaka, J., Kimura, Y., Lai-Fu, Z., Onoue, S., and Yamada, S. Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations. Int J Pharm 11-3-2008;363(1-2):112-117. View abstract.

44044            Puizina-Ivic, N. Skin aging. Acta Dermatovenerol.Alp Panonica.Adriat. 2008;17(2):47-54. View abstract.

44045            Tonon, C. and Lodi, R. Idebenone in Friedreich’s ataxia. Expert.Opin.Pharmacother. 2008;9(13):2327-2337. View abstract.

44046            Esteves, A. R., Arduino, D. M., Swerdlow, R. H., Oliveira, C. R., and Cardoso, S. M. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson’s disease cybrids. Antioxid.Redox.Signal. 2009;11(3):439-448. View abstract.

44047            Bruno, C. and DiMauro, S. Lipid storage myopathies. Curr Opin.Neurol. 2008;21(5):601-606. View abstract.

44048            Hirayama, A., Kubo, H., Mita, M., Shirota, O., and Yamamoto, Y. High-sensitivity simultaneous analysis of ubiquinol-10 and ubiquinone-10 in human plasma. J Chromatogr.Sci 2008;46(8):717-721. View abstract.

44049            Zheng, A. and Moritani, T. Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects. J Nutr Sci Vitaminol.(Tokyo) 2008;54(4):286-290. View abstract.

44050            Makhija, N., Sendasgupta, C., Kiran, U., Lakshmy, R., Hote, M. P., Choudhary, S. K., Airan, B., and Abraham, R. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac.Vasc.Anesth. 2008;22(6):832-839. View abstract.

44051            Gregersen, N., Andresen, B. S., Pedersen, C. B., Olsen, R. K., Corydon, T. J., and Bross, P. Mitochondrial fatty acid oxidation defects–remaining challenges. J Inherit.Metab Dis 2008;31(5):643-657. View abstract.

44052            Hargreaves, I. P., Lane, A., and Sleiman, P. M. The coenzyme Q10 status of the brain regions of Parkinson’s disease patients. Neurosci.Lett. 12-5-2008;447(1):17-19. View abstract.

44053            Sawicka, E. and Dlugosz, A. Toluene and P-xylene mixture exerts antagonistic effect on lipid peroxidation in vitro. Int J Occup.Med Environ Health 2008;21(3):201-209. View abstract.

44054            Skough, K., Krossen, C., Heiwe, S., Theorell, H., and Borg, K. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil.Med 2008;40(9):773-775. View abstract.

44055            Lowes, D. A., Thottakam, B. M., Webster, N. R., Murphy, M. P., and Galley, H. F. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic.Biol.Med 12-1-2008;45(11):1559-1565. View abstract.

44056            Theodossiou, T. A., Papakyriakou, A., and Hothersall, J. S. Molecular modeling and experimental evidence for hypericin as a substrate for mitochondrial complex III; mitochondrial photodamage as demonstrated using specific inhibitors. Free Radic.Biol.Med 12-1-2008;45(11):1581-1590. View abstract.

44057            Mozaffarieh, M., Grieshaber, M. C., Orgul, S., and Flammer, J. The potential value of natural antioxidative treatment in glaucoma. Surv.Ophthalmol. 2008;53(5):479-505. View abstract.

44058            Henchcliffe, C. and Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat.Clin Pract Neurol. 2008;4(11):600-609. View abstract.

44059            Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., and Richards, A. M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll.Cardiol. 10-28-2008;52(18):1435-1441. View abstract.

44060            Horvath, R., Gorman, G., and Chinnery, P. F. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics. 2008;5(4):558-568. View abstract.

44061            Caramia, G., Cocchi, M., Tonello, L., and Visci, G. [Childhood obesity: recent advances and an experimental contribution]. Pediatr Med Chir 2008;30(3):121-140. View abstract.

44062            Cheng, B., Yuan, Q. P., Sun, X. X., and Li, W. J. Enhanced production of coenzyme Q10 by overexpressing HMG-CoA reductase and induction with arachidonic acid in Schizosaccharomyces pombe. Appl Biochem.Biotechnol. 2010;160(2):523-531. View abstract.

44063            Kharaeva, Z., Gostova, E., de, Luca C., Raskovic, D., and Korkina, L. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009;25(3):295-302. View abstract.

44064            Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L., and Schapira, A. H. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur.J Neurol. 2008;15(12):1371-1379. View abstract.

44065            Wang, S. B., Weng, W. C., Lee, N. C., Hwu, W. L., Fan, P. C., and Lee, W. T. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr.Neonatol. 2008;49(4):145-149. View abstract.

44066            Qu, J., Kaufman, Y., and Washington, I. Coenzyme Q10 in the human retina. Invest Ophthalmol.Vis.Sci 2009;50(4):1814-1818. View abstract.

44067            Lee, T. I., Kao, Y. H., Chen, Y. C., and Chen, Y. J. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur.J Clin Invest 2009;39(1):23-30. View abstract.

44068            Flattery, M. Herbal therapies and cardiac side effects. Prog.Cardiovasc.Nurs. 2008;23(4):187-190. View abstract.

44069            Smith, R. A., Adlam, V. J., Blaikie, F. H., Manas, A. R., Porteous, C. M., James, A. M., Ross, M. F., Logan, A., Cocheme, H. M., Trnka, J., Prime, T. A., Abakumova, I., Jones, B. A., Filipovska, A., and Murphy, M. P. Mitochondria-targeted antioxidants in the treatment of disease. Ann N.Y.Acad.Sci 2008;1147:105-111. View abstract.

44070            Chaturvedi, R. K. and Beal, M. F. Mitochondrial approaches for neuroprotection. Ann N.Y.Acad.Sci 2008;1147:395-412. View abstract.

44071            Acworth, I. N., Ullucci, P. A., and Gamache, P. H. Determination of oxidized and reduced CoQ10 and CoQ9 in human plasma/serum using HPLC-ECD. Methods Mol.Biol. 2008;477:245-258. View abstract.

44072            Montero, R., Sanchez-Alcazar, J. A., Briones, P., Navarro-Sastre, A., Gallardo, E., Bornstein, B., Herrero-Martin, D., Rivera, H., Martin, M. A., Marti, R., Garcia-Cazorla, A., Montoya, J., Navas, P., and Artuch, R. Coenzyme Q10 deficiency associated with a mitochondrial DNA depletion syndrome: a case report. Clin Biochem. 2009;42(7-8):742-745. View abstract.

44073            Crane, F. L. The evolution of coenzyme Q. Biofactors 2008;32(1-4):5-11. View abstract.

44074            Mukai, K., Tokunaga, A., Itoh, S., Kanesaki, Y., Ouchi, A., Ohara, K., Nagaoka, S., and Abe, K. Comparison between the free-radical-scavenging activities with vitamin E and ubiquinol in biological systems based on their reaction rates: a research account. Biofactors 2008;32(1-4):49-58. View abstract.

44075            Langsjoen, P. H. and Langsjoen, A. M. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. View abstract.

44076            Adarsh, K., Kaur, H., and Mohan, V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32(1-4):145-149. View abstract.

44077            Teran, E., Chedraui, P., Racines-Orbe, M., Vivero, S., Villena, F., Duchicela, F., Nacevilla, L., Schwager, G., and Calle, A. Coenzyme Q10 levels in women with preeclampsia living at different altitudes. Biofactors 2008;32(1-4):185-190. View abstract.

44078            Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., and Hosoe, K. Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008;32(1-4):199-208. View abstract.

44079            Nukui, K., Yamagishi, T., Miyawaki, H., Kettawan, A., Okamoto, T., Belardinelli, R., Tiano, L., Littarru, G. P., and Sato, K. Blood CoQ10 levels and safety profile after single-dose or chronic administration of PureSorb-Q40: animal and human studies. Biofactors 2008;32(1-4):209-219. View abstract.

44080            Morre, D. M., Morre, D. J., Rehmus, W., and Kern, D. Supplementation with CoQ10 lowers age-related (ar) NOX levels in healthy subjects. Biofactors 2008;32(1-4):221-230. View abstract.

44081            Morre, D. J. and Morre, D. M. arNOX activity of saliva as a non-invasive measure of coenzyme Q10 response in human trials. Biofactors 2008;32(1-4):231-235. View abstract.

44082            Inui, M., Ooe, M., Fujii, K., Matsunaka, H., Yoshida, M., and Ichihashi, M. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors 2008;32(1-4):237-243. View abstract.

44083            Prahl, S., Kueper, T., Biernoth, T., Wohrmann, Y., Munster, A., Furstenau, M., Schmidt, M., Schulze, C., Wittern, K. P., Wenck, H., Muhr, G. M., and Blatt, T. Aging skin is functionally anaerobic: importance of coenzyme Q10 for anti aging skin care. Biofactors 2008;32(1-4):245-255. View abstract.

44084            Haginoya, K., Miyabayashi, S., Kikuchi, M., Kojima, A., Yamamoto, K., Omura, K., Uematsu, M., Hino-Fukuyo, N., Tanaka, S., and Tsuchiya, S. Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol.Sci 3-15-2009;278(1-2):112-114. View abstract.

44085            Rodriguez-Hernandez, A., Cordero, M. D., Salviati, L., Artuch, R., Pineda, M., Briones, P., Gomez, Izquierdo L., Cotan, D., Navas, P., and Sanchez-Alcazar, J. A. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy. 1-1-2009;5(1):19-32. View abstract.

44086            Bodmer, M., Vankan, P., Dreier, M., Kutz, K. W., and Drewe, J. Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol. 2009;65(5):493-501. View abstract.

44087            Bergamin, C. S., Rolim, L. C., Dib, S. A., and Moises, R. S. Unusual occurrence of intestinal pseudo obstruction in a patient with maternally inherited diabetes and deafness (MIDD) and favorable outcome with coenzyme Q10. Arq Bras.Endocrinol Metabol. 2008;52(8):1345-1349. View abstract.

44088            Hamilton, S. J., Chew, G. T., and Watts, G. F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009;32(5):810-812. View abstract.

44089            Lowes, D. A., Wallace, C., Murphy, M. P., Webster, N. R., and Galley, H. F. The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells. Free Radic.Res 2009;43(4):323-328. View abstract.

44090            Dunn, S. P., Bleske, B., Dorsch, M., Macaulay, T., Van, Tassell B., and Vardeny, O. Nutrition and heart failure: impact of drug therapies and management strategies. Nutr Clin Pract 2009;24(1):60-75. View abstract.

44091            Rakoczi, K., Klivenyi, P., and Vecsei, L. [Neuroprotection in Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical findings]. Ideggyogy.Sz 1-30-2009;62(1-2):25-34. View abstract.

44092            Celik, T. and Iyisoy, A. Coenzyme Q10 and coronary artery bypass surgery: what we have learned from clinical trials. J Cardiothorac.Vasc.Anesth. 2009;23(6):935-936. View abstract.

44093            Kang, E. Y., Choi, J. W., Gwak, H. S., and Chun, I. K. Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther 2009;47(3):207-214. View abstract.

44094            Pandolfo, M. Introduction. Idebenone in the treatment of Friedreich ataxia. J Neurol. 2009;256 Suppl 1:1-2. View abstract.

44095            Meier, T. and Buyse, G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol. 2009;256 Suppl 1:25-30. View abstract.

44096            Kutz, K., Drewe, J., and Vankan, P. Pharmacokinetic properties and metabolism of idebenone. J Neurol. 2009;256 Suppl 1:31-35. View abstract.

44097            Schulz, J. B., Di Prospero, N. A., and Fischbeck, K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 Suppl 1:42-45. View abstract.

44098            Liu, Z. X. and Artmann, C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern.Ther Health Med 2009;15(2):42-46. View abstract.

44099            Tsou, A. Y., Friedman, L. S., Wilson, R. B., and Lynch, D. R. Pharmacotherapy for Friedreich ataxia. CNS.Drugs 2009;23(3):213-223. View abstract.

44100            Reiter, M., Rupp, K., Baumeister, P., Zieger, S., and Harreus, U. Antioxidant effects of quercetin and coenzyme Q10 in mini organ cultures of human nasal mucosa cells. Anticancer Res 2009;29(1):33-39. View abstract.

44101            Rinaldi, C., Tucci, T., Maione, S., Giunta, A., De, Michele G., and Filla, A. Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy. J Neurol. 2009;256(9):1434-1437. View abstract.

44102            Duncan, A. J., Bitner-Glindzicz, M., Meunier, B., Costello, H., Hargreaves, I. P., Lopez, L. C., Hirano, M., Quinzii, C. M., Sadowski, M. I., Hardy, J., Singleton, A., Clayton, P. T., and Rahman, S. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84(5):558-566. View abstract.

44103            D’Andrea, G., Bussone, G., Allais, G., Aguggia, M., D’Onofrio, F., Maggio, M., Moschiano, F., Saracco, M. G., Terzi, M. G., Petretta, V., and Benedetto, C. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol.Sci 2009;30 Suppl 1:S121-S124. View abstract.

44104            Voronkova, K. V. and Meleshkov, M. N. Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. Neurosci.Behav.Physiol 2009;39(5):501-506. View abstract.

44105            Plecita-Hlavata, L., Jezek, J., and Jezek, P. Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I. Int.J Biochem Cell Biol. 2009;41(8-9):1697-1707. View abstract.

44106            Junyaprasert, V. B., Teeranachaideekul, V., Souto, E. B., Boonme, P., and Muller, R. H. Q10-loaded NLC versus nanoemulsions: stability, rheology and in vitro skin permeation. Int.J Pharm. 7-30-2009;377(1-2):207-214. View abstract.

44107            Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., and Melchiorre, C. Alzheimer’s disease: new approaches to drug discovery. Curr Opin.Chem Biol. 2009;13(3):303-308. View abstract.

44108            Sinatra, S. T. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern.Ther Health Med. 2009;15(3):44-52. View abstract.

44109            Ramirez-Tortosa, M. C., Quiles, J. L., Battino, M., Granados, S., Morillo, J. M., Bompadre, S., Newman, H. N., and Bullon, P. Periodontitis is associated with altered plasma fatty acids and cardiovascular risk markers. Nutr Metab Cardiovasc.Dis 2010;20(2):133-139. View abstract.

44110            Balercia, G., Mancini, A., Paggi, F., Tiano, L., Pontecorvi, A., Boscaro, M., Lenzi, A., and Littarru, G. P. Coenzyme Q10 and male infertility. J Endocrinol Invest 2009;32(7):626-632. View abstract.

44111            Lucangioli, S., Sabrina, F., Mario, C., and Valeria, T. A capillary electrophoretic system based on a novel microemulsion for the analysis of coenzyme Q10 in human plasma by electrokinetic chromatography. Electrophoresis 2009;30(11):1899-1905. View abstract.

44112            Kaji, S., Murayama, K., Nagata, I., Nagasaka, H., Takayanagi, M., Ohtake, A., Iwasa, H., Nishiyama, M., Okazaki, Y., Harashima, H., Eitoku, T., Yamamoto, M., Matsushita, H., Kitamoto, K., Sakata, S., Katayama, T., Sugimoto, S., Fujimoto, Y., Murakami, J., Kanzaki, S., and Shiraki, K. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol.Genet.Metab 2009;97(4):292-296. View abstract.

44113            Gonzalez, R., Ferrin, G., Hidalgo, A. B., Ranchal, I., Lopez-Cillero, P., Santos-Gonzalez, M., Lopez-Lluch, G., Briceno, J., Gomez, M. A., Poyato, A., Villalba, J. M., Navas, P., de la Mata, M., and Muntane, J. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem.Biol Interact. 9-14-2009;181(1):95-106. View abstract.

44114            El-ghoroury, E. A., Raslan, H. M., Badawy, E. A., El-Saaid, G. S., Agybi, M. H., Siam, I., and Salem, S. I. Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. Blood Coagul.Fibrinolysis 2009;20(4):248-251. View abstract.

44115            Udompataikul, M., Sripiroj, P., and Palungwachira, P. An oral nutraceutical containing antioxidants, minerals and glycosaminoglycans improves skin roughness and fine wrinkles. Int.J Cosmet.Sci 2009;31(6):427-435. View abstract.

44116            Ferrer, M. D., Tauler, P., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. A soccer match’s ability to enhance lymphocyte capability to produce ROS and induce oxidative damage. Int.J Sport Nutr Exerc.Metab 2009;19(3):243-258. View abstract.

44117            Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., and Sampaio, C. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane.Database.Syst.Rev. 2009;(3):CD006455. View abstract.

44118            Golomb, B. A., Kwon, E. K., Koperski, S., and Evans, M. A. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009;32(8):649-661. View abstract.

44119            Parashos, S. A., Swearingen, C. J., Biglan, K. M., Bodis-Wollner, I., Liang, G. S., Ross, G. W., Tilley, B. C., and Shulman, L. M. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009;66(9):1099-1104. View abstract.

44120            Scarlato, G., Bresolin, N., Moroni, I., Doriguzzi, C., Castelli, E., Comi, G., Angelini, C., and Carenzi, A. Multicenter trial with ubidecarenone: treatment of 44 patients with mitochondrial myopathies. Rev Neurol.(Paris) 1991;147(6-7):542-548. View abstract.

44121            Sikorska, M., Sandhu, J. K., Simon, D. K., Pathiraja, V., Sodja, C., Li, Y., Ribecco-Lutkiewicz, M., Lanthier, P., Borowy-Borowski, H., Upton, A., Raha, S., Pulst, S. M., and Tarnopolsky, M. A. Identification of ataxia-associated mtDNA mutations (m.4052T>C and m.9035T>C) and evaluation of their pathogenicity in transmitochondrial cybrids. Muscle Nerve 2009;40(3):381-394. View abstract.

44122            Gokbel, H., Gul, I., Belviranl, M., and Okudan, N. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J Strength Cond.Res 2010;24(1):97-102. View abstract.

44123            Shin, J. Y., Shin, J. I., Kim, J. S., Yang, Y. S., Hwang, Y., Yang, J. S., Shin, D., Seo, J. H., Jin, Y. S., Park, Y. C., Hwang, J. S., and Kweon, D. H. Assembly of Coenzyme Q10 nanostructure resembling nascent discoidal high density lipoprotein particle. Biochem.Biophys.Res Commun. 10-16-2009;388(2):217-221. View abstract.

44124            Sivitz, W. I. and Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid.Redox.Signal. 2010;12(4):537-577. View abstract.

44125            Xia, S., Xu, S., Zhang, X., Zhong, F., and Wang, Z. Nanoliposomes mediate coenzyme Q10 transport and accumulation across human intestinal Caco-2 cell monolayer. J Agric.Food Chem. 9-9-2009;57(17):7989-7996. View abstract.

44126            Orsucci, D., Filosto, M., Siciliano, G., and Mancuso, M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev. 2009;67(8):427-438. View abstract.

44127            Kocharian, A., Shabanian, R., Rafiei-Khorgami, M., Kiani, A., and Heidari-Bateni, G. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol.Young. 2009;19(5):501-506. View abstract.

44128            Mori, T. A., Burke, V., Puddey, I., Irish, A., Cowpland, C. A., Beilin, L., Dogra, G., and Watts, G. F. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27(9):1863-1872. View abstract.

44129            Lenaz, G. and Genova, M. L. Structural and functional organization of the mitochondrial respiratory chain: a dynamic super-assembly. Int.J Biochem Cell Biol. 2009;41(10):1750-1772. View abstract.

44130            Bentov, Y., Esfandiari, N., Burstein, E., and Casper, R. F. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients. Fertil.Steril. 2010;93(1):272-275. View abstract.

44131            Kaufmann, P., Thompson, J. L., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., Katz, J., Rollins, Y., Barohn, R. J., Jackson, C. E., Tiryaki, E., Lomen-Hoerth, C., Armon, C., Tandan, R., Rudnicki, S. A., Rezania, K., Sufit, R., Pestronk, A., Novella, S. P., Heiman-Patterson, T., Kasarskis, E. J., Pioro, E. P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., and Levin, B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235-244. View abstract.

44132            Abdul-Rasheed, O. F. and Farid, Y. Y. Development of a new high performance liquid chromatography method for measurement of coenzyme Q10 in healthy blood plasma. Saudi.Med J 2009;30(9):1138-1143. View abstract.

44133            Muta-Takada, K., Terada, T., Yamanishi, H., Ashida, Y., Inomata, S., Nishiyama, T., and Amano, S. Coenzyme Q10 protects against oxidative stress-induced cell death and enhances the synthesis of basement membrane components in dermal and epidermal cells. Biofactors 2009;35(5):435-441. View abstract.

44134            Sival, D. A., du Marchie Sarvaas, G. J., Brouwer, O. F., Uges, D. R., Verschuuren-Bemelmans, C. C., Maurits, N. M., Brunt, E. R., and van der Hoeven, J. H. Neurophysiological evaluation in children with Friedreich’s ataxia. Early Hum.Dev. 2009;85(10):647-651. View abstract.

44135            Patel, B. P. and Hamadeh, M. J. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr. 2009;28(6):604-617. View abstract.

44136            Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol. 2010;257(3):399-404. View abstract.

44137            Lee, D. S., Badr, M. S., and Mateika, J. H. Progressive augmentation and ventilatory long-term facilitation are enhanced in sleep apnoea patients and are mitigated by antioxidant administration. J Physiol 11-15-2009;587(Pt 22):5451-5467. View abstract.

44138            Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2009;(4):CD007791. View abstract.

44139            Jacobson, B. H., Smith, D. B., Warren, A. J., Glass, R. G., Kline, C., Fedick, J. L., and Stemm, J. Assessment of the effectiveness of a sublingual, ergogenic spray on muscle strength and power. J Strength Cond.Res 2009;23(8):2326-2330. View abstract.

44140            Yang, X., Dai, G., Li, G., and Yang, E. S. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer’s disease. J Mol.Neurosci. 2010;41(1):110-113. View abstract.

44141            Soukoulis, V., Dihu, J. B., Sole, M., Anker, S. D., Cleland, J., Fonarow, G. C., Metra, M., Pasini, E., Strzelczyk, T., Taegtmeyer, H., and Gheorghiade, M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll.Cardiol. 10-27-2009;54(18):1660-1673. View abstract.

44142            Azevedo, O., Vilarinho, L., Almeida, F., Ferreira, F., Guardado, J., Ferreira, M., Lourenco, A., Medeiros, R., and Almeida, J. Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2010;115(1):71-74. View abstract.

44143            Fetoni, A. R., Garzaro, M., Ralli, M., Landolfo, V., Sensini, M., Pecorari, G., Mordente, A., Paludetti, G., and Giordano, C. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit. 2009;15(11):R1-R8. View abstract.

44144            Chang, A. Y., Chan, J. Y., Chuang, Y. C., and Chan, S. H. Brain stem death as the vital determinant for resumption of spontaneous circulation after cardiac arrest in rats. PLoS.One. 2009;4(11):e7744. View abstract.

44145            Someya, S., Xu, J., Kondo, K., Ding, D., Salvi, R. J., Yamasoba, T., Rabinovitch, P. S., Weindruch, R., Leeuwenburgh, C., Tanokura, M., and Prolla, T. A. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc.Natl.Acad.Sci U.S.A 11-17-2009;106(46):19432-19437. View abstract.

44146            Isobe, C., Abe, T., and Terayama, Y. Increase in the oxidized/total coenzyme Q-10 ratio in the cerebrospinal fluid of Alzheimer’s disease patients. Dement.Geriatr.Cogn Disord. 2009;28(5):449-454. View abstract.

44147            Cuperus, R., Leen, R., Tytgat, G. A., Caron, H. N., and van Kuilenburg, A. B. Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma. Cell Mol.Life Sci 2010;67(5):807-816. View abstract.

44148            Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci.Lett. 1-18-2010;469(1):159-163. View abstract.

44149            Sacconi, S., Trevisson, E., Salviati, L., Ayme, S., Rigal, O., Redondo, A. G., Mancuso, M., Siciliano, G., Tonin, P., Angelini, C., Aure, K., Lombes, A., and Desnuelle, C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul.Disord. 2010;20(1):44-48. View abstract.

44150            Molyneux, S. L., Florkowski, C. M., Richards, A. M., Lever, M., Young, J. M., and George, P. M. Coenzyme Q10; an adjunctive therapy for congestive heart failure? N.Z.Med J 10-30-2009;122(1305):74-79. View abstract.

44151            Stocker, R., Bowry, V. W., and Frei, B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl.Acad Sci U.S.A 3-1-1991;88(5):1646-1650. View abstract.

44152            Gonzalez-Rubio, S., Hidalgo, A. B., Ferrin, G., Bello, R. I., Gonzalez, R., Gahete, M. D., Ranchal, I., Rodriguez, B. A., Barrera, P., Aguilar-Melero, P., Linares, C. I., Castano, J. P., Victor, V. M., de la Mata, M., and Muntane, J. Mitochondrial-driven ubiquinone enhances extracellular calcium-dependent nitric oxide production and reduces glycochenodeoxycholic acid-induced cell death in hepatocytes. Chem Res Toxicol. 2009;22(12):1984-1991. View abstract.

44153            Kerr, D. S. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol.Genet.Metab 2010;99(3):246-255. View abstract.

44154            Beal, M. F. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism.Relat Disord. 2009;15 Suppl 3:S189-S194. View abstract.

44155            Sun, H. Y. [Clinical study of Wenxikeli treatment of viral myocarditis]. Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue.Za Zhi. 2009;23(2):144-145. View abstract.

44156            Cordero, M. D., de, Miguel M., Moreno Fernandez, A. M., Carmona Lopez, I. M., Garrido, Maraver J., Cotan, D., Gomez, Izquierdo L., Bonal, P., Campa, F., Bullon, P., Navas, P., and Sanchez Alcazar, J. A. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010;12(1):R17. View abstract.

44157            Minagawa, N., Uehara, M., Seki, S., Nitta, A., and Kogawara, K. [Effects of combined addition of atovaquone and lithium on the in vitro cell growth of the pathogenic yeast Candida albicans]. Yakugaku Zasshi 2010;130(2):247-251. View abstract.

44158            Roland, L., Gagne, A., Belanger, M. C., Boutet, M., Berthiaume, L., Fraser, W. D., Julien, P., and Bilodeau, J. F. Existence of compensatory defense mechanisms against oxidative stress and hypertension in preeclampsia. Hypertens.Pregnancy. 2010;29(1):21-37. View abstract.

44159            Hertz, N. and Lister, R. E. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int.Med Res 2009;37(6):1961-1971. View abstract.

44160            Brookman, R. H. and St Cyr, J. A. Metabolic supplementation with enhanced external counterpulsation improves myocardial function in acquired cardiomyopathy: a case report. J Altern.Complement Med 2010;16(3):323-325. View abstract.

44161            Thomas, B. and Beal, M. F. Mitochondrial therapies for Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S155-S160. View abstract.

44162            Cornelli, U. Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener.Dis 2010;7(1-3):193-202. View abstract.

44163            Lopes, C. M., Martins-Lopes, P., and Souto, E. B. Nanoparticulate carriers (NPC) for oral pharmaceutics and nutraceutics. Pharmazie 2010;65(2):75-82. View abstract.

44164            Franke, A. A., Morrison, C. M., Bakke, J. L., Custer, L. J., Li, X., and Cooney, R. V. Coenzyme Q10 in human blood: native levels and determinants of oxidation during processing and storage. Free Radic.Biol Med 6-15-2010;48(12):1610-1617. View abstract.

44165            Hauser, R. A. Early pharmacologic treatment in Parkinson’s disease. Am J Manag.Care 2010;16 Suppl Implications:S100-S107. View abstract.

44166            Chen, J. J. Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag.Care 2010;16 Suppl Implications:S87-S93. View abstract.

44167            Cadoni, G., Scorpecci, A., Cianfrone, F., Giannantonio, S., Paludetti, G., and Lippa, S. Serum fatty acids and cardiovascular risk factors in sudden sensorineural hearing loss: a case-control study. Ann Otol.Rhinol.Laryngol. 2010;119(2):82-88. View abstract.

44168            Ozaki, A., Muromachi, A., Sumi, M., Sakai, Y., Morishita, K., and Okamoto, T. Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):41-47. View abstract.

44169            Bessler, H., Bergman, M., Blumberger, N., Djaldetti, M., and Salman, H. Coenzyme Q10 decreases TNF-alpha and IL-2 secretion by human peripheral blood mononuclear cells. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):77-81. View abstract.

44170            Kernt, M., Hirneiss, C., Neubauer, A. S., Ulbig, M. W., and Kampik, A. Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell death by reducing oxidative stress and stabilizing BAX / Bcl-2 ratio. Acta Ophthalmol. 2010;88(3):e78-e86. View abstract.

44171            Salami, A., Mora, R., Dellepiane, M., Manini, G., Santomauro, V., Barettini, L., and Guastini, L. Water-soluble coenzyme Q10 formulation (Q-TER((R))) in the treatment of presbycusis. Acta Otolaryngol. 2010;130(10):1154-1162. View abstract.

44172            Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A., and Murphy, M. P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019-1026. View abstract.

44173            Pardeike, J., Schwabe, K., and Muller, R. H. Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect. Int.J Pharm. 8-30-2010;396(1-2):166-173. View abstract.

44174            Gerards, M., van den Bosch, B., Calis, C., Schoonderwoerd, K., van, Engelen K., Tijssen, M., de, Coo R., van der Kooi, A., and Smeets, H. Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion. 2010;10(5):510-515. View abstract.

44175            Drinkard, B. E., Keyser, R. E., Paul, S. M., Arena, R., Plehn, J. F., Yanovski, J. A., and Di Prospero, N. A. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys.Med Rehabil. 2010;91(7):1044-1050. View abstract.

44176            Cordero, M. D., Moreno-Fernandez, A. M., Carmona-Lopez, M. I., Sanchez-Alcazar, J. A., Rodriguez, A. F., Navas, P., and de, Miguel M. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem 2010;43(13-14):1174-1176. View abstract.

44177            Pineda, M., Montero, R., Aracil, A., O’Callaghan, M. M., Mas, A., Espinos, C., Martinez-Rubio, D., Palau, F., Navas, P., Briones, P., and Artuch, R. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov Disord. 7-15-2010;25(9):1262-1268. View abstract.

44178            Belcaro, G., Cesarone, M. R., Dugall, M., Hosoi, M., Ippolito, E., Bavera, P., and Grossi, M. G. Investigation of Pycnogenol(R) in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva Med 2010;52(2 Suppl 1):21-25. View abstract.

44179            Lynch, D. R., Perlman, S. L., and Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67(8):941-947. View abstract.

44180            Safarinejad, M. R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot.Res 2010;22(5):298-309. View abstract.

44181            Esposito, M. and Carotenuto, M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol.Sci 9-25-2010; View abstract.

44182            Glover, E. I., Martin, J., Maher, A., Thornhill, R. E., Moran, G. R., and Tarnopolsky, M. A. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42(5):739-748. View abstract.

44183            Sagel, S. D., Sontag, M. K., Anthony, M. M., Emmett, P., and Papas, K. A. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst.Fibros. 10-18-2010; View abstract.

44184            Guastini, L., Mora, R., Dellepiane, M., Santomauro, V., Giorgio, M., and Salami, A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol. 2011;131(5):512-517. View abstract.

44185            Ahn, J. H., Yoo, M. H., Lee, H. J., Chung, J. W., and Yoon, T. H. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol. 2010;35(6):486-489. View abstract.

44186            Barker, P. D. Reduced G tolerance associated with supplement use. Aviat.Space Environ.Med 2011;82(2):140-143. View abstract.

44187            Shojaei, M., Djalali, M., Khatami, M., Siassi, F., and Eshraghian, M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011;5(2):114-118. View abstract.

44188            Dai, Y. L., Luk, T. H., Yiu, K. H., Wang, M., Yip, P. M., Lee, S. W., Li, S. W., Tam, S., Fong, B., Lau, C. P., Siu, C. W., and Tse, H. F. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 2011;216(2):395-401. View abstract.

44189            Lagedrost, S. J., Sutton, M. S., Cohen, M. S., Satou, G. M., Kaufman, B. D., Perlman, S. L., Rummey, C., Meier, T., and Lynch, D. R. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011;161(3):639-645. View abstract.

44190            Nadjarzadeh, A., Sadeghi, M. R., Amirjannati, N., Vafa, M. R., Motevalian, S. A., Gohari, M. R., Akhondi, M. A., Yavari, P., and Shidfar, F. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol.Invest 2011;34(8):e224-e228. View abstract.

44191            Ryo, K., Ito, A., Takatori, R., Tai, Y., Arikawa, K., Seido, T., Yamada, T., Shinpo, K., Tamaki, Y., Fujii, K., Yamamoto, Y., and Saito, I. Effects of coenzyme Q10 on salivary secretion. Clin Biochem 2011;44(8-9):669-674. View abstract.

44192            Buyse, G. M., Goemans, N., van den Hauwe, M., Thijs, D., de Groot, I. J., Schara, U., Ceulemans, B., Meier, T., and Mertens, L. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul.Disord. 2011;21(6):396-405. View abstract.

44193            Fumagalli, S., Fattirolli, F., Guarducci, L., Cellai, T., Baldasseroni, S., Tarantini, F., Di, Bari M., Masotti, G., and Marchionni, N. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. 2011;34(4):211-217. View abstract.

44194            Cooney, R. V., Dai, Q., Gao, Y. T., Chow, W. H., Franke, A. A., Shu, X. O., Li, H., Ji, B., Cai, Q., Chai, W., and Zheng, W. Low plasma coenzyme Q(10) levels and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1124-1130. View abstract.

44195            Cordero, M. D., Alcocer-Gomez, E., de, Miguel M., Cano-Garcia, F. J., Luque, C. M., Fernandez-Riejo, P., Fernandez, A. M., and Sanchez-Alcazar, J. A. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion. 2011;11(4):623-625. View abstract.

44196            Lekoubou, A., Kouame-Assouan, A. E., Cho, T. H., Luaute, J., Nighoghossian, N., and Derex, L. Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. Rev.Neurol.(Paris) 2011;167(11):852-855. View abstract.

44197            Slater, S. K., Nelson, T. D., Kabbouche, M. A., Lecates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., and Hershey, A. D. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011;31(8):897-905. View abstract.

44198            van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2011;(6):CD003917. View abstract.

44199            Gul, I., Gokbel, H., Belviranli, M., Okudan, N., Buyukbas, S., and Basarali, K. Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10. J Sports Med Phys.Fitness 2011;51(2):305-312. View abstract.

44200            Shilov, A. M., Mel’nik, M. V., Voevodina, E. S., Osiia, A. O., and Griaznov, D. A. [Prophylaxis of ischemic heart lesions during chronic heart failure with complex therapy using Q10 coenzyme]. Anesteziol.Reanimatol. 2011;(2):34-38. View abstract.

44201            Spurney, C. F., Rocha, C. T., Henricson, E., Florence, J., Mayhew, J., Gorni, K., Pasquali, L., Pestronk, A., Martin, G. R., Hu, F., Nie, L., Connolly, A. M., and Escolar, D. M. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011;44(2):174-178. View abstract.

44202            Patchett, D. C. and Grover, M. L. Mitochondrial myopathy presenting as rhabdomyolysis. J Am Osteopath.Assoc. 2011;111(6):404-405. View abstract.

44203            Meier, T., Perlman, S. L., Rummey, C., Coppard, N. J., and Lynch, D. R. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284-291. View abstract.

44204            Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., and Chinnery, P. F. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 2011;134(Pt 9):2677-2686. View abstract.

44205            Tang, K. F., Xing, Y., Wu, C. Y., Liu, R. Z., Wang, X. Y., and Xing, J. P. [Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia]. Zhonghua Nan.Ke.Xue. 2011;17(7):615-618. View abstract.

44206            Traber, G., Baumgartner, M. R., Schwarz, U., Pangalu, A., Donath, M. Y., and Landau, K. Subacute bilateral visual loss in methylmalonic acidemia. J Neuroophthalmol. 2011;31(4):344-346. View abstract.

44207            Mikhin, V. P., Kharchenko, A. V., Rosliakova, E. A., and Cherniatina, M. A. [Application of coenzyme Q(10) in combination therapy of arterial hypertension]. Kardiologiia. 2011;51(6):26-31. View abstract.

44208            Sieswerda, E., van Dalen, E. C., Postma, A., Cheuk, D. K., Caron, H. N., and Kremer, L. C. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst.Rev. 2011;(9):CD008011. View abstract.

44209            Simonenko, V. B., Stepaniants, O. S., and Teslia, A. N. [Myocardial cytoprotectors, a reserve therapeutic modality for patients with stable angina of effort]. Klin.Med (Mosk) 2011;89(4):34-36. View abstract.

44210            Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012;28(3):250-255. View abstract.

44211            Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., and George, P. M. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25(2):261-270. View abstract.

44212            Liu, J., Wang, L., Zhan, S. Y., and Xia, Y. Coenzyme Q10 for Parkinson’s disease. Cochrane Database Syst.Rev. 2011;(12):CD008150. View abstract.

44213            Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., and Scott, R. S. Pharmacokinetic comparison of a generic coenzyme Q(1)(0) solubilizate and a formulation with soybean phytosterols. Phytother.Res. 2012;26(7):1092-1096. View abstract.

44214            Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012;28(7-8):767-772. View abstract.

44215            Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2012;4:CD007791. View abstract.

44216            Mischley, L. K., Allen, J., and Bradley, R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J.Neurol.Sci. 7-15-2012;318(1-2):72-75. View abstract.

44217            Hernandez-Ojeda, J., Cardona-Munoz, E. G., Roman-Pintos, L. M., Troyo-Sanroman, R., Ortiz-Lazareno, P. C., Cardenas-Meza, M. A., Pascoe-Gonzalez, S., and Miranda-Diaz, A. G. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J.Diabetes Complications 2012;26(4):352-358. View abstract.

44218            Bookstaver, D. A., Burkhalter, N. A., and Hatzigeorgiou, C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am.J.Cardiol. 8-15-2012;110(4):526-529. View abstract.

44219            Cyrus-Hajmassy, M. [Bilateral visual deterioration in excessive tobacco and alcohol consumption]. Ophthalmologe 2012;109(9):901-906. View abstract.

44220            Mortensen, S. A., Vadhanavikit, S., Muratsu, K., and Folkers, K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-162. View abstract.

44221            Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990;12(3):163-168. View abstract.

44222            Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169-171. View abstract.

44223            Manzoli, U., Rossi, E., Littarru, G. P., Frustaci, A., Lippa, S., Oradei, A., and Aureli, V. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React. 1990;12(3):173-178. View abstract.

44224            Armstrong, M. J. and Miyasaki, J. M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 8-7-2012;79(6):597-603. View abstract.

44225            Larijani, V. N., Ahmadi, N., Zeb, I., Khan, F., Flores, F., and Budoff, M. Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. Nutrition 2013;29(1):71-75. View abstract.

44226            Cordero, M. D., Cotan, D., del-Pozo-Martin, Y., Carrion, A. M., de, Miguel M., Bullon, P., and Sanchez-Alcazar, J. A. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 2012;28(11-12):1200-1203. View abstract.

44227            Bloomer, R. J., Canale, R. E., McCarthy, C. G., and Farney, T. M. Impact of oral ubiquinol on blood oxidative stress and exercise performance. Oxid.Med.Cell Longev. 2012;2012:465020. View abstract.

44228            Fogagnolo, P., Sacchi, M., Ceresara, G., Paderni, R., Lapadula, P., Orzalesi, N., and Rossetti, L. The effects of topical coenzyme Q10 and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica 2013;229(1):26-31. View abstract.

44229            Stacpoole, P. W., DeGrauw, T. J., Feigenbaum, A. S., Hoppel, C., Kerr, D. S., McCandless, S. E., Miles, M. V., Robinson, B. H., and Tang, P. H. Design and implementation of the first randomized controlled trial of coenzyme CoQ(1)(0) in children with primary mitochondrial diseases. Mitochondrion. 2012;12(6):623-629. View abstract.

44230            Kato, T., Yoneda, S., Kako, T., Koketsu, M., Hayano, I., and Fujinami, T. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther.Toxicol 1990;28(3):123-126. View abstract.

44231            Busetto, G. M., Koverech, A., Messano, M., Antonini, G., De, Berardinis E., and Gentile, V. Prospective open-label study on the efficacy and tolerability of a combination of nutritional supplements in primary infertile patients with idiopathic astenoteratozoospermia. Arch.Ital.Urol.Androl 2012;84(3):137-140. View abstract.

44232            Fotino, A. D., Thompson-Paul, A. M., and Bazzano, L. A. Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis. Am.J.Clin.Nutr. 2013;97(2):268-275. View abstract.

44233            Deichmann, R. E., Lavie, C. J., and Dornelles, A. C. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys.Sportsmed. 2012;40(4):88-95. View abstract.

44234            Barboni, P., Valentino, M. L., La, Morgia C., Carbonelli, M., Savini, G., De, Negri A., Simonelli, F., Sadun, F., Caporali, L., Maresca, A., Liguori, R., Baruzzi, A., Zeviani, M., and Carelli, V. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain 2013;136(Pt 2):e231. View abstract.

44235            Klopstock, T., Metz, G., Yu-Wai-Man, P., Buchner, B., Gallenmuller, C., Bailie, M., Nwali, N., Griffiths, P. G., von, Livonius B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., and Chinnery, P. F. Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy. Brain 2013;136(Pt 2):e230. View abstract.

44236            Desnuelle, C., Pellissier, J. F., Serratrice, G., Pouget, J., and Turnbull, D. M. [Kearns-Sayre syndrome: mitochondrial encephalomyopathy caused by deficiency of the respiratory chain]. Rev Neurol (Paris) 1989;145(12):842-850. View abstract.

44237            Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 7-1-1988;66(13):583-590. View abstract.

44238            Karlsson, J., Sylven, C., Jansson, E., Book, K., Muratsu, K., and Folkers, K. Coenzyme Q10 and key enzyme activities in papillary muscle related to left ventricle function in mitral valve disease. Mol.Cell Biochem 1988;84(1):59-64. View abstract.

44239            Bresolin, N., Bet, L., Ferrante, C., Binda, A., Carenzi, A., Moggio, M., Comi, G., and Scarlato, G. Immunological and biochemical studies and pilot therapeutic trial with ubidecarenone in Kearns-Sayre patients. Adv Neurol 1988;48:239-256. View abstract.

44240            Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., Ferrante, C., Carenzi, A., and Scarlato, G. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988;38(6):892-899. View abstract.

44241            Ghiringhelli, G. [Therapy with ubidecarenone in various cardiopathies with and without decompensation. Comparison with a standard therapy]. Boll.Chim.Farm. 1986;125(3):28S-33S. View abstract.

44242            Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., and Morishita, N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther.Toxicol 1986;24(10):536-541. View abstract.

44243            Goda, S., Hamada, T., Ishimoto, S., Kobayashi, T., Goto, I., and Kuroiwa, Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol. 1987;234(1):62-63. View abstract.

44244            Folkers, K. and Wolaniuk, A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp.Clin Res 1985;11(8):539-545. View abstract.

44245            Oda, T. Effect of coenzyme Q10 on stress-induced cardiac dysfunction in paediatric patients with mitral valve prolapse: a study by stress echocardiography. Drugs Exp.Clin Res 1985;11(8):557-576. View abstract.

44246            Langsjoen, P. H., Vadhanavikit, S., and Folkers, K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exp.Clin Res 1985;11(8):577-579. View abstract.

44247            Mortensen, S. A., Vadhanavikit, S., Baandrup, U., and Folkers, K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp.Clin Res 1985;11(8):581-593. View abstract.

44248            Folkers, K., Vadhanavikit, S., and Mortensen, S. A. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl.Acad Sci U.S.A 1985;82(3):901-904. View abstract.

44249            Langsjoen, P. H., Vadhanavikit, S., and Folkers, K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(12):4240-4244. View abstract.

44250            Folkers, K., Wolaniuk, J., Simonsen, R., Morishita, M., and Vadhanavikit, S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(13):4513-4516. View abstract.

44251            Ogasahara, S., Nishikawa, Y., Yorifuji, S., Soga, F., Nakamura, Y., Takahashi, M., Hashimoto, S., Kono, N., and Tarui, S. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology 1986;36(1):45-53. View abstract.

44252            Ogasahara, S., Yorifuji, S., Nishikawa, Y., Takahashi, M., Wada, K., Hazama, T., Nakamura, Y., Hashimoto, S., Kono, N., and Tarui, S. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985;35(3):372-377. View abstract.

44253            Gini, M., Schiavi, M., and Mazzola, C. [Ubidecarenone (coenzyme Q10) in the therapy of chronic cor pulmonale]. Boll.Chim.Farm. 1985;124(4):21S-28S. View abstract.

44254            Okamoto, T., Fukui, K., Nakamoto, M., Kishi, T., Okishio, T., Yamagami, T., Kanamori, N., Kishi, H., and Hiraoka, E. High-performance liquid chromatography of coenzyme Q-related compounds and its application to biological materials. J Chromatogr. 7-12-1985;342(1):35-46. View abstract.

44255            Barkworth, M. F., Dyde, C. J., Johnson, K. I., and Schnelle, K. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses. Arzneimittelforschung 1985;35(11):1704-1707. View abstract.

44256            Matsumura, T., Saji, S., Nakamura, R., and Folkers, K. Evidence for enhanced treatment of periodontal disease by therapy with coenzyme Q. Int J Vitam.Nutr Res 1973;43(4):537-548. View abstract.

44257            Littarru, G. P., Nakamura, R., Ho, L., Folkers, K., and Kuzell, W. C. Deficiency of coenzyme Q 10 in gingival tissue from patients with periodontal disease. Proc.Natl.Acad.Sci U.S.A 1971;68(10):2332-2335. View abstract.

44258            Redfearn, E. R. Mode of action of ubiquinones (coenzymes Q) in electron transport systems. Vitam Horm 1966;24:465-488. View abstract.

44259            Okuyama, S. and Mishina, H. Principia of cancer therapy. VI. Application of ubiquinone ointment for intractable radiation ulcers: an expanded cytochrome C effect? Sci Rep.Res Inst.Tohoku Univ [Med] 1983;30(1-4):36-39. View abstract.

44260            Okamura, T., Sunamori, M., Amano, J., Hirooka, Y., Ozeki, M., Tanaka, A., and Suzuki, A. Combined treatment of coenzyme Q10 and aprotinin with intraaortic balloon pumping following aorto-coronary bypass surgery. Jpn.J Surg 1984;14(2):97-103. View abstract.

44261            Ishihara, Y., Uchida, Y., Kitamura, S., and Takaku, F. [Effect of coenzyme Q10 on guinea pig trachea and lung]. Nihon Kyobu Shikkan Gakkai Zasshi 1984;22(4):249-254. View abstract.

44262            Tajima, M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. Gan No Rinsho 1984;30(9 Suppl):1211-1216. View abstract.

44263            Oda, T. and Hamamoto, K. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jpn.Circ.J 1984;48(12):1387. View abstract.

44264            Suzuki, H., Naitoh, T., Kuniyoshi, S., Banba, N., Kuroda, H., Suzuki, Y., Hiraiwa, M., Yamazaki, N., Ishikawa, M., Hashigami, Y., and . Cardiac performance and coenzyme Q10 in thyroid disorders. Endocrinol Jpn. 1984;31(6):755-761. View abstract.

44265            Cortes, E. P., Gupta, M., Chou, C., Amin, V. C., and Folkers, K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat.Rep. 1978;62(6):887-891. View abstract.

44266            Okuma, K., Furuta, I., and Ota, K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho 1984;11(3):502-508. View abstract.

44267            Tsubaki, K., Horiuchi, A., Kitani, T., Taniguchi, N., Masaoka, T., Shibata, H., Yonezawa, T., Tsubakio, T., Kawagoe, H., Shinohara, Y., and . [Investigation of the preventive effect of CoQ10 against the side- effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho 1984;11(7):1420-1427. View abstract.

44268            Tanaka, J., Tominaga, R., Yoshitoshi, M., Matsui, K., Komori, M., Sese, A., Yasui, H., and Tokunaga, K. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann.Thorac.Surg. 1982;33(2):145-151. View abstract.

44269            Takimoto, M., Sakurai, T., Kodama, K., Yokoi, H., Suzuki, Y., Enomoto, K., and Okada, N. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. Gan To Kagaku Ryoho 1982;9(1):116-121. View abstract.

44270            Folkers, K., Drzewoski, J., Richardson, P. C., Ellis, J., Shizukuishi, S., and Baker, L. Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients by therapy with coenzyme Q10. Res Commun.Chem Pathol.Pharmacol 1981;31(1):129-140. View abstract.

44271            Suzuki, Y., Kadowaki, H., Atsumi, Y., Hosokawa, K., Katagiri, H., Kadowaki, T., Oka, Y., Uyama, K., Mokubo, A., Asahina, T., and . A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr.J 1995;42(2):141-145. View abstract.

44272            Laaksonen, R., Riihimaki, A., Laitila, J., Martensson, K., Tikkanen, M. J., and Himberg, J. J. Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med 1995;125(4):517-521. View abstract.

44273            Mancini, A., De, Marinis L., Oradei, A., Hallgass, M. E., Conte, G., Pozza, D., and Littarru, G. P. Coenzyme Q10 concentrations in normal and pathological human seminal fluid. J Androl 1994;15(6):591-594. View abstract.

44274            Tsuyama, Y., Adachi-Usami, E., and Takeda, N. A case of Kearns-Shy syndrome with later onset. Ophthalmologica 1993;206(3):149-151. View abstract.

44275            Kuklinski, B., Weissenbacher, E., and Fahnrich, A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol.Aspects Med 1994;15 Suppl:s143-s147. View abstract.

44276            Oda, T. Recovery of load-induced left ventricular diastolic dysfunction by coenzyme Q10: echocardiographic study. Mol.Aspects Med 1994;15 Suppl:s149-s154. View abstract.

44277            Morisco, C., Nappi, A., Argenziano, L., Sarno, D., Fonatana, D., Imbriaco, M., Nicolai, E., Romano, M., Rosiello, G., and Cuocolo, A. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol.Aspects Med 1994;15 Suppl:s155-s163. View abstract.

44278            Langsjoen, H., Langsjoen, P., Langsjoen, P., Willis, R., and Folkers, K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol.Aspects Med 1994;15 Suppl:s165-s175. View abstract.

44279            Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., and Iacono, A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non- Hodgkin lymphoma. Mol.Aspects Med 1994;15 Suppl:s207-s212. View abstract.

44280            Lockwood, K., Moesgaard, S., Hanioka, T., and Folkers, K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol.Aspects Med 1994;15 Suppl:s231-s240. View abstract.

44281            Mancini, A., Conte, B., De, Marinis L., Hallgass, M. E., Pozza, D., Oradei, A., and Littarru, G. P. Coenzyme Q10 levels in human seminal fluid: diagnostic and clinical implications. Mol.Aspects Med 1994;15 Suppl:s249-s255. View abstract.

44282            Folkers, K., Moesgaard, S., and Morita, M. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol.Aspects Med 1994;15 Suppl:s281-s285. View abstract.

44283            Weber, C., Jakobsen, T. S., Mortensen, S. A., Paulsen, G., and Holmer, G. Effect of dietary coenzyme Q10 as an antioxidant in human plasma. Mol.Aspects Med 1994;15 Suppl:s97-s102. View abstract.

44284            Ishiyama, T., Morita, Y., Toyama, S., Yamagami, T., and Tsukamoto, N. A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn.Heart J 1976;17(1):32-42. View abstract.

44285            Berio, A. and Piazzi, A. Improvement of Kearns-Sayre syndrome with controlled carbohydrate intake and coenzyme Q10 therapy. Ophthalmologica 1994;208(6):342-343. View abstract.

44286            Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. VIII. Adminstration of coenzyme Q10 to patients with essential hypertension. Res Commun.Chem.Pathol.Pharmacol 1976;14(4):721-727. View abstract.

44287            Weber, C., Sejersgard, Jakobsen T., Mortensen, S. A., Paulsen, G., and Holmer, G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam.Nutr Res 1994;64(4):311-315. View abstract.

44288            Rengo, F., Abete, P., Landino, P., Leosco, D., Covelluzzi, F., Vitale, D., Fedi, V., and Ferrara, N. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71(8 Suppl):S124-S128. View abstract.

44289            Lampertico, M. and Comis, S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993;71(8 Suppl):S129-S133. View abstract.

44290            Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin Investig. 1993;71(8 Suppl):S140-S144. View abstract.

44291            Baggio, E., Gandini, R., Plancher, A. C., Passeri, M., and Carmosino, G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators. Clin Investig. 1993;71(8 Suppl):S145-S149. View abstract.

44292            Judy, W. V., Stogsdill, W. W., and Folkers, K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig. 1993;71(8 Suppl):S155-S161. View abstract.

44293            Fujimoto, S., Kurihara, N., Hirata, K., and Takeda, T. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. Clin Investig. 1993;71(8 Suppl):S162-S166. View abstract.

44294            Chen, Y. F., Lin, Y. T., and Wu, S. C. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac.Cardiovasc.Surg. 1994;107(1):242-247. View abstract.

44295            Tribble, D. L., van den Berg, J. J., Motchnik, P. A., Ames, B. N., Lewis, D. M., Chait, A., and Krauss, R. M. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl.Acad Sci U.S.A 2-1-1994;91(3):1183-1187. View abstract.

44296            Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O’Connor, D., Sherwin, A., Karpati, G., Andermann, F., and Arnold, D. L. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43(5):884-890. View abstract.

44297            Folkers, K., Morita, M., and McRee, J., Jr. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys.Res Commun. 5-28-1993;193(1):88-92. View abstract.

44298            Porter, D. A., Costill, D. L., Zachwieja, J. J., Krzeminski, K., Fink, W. J., Wagner, E., and Folkers, K. The effect of oral coenzyme Q10 on the exercise tolerance of middle- aged, untrained men. Int J Sports Med 1995;16(7):421-427. View abstract.

44299            Laaksonen, R., Fogelholm, M., Himberg, J. J., Laakso, J., and Salorinne, Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur.J Appl.Physiol Occup.Physiol 1995;72(1-2):95-100. View abstract.

44300            Gold, R., Seibel, P., Reinelt, G., Schindler, R., Landwehr, P., Beck, A., and Reichmann, H. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur.Neurol. 1996;36(4):191-196. View abstract.

44301            Lagendijk, J., Ubbink, J. B., and Vermaak, W. J. Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress. J Lipid Res 1996;37(1):67-75. View abstract.

44302            Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., and Folstein, S. E. A controlled trial of idebenone in Huntington’s disease. Mov Disord. 1996;11(5):549-554. View abstract.

44303            Malm, C., Svensson, M., Sjoberg, B., Ekblom, B., and Sjodin, B. Supplementation with ubiquinone-10 causes cellular damage during intense exercise. Acta Physiol Scand. 1996;157(4):511-512. View abstract.

44304            Ma, A., Zhang, W., and Liu, Z. Effect of protection and repair of injury of mitochondrial membrane- phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53-55. View abstract.

44305            Prieme, H., Loft, S., Nyyssonen, K., Salonen, J. T., and Poulsen, H. E. No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2′- deoxyguanosine excretion in smokers. Am J Clin Nutr 1997;65(2):503-507. View abstract.

44306            Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., and Beal, M. F. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann.Neurol. 1997;41(2):160-165. View abstract.

44307            Lagendijk, J., Ubbink, J. B., Delport, R., Vermaak, W. J., and Human, J. A. Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Res Commun.Mol Pathol.Pharmacol. 1997;95(1):11-20. View abstract.

44308            Karlsson, J., Lin, L., Sylven, C., and Jansson, E. Muscle ubiquinone in healthy physically active males. Mol.Cell Biochem 3-23-1996;156(2):169-172. View abstract.

44309            Karlsson, J., Lin, L., Gunnes, S., Sylven, C., and Astrom, H. Muscle ubiquinone in male effort angina patients. Mol.Cell Biochem 3-23-1996;156(2):173-178. View abstract.

44310            Karlsson, J., Gunnes, S., and Semb, B. Muscle fibers, ubiquinone and exercise capacity in effort angina. Mol Cell Biochem 3-23-1996;156(2):179-184. View abstract.

44311            Kim, Y., Sawada, Y., Fujiwara, G., Chiba, H., and Nishimura, T. Therapeutic effect of co-enzyme Q10 on idiopathic dilated cardiomyopathy: assessment by iodine-123 labelled 15-(p-iodophenyl)- 3(R,S)-methylpentadecanoic acid myocardial single-photon emission tomography. Eur.J Nucl.Med 1997;24(6):629-634. View abstract.

44312            Yamashita, S. and Yamamoto, Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal.Biochem 7-15-1997;250(1):66-73. View abstract.

44313            Villalba, J. M., Navarro, F., Gomez-Diaz, C., Arroyo, A., Bello, R. I., and Navas, P. Role of cytochrome b5 reductase on the antioxidant function of coenzyme Q in the plasma membrane. Mol.Aspects Med 1997;18 Suppl:S7-13. View abstract.

44314            Oda, T. Recovery of the systolic time intervals by coenzyme Q10 in patients with a load-induced cardiac dysfunction. Mol.Aspects Med 1997;18 Suppl:S153-S158. View abstract.

44315            Suzuki, Y., Taniyama, M., Muramatsu, T., Atsumi, Y., Hosokawa, K., Asahina, T., Shimada, A., Murata, C., and Matsuoka, K. Diabetes mellitus associated with 3243 mitochondrial tRNA(Leu(UUR)) mutation: clinical features and coenzyme Q10 treatment. Mol.Aspects Med 1997;18 Suppl:S181-S188. View abstract.

44316            Strijks, E., Kremer, H. P., and Horstink, M. W. Q10 therapy in patients with idiopathic Parkinson’s disease. Mol.Aspects Med. 1997;18 Suppl:S237-S240. View abstract.

44317            Weber, C., Bysted, A., and Holmer, G. Coenzyme Q10 in the diet–daily intake and relative bioavailability. Mol.Aspects Med 1997;18 Suppl:S251-S254. View abstract.

44318            Ylikoski, T., Piirainen, J., Hanninen, O., and Penttinen, J. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Mol.Aspects Med 1997;18 Suppl:S283-S290. View abstract.

44319            Mizuno, M., Quistorff, B., Theorell, H., Theorell, M., and Chance, B. Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. Mol.Aspects Med 1997;18 Suppl:S291-S298. View abstract.

44320            Sinatra, S. T. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. Mol.Aspects Med 1997;18 Suppl:S299-S305. View abstract.

44321            Shults, C. W., Haas, R. H., Passov, D., and Beal, M. F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann.Neurol. 1997;42(2):261-264. View abstract.

44322            Barbiroli, B., Frassineti, C., Martinelli, P., Iotti, S., Lodi, R., Cortelli, P., and Montagna, P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol.Biol (Noisy.-le-grand) 1997;43(5):741-749. View abstract.

44323            Sinatra, S. T. Coenzyme Q10: a vital therapeutic nutrient for the heart with special application in congestive heart failure. Conn.Med 1997;61(11):707-711. View abstract.

44324            Costeff, H., Apter, N., Elpeleg, O. N., Prialnic, M., and Bohles, H. J. Ineffectiveness of oral coenzyme Q10 supplementation in 3- methylglutaconic aciduria, type 3. Brain Dev. 1998;20(1):33-35. View abstract.

44325            Chopra, R. K., Goldman, R., Sinatra, S. T., and Bhagavan, H. N. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam.Nutr Res 1998;68(2):109-113. View abstract.

44326            Mancini, A., Conte, G., Milardi, D., De Marinis, L., and Littarru, G. P. Relationship between sperm cell ubiquinone and seminal parameters in subjects with and without varicocele. Andrologia 1998;30(1):1-4. View abstract.

44327            Palomaki, A., Malminiemi, K., Solakivi, T., and Malminiemi, O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39(7):1430-1437. View abstract.

44328            Zhang, Y., Eriksson, M., Dallner, G., and Appelkvist, E. L. Analysis of ubiquinone and tocopherol levels in normal and hyperlipidemic human plasma. Lipids 1998;33(8):811-815. View abstract.

44329            Kaikkonen, J., Kosonen, L., Nyyssonen, K., Porkkala-Sarataho, E., Salonen, R., Korpela, H., and Salonen, J. T. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic.Res 1998;29(1):85-92. View abstract.

44330            Singh, R. B., Wander, G. S., Rastogi, A., Shukla, P. K., Mittal, A., Sharma, J. P., Mehrotra, S. K., Kapoor, R., and Chopra, R. K. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc.Drugs Ther. 1998;12(4):347-353. View abstract.

44331            Karlsson J, Diamant B Folkers K and et al. Skeleton muscle and blood CoQ10 in health and disease. In: Lenaz G, Barnabei O Rabbi A and Battino M. Highlights in Ubiquinone Research. London: Taylor & Francis;1990.

44332            Folkers K. Critique of coenzyme Q in biochemical and biomedical research and in ten years of clinical research on cardiovascular disease. J Mol Med 2002;2:431-460.

44333            Pogessi L, Galanti G, Corneglio M, and et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 1991;49 :878-886.

44334            SA Mortensen, A Kumar P Dolliner KJ Filipiak D Pella U Alehagen G Steurer GP Littarru F Rosenfeldt. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure 2013;15:S1-S20.

44335            Yikoski T, Piirainen J, Hanninen O, and et al. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Molec Aspects Med 1997;18 Suppl:s283-s290.

44336            Mazzola C, Guffanti EE, Vaccarella A, and et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research 1987;41(6):923-932.

44337            Schardt F, Welzel D, Scheiss W, and et al. Effect of coenzyme Q10 on ischemia-induced ST-segment depression: a double-blind, placebo-controlled, crossover study. In: Folkers, K and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1985.

44338            Roberts J. The effects of coenzyme Q10 on excercise performance. Med Sci Sports Exerc 1990;22((suppl)):S87.

44339            Judy WV, Folkers K, and Hall JH. Improved long-term survival in conezyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.

44340            Judy, W. V., Hall, J. H., Toth, P. D., and Folkers, K. Double blind double cross over study of coenzyme Q10 in heart failure. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1986.

44341            Langsjoen PH. Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1991.

44342            Yamagami T, Takagi M, Akagami H, and et al. Effect of coenzyme Q10 on essential hypertension: a double-blind controlled study. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects on Coenzyme Q. Amsterdam: Elsevier;1986.

44343            Digiesi V, Cantini F, and Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Current Therapeutic Research 1990;47(5):841-845.

44344            Balercia G, Arnaldi G, Lucarelli G, and et al. Effects of exogenous CoQ10 administration in patients with idiopathic asthenozoospermia. International Journal of Andrology 2000;Suppl 23:43.

44345            Kelly P, Vasu S Getato M McNurlan M Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients (abstr). J Am Coll Cardiol 2005;45:3A.

44346            Young JM, Florkowski CM Molyneux SL McEwan RG Frampton CM George PM. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Circulation 2007;114:II41.

44347            Singh RB, Khanna HK, and Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med 2000;10:281-288.

44348            van Gaal L, Folkers K and Yamamura Y. Exploratory study of coenzyme Q10 in obesity. In: Folkers K and Yamura Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier Science Publications;1984.

44349            Oda T. Coenzyme Q10 therapy on the cardiac dysfunction in patients with mitral valve prolapse: dose vs effect and dose vs serum level of coenzyme Q10. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1986.

44350            Compagnoni G, Bargossi A, Azzali A, and et al. Q10 (Ubiquinone) plasma levels in mother and neonate. 1822. Pediatric Research 1996;39(4):306.

44351            Mari D, Alleva R, Tomasetti M, and et al. Reduction of chemotoxicity and enhancement of antioxidant capacity of plasma in cancer patients treated with conventional therapy plus CoQ10. First Conference of the International Coenzyme Q10 Association 2002;

44352            Serra G, Lissoni F, Piemonti C, and et al. Evaluation of coenzyme Q10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littaru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.

44353            Teerlink T, Musch EE, Baker SJL, and et al. Resistance of low density lipoprotein against in vitro oxidation is associated with its coenzyme Q10 content in type 2 diabetes. First Conference of the International Coenzyme Q10 Association 2002;

44354            Teran E, Feelisch M, Sazanov L, and et al. Inhibition of purified mitochondrial complex I by nitric oxide may be mediated by direct reaction with ubiquinone. Acta Physiologica Scandinavica.Supplementum 1999;167(645):5.

44355            Shumaev KB, Ruuge EK, Lankin VZ, and et al. Effect of coenzyme Q on the formation of tocopheroxyl radicals in model systems. First Conference of the International Coenzyme Q10 Association 2002;

44356            Finckh B, Boda V, Horn A, and et al. Reduced and oxidized plasma coenzyme Q10 as part of a complex monitoring of oxidative stress in micro blood samples from preterm babies. First Conference of the International Coenzyme Q10 Association 2002;

44357            Lyon W, Pepe S, Marasco S, and et al. Effect of topical and systemic coenzyme Q10 therapy on cardiac Q10 content and mitochondrial function. The Australian and New Zealand Journal of Surgery 2000;70 Supplement:A47-A48.

44358            Digiesi V, Cantini F, Bisi G, and et al. Mechanism of action of coenzyme Q10 in essential hypertension. Current Therapeutic Research 1992;51(5):668-672.

44359            Weber C, Bysted A, and Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutrition Research 1997;17(6):941-945.

44360            Wahlqvist ML, Wattanapenpaiboon N, Savige GS, and et al. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr 1998;7(1):37-40.

44361            Scararmucci A, Arnaldi G, Balercia G, and et al. Coenzyme Q10 determination in idiopathic oligoasthenospermia and varicocele. Int J Andrology 1997;20:95.

44362            Becker K. Ubiquinone-10 plasma concentrations in healthy European children. Redox Report 1995;1:97-98.

44363            Folkers K. Perspectives from research on vitamins and hormones. J Chem Educ 1984;61(9):747-756.

44364            Schneeberger, W., Muller-Steinwachs, J., Anda, L. P., Fuchs, W., Zilliken, F., Lyson, K., Muratsu, K., and Folkers, K. A clinical double-blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1986.

44365            Ursini T. Coenzyme Q10 treatment of heart failure in the elderly: preliminary results. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1991.

44366            Muller-Steinwachs, J, Anda, LP, and Zilliken, F. Eine klinische Doppel-blind-studie mit CoQ10 und vitamin E bei hertzkranken patienten. De Orthomoleculaire Koerier 1990;5(24):4-11.

44367            Syrkin A, Kogan A, Drynitsina S, and et al. The effect of soluble form of coenzyme Q10 on the oxygen free radical processes and clinical course in patients with coronary heart disease – stable angina pectoris. First Conference of the International Coenzyme Q10 Association 2002;

44368            Beyer RE, Nordenbrand K, and Ernster L. The function of coenzyme Q in free radical production and as an antioxidant: a review. Chemica Scripta 1987;27:145-153.

44369            Weber M, Andler W, Enzmann F, and et al. Increased oxidative stress in glycogen storage disease type IB: preliminary results of an antioxidative treatment with coenzyme Q10, selenium and ascorbic acid. First Conference of the International Coenzyme Q10 Association 2002;

44370            Centre for Reviews and Dissemination. Idebenone (SNT-MC17) for Friedreich’s ataxia: horizon scanning technology briefing (Project record). 2013;

44371            Imanaka K, Izumiyama K, and Sakaguchi T et al. Effect of coenzyme Q10 and azelastin on protecting radiation pneumonitis with lung cancer. Journal of Japan Society for Cancer Therapy 1994;29:2010-2015.

44372            Wander GS, Singh RB, and Shukla PK. Randomized double blind trial of hydrosoluble coenzyme Q10 in hypertensives with oxidative stress and coronary artery disease. First Conference of the International Coenzyme Q10 Association 2002;

44373            Wyss V, Lubich T Ganzit GP Cesaretti D Fiorella PL Dei C Rocini C Bargossi AM Battistoni R Lippi A Grossi G Sprovieri G Battino M. Remarks on prolonged ubiquinone administration in physical exercise. Highlights in Ubiquinone Research 1990;303-308.

44374            Zeppilli P, Merlino B De Luca A Palmieri V Santini C Vannicelli R La Rosa Gangi M Cacese R Cameli S Servidei S Ricci E Silvestri G Lippa S Oradei A Littarru GP. Influence of coenzyme Q10 on physical work capacity in athletes, sedentary people and patients with mitochondrial disease. Biochemical and clinical aspects of Coenzyme Q10. 1991;6

44375            Amadio E, Palermo R Peloni G Littarru G. Effect of CoQ10 administration on V02max and diastolic function in athletes. Biomedical and clinical aspects of Coenzyme Q10. 1991;525-533.

44376            Fiorella PL, Bargossi AM Grossi G Motta R Senaldi R Battino M Sassi S Sprovieri G Lubich T. Metabolic effects of coenzyme Q10 treatment in high level athletes. Biomedical and clinical aspects of Coenzyme Q10 1991;513-520.

44377            Wilkinson EG, Arnold RM, Folkers K, and et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Research Communications in Chemical Pathology and Pharmacology 1975;12(1):111-124.

44378            Scaglione F, Lundstrom B, Barbieri B, and et al. Coenzyme Q10 as an immunoenhancer. A single blind placebo-controlled and randomized clinical study [abstract]. First Conference of the International Coenzyme Q10 Association 1998;

44379            Gvozdjakova A, Kucharska J, Lepies P, and et al. Decreased level of sperm coenzyme Q10, mitochondrial respiration and energy production in infertile patients therapeutic effect on coenzyme Q10 (a pilot study). First Conference of the International Coenzyme Q10 Association 2002;

44380            Servidei S, Spinazzola A, Crociani P, and et al. Replacement therapy is effective in familial mitochondrial encephalomyopathy with muscle coenzyme Q10 deficiency. Neurology 1996;46:A420.

44381            Bresolin N, Cossutta E, Angelini C, and et al. Fifty patients with mitochondrial myopathy treated with ubidecarenone. First multicentric study. J Neurology 1988;235:S79.

44382            Oda T. Effect of coenzyme Q10 on load-induced cardiac dysfunction: double blind study and investigation of dose-response relationship. In: Lenaz G, Barnabei O Rabbi A and et al. Highlights in Ubiquinone Research. London: Taylor and Francis;1990.

44383            Oda T. Dose-effect relationship and critical dose of coenzyme Q10 on load-induced cardiac dysfunction in pediatric patients with mitral valve prolapse. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1991.

44384            Judy WV, Willis RA, and Folkers K. Regression of prostate cancer and plasma specific antigens (PSA) in patients on treatment with COQ10. First Conference of the International Coenzyme Q10 Association 2002;

44385            Aoki S and Yamaguchi K. [Clinical experiences in use of cinnarizine and CoQ10 for treatment of sensorineural tinnitus]. Shinyaku to Rinsho 1970;29:1541-1546.

44386            Rastogi SS, Singh RB, and Shukla PK. Randomized, double blind, placebo controlled trial of hydrosoluble coenzyme Q10 in patients with hyperinsulinemia. First Conference of the International Coenzyme Q10 Association 2002;

44387            Gvozdjakova A, Kucharska J, Braunova Z, and et al. Beneficial effect of CoQ10 on the antioxidative status and metabolism of fats and sugars in diabetic patients. First Conference of the International Coenzyme Q10 Association 2002;

44388            Koroshetz WJ. Care-HD: NINDS multicenter trial in Huntington’s disease to test whether specific doses of coenzyme Q10 and remacemide slow disease progression. First Conference of the International Coenzyme Q10 Association 2002;

44389            Feigin A, Kieburtz K, Como P, and et al. An open-label trial of coenzyme Q10 (CoQ) in Huntington’s disease (HD) [abstract]. Neurology 1994;44(suppl 2):A397-A398.

9141               Lanca S, Alves A, Vieira AI, et al. Chromium-induced toxic hepatitis. Eur J Intern Med 2002;13:518-20.. View abstract.

10538            Vimokesant S, Kunjara S, Rungruangsak K, et al. Beriberi caused by antithiamin factors in food and its prevention. Ann N Y Acad Sci 1982;378:123-36. View abstract.

13561            Health Canada. Labelling Standard: Mineral Supplements. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/label-etiquet-pharm/minsup_e.html (Accessed 14 November 2005).

13562            Piekos R, Paslawska S. Studies on the optimum conditions of extraction of silicon species from plants with water. I. Equisetum arvense L. Herb. Planta Med 1975;27:145-50. View abstract.

13563            Sudan BJ. Seborrhoeic dermatitis induced by nicotine of horsetails (Equisetum arvense L.). Contact Dermatitis 1985;13:201-2. View abstract.

13564            Oh H, Kim DH, Cho JH, Kim YC. Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from Equisetum arvense. J Ethnopharmacol 2004;95:421-4.. View abstract.

13565            Sakurai N, Iizuka T, Nakayama S, et al. [Vasorelaxant activity of caffeic acid derivatives from Cichorium intybus and Equisetum arvense]. Yakugaku Zasshi 2003;123:593-8. View abstract.

13566            Dos Santos JG Jr, Blanco MM, Do Monte FH, et al. Sedative and anticonvulsant effects of hydroalcoholic extract of Equisetum arvense. Fitoterapia 2005;76:508-13. View abstract.

13567            Langhammer L, Blaszkiewitz K, Kotzorek I. Evidence of toxic adulteration of equisetum. Dtsch Apoth Ztg 1972;112:1751-94.

13568            Correia H, Gonzalez-Paramas A, Amaral MT, et al. Characterisation of polyphenols by HPLC-PAD-ESI/MS and antioxidant activity in Equisetum telmateia. Phytochem Anal 2005;16:380-7. View abstract.

13569            Do Monte FH, dos Santos JG Jr, Russi M, et al. Antinociceptive and anti-inflammatory properties of the hydroalcoholic extract of stems from Equisetum arvense L. in mice. Pharmacol Res 2004;49:239-43. View abstract.

13570            Husson GP, Vilagines R, Delaveau P. [Antiviral properties of various extracts of natural origin]. Ann Pharm Fr 1986; 44:41-8. View abstract.

13571            Ramos JJ, Ferrer LM, Garcia L, et al. Polioencephalomalacia in adult sheep grazing pastures with prostrate pigweed. Can Vet J 2005;46:59-61. View abstract.

13572            Henderson JA, Evans EV, McIntosh RA. The antithiamine action of Equisetum. J Am Vet Med Assoc 1952;120:375-8. View abstract.

13573            Fabre B, Geay B, Beaufils P. Thiaminase activity in equisetum arvense and its extracts. Plant Med Phytother 1993;26:190-7.

13574            Perez Gutierrez RM, Laguna GY, Walkowski A. Diuretic activity of Mexican equisetum. J Ethnopharmacol 1985;14:269-72. View abstract.

13575            Lemus I, Garcia R, Erazo S, et al. Diuretic activity of an Equisetum bogotense tea (Platero herb): evaluation in healthy volunteers. J Ethnopharmacol 1996;54:55-8. View abstract.

13576            Revilla MC, Andrade-Cetto A, Islas S, Wiedenfeld H. Hypoglycemic effect of Equisetum myriochaetum aerial parts on type 2 diabetic patients. J Ethnopharmacol 2002;81:117-20. View abstract.

13577            Agustin-Ubide MP, Martinez-Cocera C, Alonso-Llamazares A, et al. Diagnostic approach to anaphylaxis by carrot, related vegetables and horsetail (Equisetum arvense) in a homemaker. Allergy 2004;59:786-7. View abstract.

55572            Graefe, E. U. and Veit, M. Urinary metabolites of flavonoids and hydroxycinnamic acids in humans after application of a crude extract from Equisetum arvense. Phytomedicine 1999;6(4):239-246. View abstract.

55573            Stajner, D., Popovic, B. M., Canadanovic-Brunet, J., and Boza, P. Free radical scavenging activity of three Equisetum species from Fruska gora mountain. Fitoterapia 2006;77(7-8):601-604. View abstract.

55574            Nitta, A., Yoshida, S., and Tagaeto, T. A comparative study of crude drugs in Southeast Asia. X. Crude drugs derived from Equisetum species. Chem Pharm Bull (Tokyo) 1977;25(5):1135-1139. View abstract.

55575            D’Agostino, M., Dini, A., Pizza, C., Senatore, F., and Aquino, R. Sterols from Equisetum arvense. Boll.Soc Ital.Biol Sper. 12-30-1984;60(12):2241-2245. View abstract.

55576            Tiktinskii, O. L. and Bablumian, I. A. [Therapeutic action of Java tea and field horsetail in uric acid diathesis]. Urol.Nefrol.(Mosk) 1983;3(1):47-50. View abstract.

55577            Maeda, H., Miyamoto, K., and Sano, T. Occurrence of dermatitis in rats fed a cholesterol diet containing field horsetail (Equisetum arvense L.). J Nutr Sci Vitaminol.(Tokyo) 1997;43(5):553-563. View abstract.

55578            Corletto F. [Female climacteric osteoporosis therapy with titrated horsetail (Equisetum arvense) extract plus calcium (osteosil calcium): randomized double blind study]. Miner Ortoped Traumatol 1999;50:201-206.

55579            Henderson JA, Evans EV, and McIntosh RA. The antithiamine action of Equisetum. J Amer Vet Med Assoc 1952;120:375-378.

3501               Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci 1986;39:263-8. View abstract.

3502               O’Dwyer PJ, et al. Use of polar solvents in chemoprevention of 1,2-dimethylhydrazine-induced colon cancer. Cancer 1988;62:944-8. View abstract.

3503               McCabe D, et al. Polar solvents in the chemoprevention of dimethylbenzanthracene-induced rat mammary cancer. Arch Surg 1986;62:1455-9. View abstract.

3504               Klandorf H, et al. Dimethyl sulfoxide modulation of diabetes onset in NOD mice. Diabetes 1998;62:194-7.

8574               Barrager E, Veltmann JR Jr, Schauss AG, Schiller RN. A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. J Altern Complement Med 2002;8:167-73. View abstract.

8575               Jacob S, Lawrence RM, Zucker M. The Miracle of MSM: The Natural Solution for Pain. New York: Penguin-Putnam, 1999.

8576               Murav’ev IuV, Venikova MS, Pleskovskaia GN, et al. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991;37-9. View abstract.

8577               Allen LV. Methyl sulfonylmethane for snoring. US Pharm 2000;92-4.

10625            Hucker HB, Ahmad PM, Miller EA, et al. Metabolism of dimethyl sulphoxide to dimethyl sulphone in the rat and man. Nature 1966;209:619-20.

12000            Gaby AR. Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: more data needed on pollen counts and questionnaire. J Altern Complement Med 2002;8:229.

12351            Lin A, Nguy CH, Shic F, Ross BD. Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy. Toxicol Lett 2001;123:169-77. View abstract.

12469            Usha PR, Naidu MUR. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combinations. Clin Drug Invest 2004;24:353-63.

14335            Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006;14:286-94. View abstract.

17127            Brien S, Prescott P, Lewith G. Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med 2009 May 27. [Epub ahead of print]. View abstract.

19312            Debbi EM, Agar G, Fichman G, et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complement Altern Med. 2011 Jun 27;11:50. View abstract.

19313            Notarnicola A, Tafuri S, Fusaro L, et al. The “MESACA” study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011 Oct;28:894-906. View abstract.

19314            Xie Q, Shi R, Xu G, et al. Effects of AR7 Joint Complex on arthralgia for patients with osteoarthritis: results of a three-month study in Shanghai, China. Nutr J. 2008 Oct 27;7:31. View abstract.

19315            Tripathi R, Gupta S, Rai S, et al. Effect of topical application of methylsulfonylmethane (MSM), EDTA on pitting edema and oxidative stress in a double blind, placebo-controlled study. Cell Mol Biol (Noisy-le-grand). 2011 Feb 12;57:62-9. View abstract.

19316            Kalman DS, Feldman S, Scheinberg AR, et al. Influence of methylsulfonylmethane on markers of exercise recovery and performance in healthy men: a pilot study. J Int Soc Sports Nutr. 2012 Sep 27;9:46. View abstract.

19317            Gulick DT, Agarwal M, Josephs J, et al. Effects of MagPro on muscle performance. J Strength Cond Res. 2012 Sep;26:2478-83. View abstract.

19318            Joksimovic N, Spasovski G, Joksimovic V, et al. Efficacy and tolerability of hyaluronic acid, tea tree oil and methyl-sulfonyl-methane in a new gel medical device for treatment of haemorrhoids in a double-blind, placebo-controlled clinical trial. Updates Surg 2012;64:195-201. View abstract.

19319            Berardesca E, Cameli N, Cavallotti C, et al. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol. 2008 Mar;7:8-14. View abstract.

19320            Barmaki S, Bohlooli S, Khoshkhahesh F, et al. Effect of methylsulfonylmethane supplementation on exercise – Induced muscle damage and total antioxidant capacity. J Sports Med Phys Fitness. 2012 Apr;52:170-4. View abstract.

19321            Notarnicola A, Pesce V, Vicenti G, et al. SWAAT study: extracorporeal shock wave therapy and arginine supplementation and other nutraceuticals for insertional Achilles tendinopathy. Adv Ther. 2012 Sep;29:799-814. View abstract.

19322            Gumina S, Passaretti D, Gurzì MD, et al. Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain in rotator cuff tear repair: a prospective randomized study. Curr Med Res Opin. 2012 Nov;28:1767-74. View abstract.

19323            Nakhostin-Roohi B, Barmaki S, Khoshkhahesh F, et al. Effect of chronic supplementation with methylsulfonylmethane on oxidative stress following acute exercise in untrained healthy men. J Pharm Pharmacol. 2011 Oct;63:1290-4. View abstract.

19324            Moazzami AA, Zhang JX, Kamal-Eldin A, et al. Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients. J Nutr. 2011 Dec;141:2126-32. View abstract.

47132            Ameye, L. G. and Chee, W. S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006;8(4):R127. View abstract.

47845            Brien, S., Prescott, P., Bashir, N., Lewith, H., and Lewith, G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis.Cartilage. 2008;16(11):1277-1288. View abstract.

47901            Layman, D. L. and Jacob, S. W. The absorption, metabolism and excretion of dimethyl sulfoxide by rhesus monkeys. Life Sci 12-23-1985;37(25):2431-2437. View abstract.

63886            Gaby, A. R. Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: more data needed on pollen counts and questionnaire. J.Altern.Complement Med. 2002;8(3):229. View abstract.

63887            Horvath, K., Noker, P. E., Somfai-Relle, S., Glavits, R., Financsek, I., and Schauss, A. G. Toxicity of methylsulfonylmethane in rats. Food Chem Toxicol 2002;40(10):1459-1462. View abstract.

63888            Engelke, U. F., Tangerman, A., Willemsen, M. A., Moskau, D., Loss, S., Mudd, S. H., and Wevers, R. A. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR. NMR Biomed. 2005;18(5):331-336. View abstract.

63889            Lopez, H. L. Nutritional interventions to prevent and treat osteoarthritis. Part II: focus on micronutrients and supportive nutraceuticals. PM.R. 2012;4(5 Suppl):S155-S168. View abstract.

63890            Beilke, M. A., Collins-Lech, C., and Sohnle, P. G. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987;110(1):91-96. View abstract.

63891            Hucker, H. B., Ahmad, P. M., Miller, E. A., and Brobyn, R. Metabolism of dimethyl sulphoxide to dimethyl sulphone in the rat and man. Nature 2-5-1966;209(5023):619-620. View abstract.

63892            Usha, P. R. and Naidu, M. U. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004;24:353-363.

63893            Kim, L. S., Axelrod, L. J., Howard, P., Buratovich, N., and Waters, R. F. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006;14(3):286-294.

3501               Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci 1986;39:263-8. View abstract.

3502               O’Dwyer PJ, et al. Use of polar solvents in chemoprevention of 1,2-dimethylhydrazine-induced colon cancer. Cancer 1988;62:944-8. View abstract.

3503               McCabe D, et al. Polar solvents in the chemoprevention of dimethylbenzanthracene-induced rat mammary cancer. Arch Surg 1986;62:1455-9. View abstract.

3504               Klandorf H, et al. Dimethyl sulfoxide modulation of diabetes onset in NOD mice. Diabetes 1998;62:194-7.

8574               Barrager E, Veltmann JR Jr, Schauss AG, Schiller RN. A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. J Altern Complement Med 2002;8:167-73. View abstract.

8575               Jacob S, Lawrence RM, Zucker M. The Miracle of MSM: The Natural Solution for Pain. New York: Penguin-Putnam, 1999.

8576               Murav’ev IuV, Venikova MS, Pleskovskaia GN, et al. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991;37-9. View abstract.

8577               Allen LV. Methyl sulfonylmethane for snoring. US Pharm 2000;92-4.

10625            Hucker HB, Ahmad PM, Miller EA, et al. Metabolism of dimethyl sulphoxide to dimethyl sulphone in the rat and man. Nature 1966;209:619-20.

12000            Gaby AR. Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: more data needed on pollen counts and questionnaire. J Altern Complement Med 2002;8:229.

12351            Lin A, Nguy CH, Shic F, Ross BD. Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy. Toxicol Lett 2001;123:169-77. View abstract.

12469            Usha PR, Naidu MUR. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combinations. Clin Drug Invest 2004;24:353-63.

14335            Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006;14:286-94. View abstract.

17127            Brien S, Prescott P, Lewith G. Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med 2009 May 27. [Epub ahead of print]. View abstract.

19312            Debbi EM, Agar G, Fichman G, et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complement Altern Med. 2011 Jun 27;11:50. View abstract.

19313            Notarnicola A, Tafuri S, Fusaro L, et al. The “MESACA” study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011 Oct;28:894-906. View abstract.

19314            Xie Q, Shi R, Xu G, et al. Effects of AR7 Joint Complex on arthralgia for patients with osteoarthritis: results of a three-month study in Shanghai, China. Nutr J. 2008 Oct 27;7:31. View abstract.

19315            Tripathi R, Gupta S, Rai S, et al. Effect of topical application of methylsulfonylmethane (MSM), EDTA on pitting edema and oxidative stress in a double blind, placebo-controlled study. Cell Mol Biol (Noisy-le-grand). 2011 Feb 12;57:62-9. View abstract.

19316            Kalman DS, Feldman S, Scheinberg AR, et al. Influence of methylsulfonylmethane on markers of exercise recovery and performance in healthy men: a pilot study. J Int Soc Sports Nutr. 2012 Sep 27;9:46. View abstract.

19317            Gulick DT, Agarwal M, Josephs J, et al. Effects of MagPro on muscle performance. J Strength Cond Res. 2012 Sep;26:2478-83. View abstract.

19318            Joksimovic N, Spasovski G, Joksimovic V, et al. Efficacy and tolerability of hyaluronic acid, tea tree oil and methyl-sulfonyl-methane in a new gel medical device for treatment of haemorrhoids in a double-blind, placebo-controlled clinical trial. Updates Surg 2012;64:195-201. View abstract.

19319            Berardesca E, Cameli N, Cavallotti C, et al. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol. 2008 Mar;7:8-14. View abstract.

19320            Barmaki S, Bohlooli S, Khoshkhahesh F, et al. Effect of methylsulfonylmethane supplementation on exercise – Induced muscle damage and total antioxidant capacity. J Sports Med Phys Fitness. 2012 Apr;52:170-4. View abstract.

19321            Notarnicola A, Pesce V, Vicenti G, et al. SWAAT study: extracorporeal shock wave therapy and arginine supplementation and other nutraceuticals for insertional Achilles tendinopathy. Adv Ther. 2012 Sep;29:799-814. View abstract.

19322            Gumina S, Passaretti D, Gurzì MD, et al. Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain in rotator cuff tear repair: a prospective randomized study. Curr Med Res Opin. 2012 Nov;28:1767-74. View abstract.

19323            Nakhostin-Roohi B, Barmaki S, Khoshkhahesh F, et al. Effect of chronic supplementation with methylsulfonylmethane on oxidative stress following acute exercise in untrained healthy men. J Pharm Pharmacol. 2011 Oct;63:1290-4. View abstract.

19324            Moazzami AA, Zhang JX, Kamal-Eldin A, et al. Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients. J Nutr. 2011 Dec;141:2126-32. View abstract.

47132            Ameye, L. G. and Chee, W. S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 2006;8(4):R127. View abstract.

47845            Brien, S., Prescott, P., Bashir, N., Lewith, H., and Lewith, G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis.Cartilage. 2008;16(11):1277-1288. View abstract.

47901            Layman, D. L. and Jacob, S. W. The absorption, metabolism and excretion of dimethyl sulfoxide by rhesus monkeys. Life Sci 12-23-1985;37(25):2431-2437. View abstract.

63886            Gaby, A. R. Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: more data needed on pollen counts and questionnaire. J.Altern.Complement Med. 2002;8(3):229. View abstract.

63887            Horvath, K., Noker, P. E., Somfai-Relle, S., Glavits, R., Financsek, I., and Schauss, A. G. Toxicity of methylsulfonylmethane in rats. Food Chem Toxicol 2002;40(10):1459-1462. View abstract.

63888            Engelke, U. F., Tangerman, A., Willemsen, M. A., Moskau, D., Loss, S., Mudd, S. H., and Wevers, R. A. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR. NMR Biomed. 2005;18(5):331-336. View abstract.

63889            Lopez, H. L. Nutritional interventions to prevent and treat osteoarthritis. Part II: focus on micronutrients and supportive nutraceuticals. PM.R. 2012;4(5 Suppl):S155-S168. View abstract.

63890            Beilke, M. A., Collins-Lech, C., and Sohnle, P. G. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987;110(1):91-96. View abstract.

63891            Hucker, H. B., Ahmad, P. M., Miller, E. A., and Brobyn, R. Metabolism of dimethyl sulphoxide to dimethyl sulphone in the rat and man. Nature 2-5-1966;209(5023):619-620. View abstract.

63892            Usha, P. R. and Naidu, M. U. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004;24:353-363.

63893            Kim, L. S., Axelrod, L. J., Howard, P., Buratovich, N., and Waters, R. F. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006;14(3):286-294.

3902               Barlet A, Albrecht J, Aubert A, et al. [Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled, double-blind, multicenter study]. Wien Klin Wochenschr 1990;102:667-73. View abstract.

3903               Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 1998;14:127-39. View abstract.

3904               Dufour B, Choquenet C, Revol M, et al. Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma. Ann Urol (Paris) 1984;18:193-5. View abstract.

4301               Yablonsky F, Nicolas V, Riffaud JP, Bellamy F. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 1997;157:2381-7. View abstract.

4302               Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia. A review of 25 years of published experience. Curr Ther Res 1995;56:796-817.

5942               Berges RR, Windeler J, Trampisch HJ, et al. Randomized, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995;345:1529-32. View abstract.

6368               Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 1999;54:473-8. View abstract.

6769               Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 2000;28:201-9. View abstract.

8520               Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 1996;28:49-53.. View abstract.

10425            Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000;109:654-64.. View abstract.

10426            Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;CD001044.. View abstract.

11226            Santa Maria Margalef A, Paciucci Barzanti R, Reventos Puigjaner J, et al. [Antimitogenic effect of Pygeum africanum extracts on human prostatic cancer cell lines and explants from benign prostatic hyperplasia]. Arch Esp Urol 2003;56:369-78. View abstract.

70214            Choo, M. S., Bellamy, F., and Constantinou, C. E. Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone. Urology 2000;55(2):292-298. View abstract.

70215            McQueen, C. E. and Bryant, P. J. Pygeum. Am J Health Syst Pharm 1-15-2001;58(2):120-123. View abstract.

70216            Yoshimura, Y., Yamaguchi, O., Bellamy, F., and Constantinou, C. E. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology 2003;61(2):474-478. View abstract.

70217            Strong, K. M. African plum and benign prostatic hypertrophy. J Herb.Pharmacother. 2004;4(1):41-46. View abstract.

70218            [Tadenan (Pygeum africanum extract) in the treatment of patients with benign prostatic hyperplasia]. Urologiia. 2004;(5):70-72. View abstract.

70219            Melo, E. A., Bertero, E. B., Rios, L. A., and Mattos, D., Jr. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz.J Urol. 2002;28(5):418-425. View abstract.

70220            Schleich, S., Papaioannou, M., Baniahmad, A., and Matusch, R. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med 2006;72(9):807-813. View abstract.

70221            Hutchison, A., Farmer, R., Verhamme, K., Berges, R., and Navarrete, R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007;51(1):207-215. View abstract.

70222            Shenouda, N. S., Sakla, M. S., Newton, L. G., Besch-Williford, C., Greenberg, N. M., MacDonald, R. S., and Lubahn, D. B. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007;31(1):72-81. View abstract.

70223            Dedhia, R. C. and McVary, K. T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J.Urol. 2008;179(6):2119-2125. View abstract.

70224            Edwards, J. L. Diagnosis and management of benign prostatic hyperplasia. Am.Fam.Physician 5-15-2008;77(10):1403-1410. View abstract.

70225            Papaioannou, M., Schleich, S., Prade, I., Degen, S., Roell, D., Schubert, U., Tanner, T., Claessens, F., Matusch, R., and Baniahmad, A. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J.Cell Mol.Med. 7-4-2008. View abstract.

70226            Bassi, P., Artibani, W., De, Luca, V, Zattoni, F., and Lembo, A. [Standardized extract of Pygeum africanum in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo]. Minerva Urol.Nefrol. 1987;39(1):45-50. View abstract.

70227            Maver, A. [Medical treatment of fibroadenomatous hypertrophy of the prostate with a new plant substance]. Minerva Med 5-16-1972;63(37):2126-2136. View abstract.

70228            Bongi, G. [Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study]. Minerva Urol 1972;24(4):129-139. View abstract.

70229            Donkervoort, T., Sterling, A., van Ness, J., and Donker, P. J. A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy. Eur Urol. 1977;3(4):218-225. View abstract.

70230            Krzeski, T., Kazon, M., Borkowski, A., Witeska, A., and Kuczera, J. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. Clin Ther 1993;15(6):1011-1020. View abstract.

70231            Paubert-Braquet, M., Cave, A., Hocquemiller, R., Delacroix, D., Dupont, C., Hedef, N., and Borgeat, P. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat.Cell Signal. 1994;9(3):285-290. View abstract.

70232            Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabriel, M., Pierre-Malice, M., and Gibelin, B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51. View abstract.

70233            Mathe, G., Orbach-Arbouys, S., Bizi, E., and Court, B. The so-called phyto-estrogenic action of Pygeum africanum extract. Biomed.Pharmacother. 1995;49(7-8):339-340. View abstract.

70234            Mathe, G., Hallard, M., Bourut, C. H., and Chenu, E. A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Biomed.Pharmacother. 1995;49(7-8):341-343. View abstract.

70235            Levin, R. M., Riffaud, J. P., Bellamy, F., Rohrmann, D., Habib, M., Krasnopolsky, L., Zhao, Y., and Wein, A. J. Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. J Urol. 1996;155(4):1466-1470. View abstract.

70236            Thieblot, L., Grizard, G., and Boucher, D. [Effect of V 1326 (active principle of Pygeum africanum bark extract) on hypophyseo-genito-adrenal axis in rats]. Therapie 1977;32(1):99-110. View abstract.

70237            Brackman F and Autet W. Once and twice daily dosage regimens of Pygeum africanum extract (PA): a double-blind study in patients with benign prostatic hyperplasia (BPH) [abstract]. J Urology 1999;161(4S):361.

70238            Andro M and Riffaud J. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr Ther Res 1995;56(8):796-817.

70239            Paubert-Braquet M, Monboisse JC, Servant-Saez N, and et al. Inhibition of bFGF and EGF-induced proliferation of 3T3 fibroblasts by extract of Pygeum africanum (Tadenan). Biomed Pharmacother 1994;48(Suppl 1):43-47.

70240            Choo M, Constantinou CE, and Bellamy F. Beneficial effects of Pygeum africanum extract (PA) on dihydrotestosterone (DHT) induced modifications of micturition and prostate growth in rat [abstract]. J Urology 1999;161(4S):229.

70241            Clavert A, Cranz C, Riffaud JP, and et al. [Effects of an extract of the bark of Pygeum africanum (V.1326) on prostatic secretions in the rat and in man]. Annales D’Urologie 1986;20(5):341-343.

70242            Blitz M, Garbit JL, Masson JC, and et al. [Controlled study on the effect of a medical treatment on subjects consulting for the first time for prostatic adenoma]. Lyon Mediterr Med 1985;21:11.

70243            Frasseto G, Bertoglio S, Mancuso S, and et al. [Study of the efficacy and tolerability of Tadenan 50 in patients with prostatic hypertrophy]. Progresso Medico 1986;42:49-53.

70244            Gagliardi V, Apicella F, Pino P, and et al. Terapia medica dell’ipertrofia prostatica. Sperimentazione clinica controllata. Arch Ital Urol Nefrol Andrologia 1983;55:51-59.

70245            Giacobini S, von Heland M, de Natale G, and et al. Valutazione clinica e morfo-funzionale del trattamento a doppio cieco con placebo, Tadenan 50 e Tadenan 50 associato a Farlutal nei pazienti con ipertrofia prostatica benigna. Antologia Medica Italiana 1986;6:1-10.

70246            Mandressi A, Tarallo U, Maggioni A, and et al. Terapia medica dell’adenoma prostatico: confronto della efficacia dell’estratto di Serenoa repens (Permixon) versus l’estratto di Pigeum africanum e placebo. Valutazione in doppio cieco. Urologia 1983;50(4):752-757.

70247            Mehrsai AR, Pourmand G, and Taheri M. Evaluation of the clinical and urodynamic effects of Pygeum africanum (Tadenan) in the treatment of benign prostatic hyperplasia (BPH) [abstract]. Br J Urol 1997;80(suppl 2):227.

70248            Ranno S, Minaldi G, Viscusi G, and et al. [Efficacy and tolerability in the treatment of prostatic adenoma with Tadenan 50]. Progresso Medico 1986;42:165-169.

70249            Rigatti P, Zennaro F, Fraschini O, and et al. L’impegio del Tadenan nell’adenoma prostatico. Ricerca clinica controllata. Atti della Accademia medica lombarda 1983;38:1-4.

70250            Rizzo M. Terapia medica dell’adenoma della prostata: valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo. Farmacia Terapia 1985;2:105-110.

70251            Barth H. Non hormonal treatment of benighn prostatic hypertrophy. Clinical evaluation of the active extract of Pygeum africanum. Proc Symp Benign Prostat Hypertrophy 1981;1:45-48.

70252            Pavone-Macaluso M. Cyproterone acetate versus Pygeum africanum in the treatment of BPH. A multicentric, randomized study [abstract]. British Journal of Urology 1997;80(suppl 2):207.

2                      Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.

3                      Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.

4                      Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.

5                      Foster S, Tyler VE. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.

11                    Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.

12                    McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association’s Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.

18                    Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.

19                    Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.

4111               Vandenplas O, Depelchin S, Toussaint G, et al. Occupational asthma caused by sarsaparilla root dust. J Allergy Clin Immunol 1996;97:1416-8.

4912               Electronic Code of Federal Regulations. Title 21. Part 182 — Substances Generally Recognized As Safe. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid= 786bafc6f6343634fbf79fcdca7061e1&rgn=div5&view= text&node=21:3.0.1.1.13&idno=21

6002               Fetrow CW, Avila JR. Professional’s Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.

14409            Barron RL, Vanscoy GJ. Natural products and the athlete: facts and folklore. Ann Pharmacother 1993;27:607-15. View abstract.

36109            Thabrew, M. I., Mitry, R. R., Morsy, M. A., and Hughes, R. D. Cytotoxic effects of a decoction of Nigella sativa, Hemidesmus indicus and Smilax glabra on human hepatoma HepG2 cells. Life Sci. 8-5-2005;77(12):1319-1330. View abstract.

73124            Cai, Y., Chen, T., and Xu, Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm.Res 2003;52(8):334-340. View abstract.

73125            Wang, J., Zhao, Y., and Xu, Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-alpha production and T lymphocytes adhesion. J Pharm Pharmacol. 2004;56(4):495-502. View abstract.

73126            Shu, X. S., Gao, Z. H., and Yang, X. L. Supercritical fluid extraction of sapogenins from tubers of Smilax china. Fitoterapia 2004;75(7-8):656-661. View abstract.

73127            Kuo, Y. H., Hsu, Y. W., Liaw, C. C., Lee, J. K., Huang, H. C., and Kuo, L. M. Cytotoxic phenylpropanoid glycosides from the stems of Smilax china. J Nat.Prod. 2005;68(10):1475-1478. View abstract.

73128            Sautour, M., Miyamoto, T., and Lacaille-Dubois, M. A. Steroidal saponins from Smilax medica and their antifungal activity. J Nat.Prod. 2005;68(10):1489-1493. View abstract.

73129            Chu, K. T. and Ng, T. B. Smilaxin, a novel protein with immunostimulatory, antiproliferative, and HIV-1-reverse transcriptase inhibitory activities from fresh Smilax glabra rhizomes. Biochem.Biophys.Res Commun. 2-3-2006;340(1):118-124. View abstract.

73130            Wang, J., Li, Q., Ivanochko, G., and Huang, Y. Anticancer effect of extracts from a North American medicinal plant–wild sarsaparilla. Anticancer Res 2006;26(3A):2157-2164. View abstract.

73131            Huang, Y. G., Li, Q. Z., Ivanochko, G., and Wang, R. Novel selective cytotoxicity of wild sarsaparilla rhizome extract. J Pharm Pharmacol 2006;58(10):1399-1403. View abstract.

73132            Vandenplas, O., Depelchin, S., Toussaint, G., Delwiche, J. P., Weyer, R. V., and Saint-Remy, J. M. Occupational asthma caused by sarsaparilla root dust. J Allergy Clin Immunol. 1996;97(6):1416-1418. View abstract.

12                    McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association’s Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.

2737               Ludwig DS, Pereira MA, Kroenke CH, et al. Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. JAMA 1999;282:1539-46. View abstract.

2956               Davy BM, Melby CL, Beske SD, et al. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr 2002;132:394-8.. View abstract.

4820               Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-55. View abstract.

4912               Electronic Code of Federal Regulations. Title 21. Part 182 — Substances Generally Recognized As Safe. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid= 786bafc6f6343634fbf79fcdca7061e1&rgn=div5&view= text&node=21:3.0.1.1.13&idno=21

4960               FDA Talk Paper. FDA Allows Whole Oat Foods to make Claim on Reducing the Risk of Heart Disease. 1997. Available at: vm.cfsan.fda.gov/~lrd/tpoats.html.

4961               Wursch P, Pi-Sunyer FX. The role of viscous soluble fiber in the metabolic control of diabetes. A review with special emphasis on cereals rich in beta-glucan. Diabetes Care 1997;20:1774-80. View abstract.

4962               Pietinen P, Rimm EB, Korhonen P, et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The alpha-tocopherol, beta-carotene cancer prevention study. Circulation 1996;94:2720-7. View abstract.

4963               Van Horn L. Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutr Committee, Am Heart Assn. Circulation 1997;95:2701-4. View abstract.

4964               Rimm EB, Ascherio A, Giovannucci E, et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996;275:447-51. View abstract.

4965               He J, Klag MJ, Whelton PK, et al. Oats and buckwheat intakes and cardiovascular disease risk factors in an ethnic minority of China. Am J Clin Nutr 1995;61:366-72. View abstract.

4966               Khaw KT, Barrett-Connor E. Dietary fiber and reduced ischemic heart disease mortality rates in men and women: a 12-year prospective study. Am J Epidemiol 1987;126:1093-102. View abstract.

4967               Morris JN, Marr JW, Clayton DG. Diet and heart: a postscript. Br Med J 1977;2:1307-14. View abstract.

4968               Kromhout D, de Lezenne C, Coulander C. Diet, prevalence and 10-year mortality from coronary heart disease in 871 middle-aged men. The Zutphen Study. Am J Epidemiol 1984;119:733-41. View abstract.

4969               American Dietetic Association Website. Available at: www.eatright.org/adap1097.html (Accessed 16 July 1999).

4970               Chen HL, Haack VS, Janecky CW, et al. Mechanisms by which wheat bran and oat bran increase stool weight in humans. Am J Clin Nutr 1998;68:711-9. View abstract.

4972               Kwiterovich PO Jr. The role of fiber in the treatment of hypercholesterolemia in children and adolescents. Pediatrics 1995;96:1005-9. View abstract.

4973               Romero AL, Romero JE, Galaviz S, Fernandez ML. Cookies enriched with psyllium or oat bran lower plasma LDL cholesterol in normal and hypercholesterolemic men from Northern Mexico. J Am Coll Nutr 1998;17:601-8. View abstract.

4974               Marlett JA, Hosig KB, Vollendorf NW, et al. Mechanism of serum cholesterol reduction by oat bran. Hepatol 1994;20:1450-7. View abstract.

4975               Poulter N, Chang CL, Cuff A, et al. Lipid profiles after the daily consumption of an oat-based cereal: a controlled crossover trial. Am J Clin Nutr 1994;59:66-9. View abstract.

4976               Braaten JT, Wood PJ, Scott FW, et al. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr 1994;48:465-74. View abstract.

4977               Ripsin CM, Keenan JM, Jacobs DR Jr, et al. Oat products and lipid lowering. A meta-analysis. JAMA 1992;267:3317-25. View abstract.

4979               Cooper SG, Tracey EJ. Small-bowel obstruction caused by oat-bran bezoar. N Engl J Med 1989;320:1148-9.

4980               Pick ME, Hawrysh ZJ, Gee MI, et al. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. J Am Diet Assoc 1996;96:1254-61. View abstract.

4981               Wood PJ, Braaten JT, Scott FW, et al. Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load. Br J Nutr 1994;72:731-43. View abstract.

4982               Braaten JT, Scott FW, Wood PJ, et al. High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetes. Diabet Med 1994;11:312-8. View abstract.

4983               Braaten JT, Wood PJ, Scott FW, Riedel KD, et al. Oat gum lowers glucose and insulin after an oral glucose load. Am J Clin Nutr 1991;53:1425-30. View abstract.

4984               Arffmann S, Hojgaard L, Giese B, Krag E. Effect of oat bran on lithogenic index of bile and bile acid metabolism. Digestion 1983;28:197-200. View abstract.

4985               Rosario PG, Gerst PH, Prakash K, Albu E. Dentureless distention: oat bran bezoars cause obstruction. J Am Geriatr Soc 1990;38:608.

5104               Reddy BS. Role of dietary fiber in colon cancer: an overview. Am J Med 1999;106:16S-9S. View abstract.

5105               Almy TP. Fiber and the gut. Am J Med 1981;71:193-5.

5106               Almy TP, Howell DA. Medical progress; Diverticular disease of the colon. N Engl J Med 1980;302:324-31.

5107               Kritchevsky D. Dietary fibre and cancer. Eur J Cancer Prev 1997;6:435-41. View abstract.

5108               Dwyer JT, Goldin B, Gorbach S, Patterson J. Drug therapy reviews: dietary fiber and fiber supplements in the therapy of gastrointestinal disorders. Am J Hosp Pharm 1978;35:278-87. View abstract.

5786               Davidson MH, Dugan LD, Burns JH, et al. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. JAMA 1991;265:1833-9. View abstract.

5787               Ripsen CM, Keenan JM, Jacobs DR, et al. Oat products and lipid lowering. A meta-analysis. JAMA 1992;267:3317-25. View abstract.

5788               Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42. View abstract.

5789               Lia A, Hallmans G, Sandberg AS, et al. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr 1995;62:1245-51. View abstract.

5792               Food and Drug Administration. Food labeling: health claims: oats and coronary heart disease. Fed Regist 1996;61:296-313.

5794               Van Horn LV, Liu K, Parker D, et al. Serum lipid response to oat product intake with a fat-modified diet. J Am Diet Assoc 1986;86:759-64. View abstract.

5795               Anderson JW, Gilinsky NH, Deakins DA, et al. Lipid responses of hypocholesterolemic men to oat-bran and wheat-bran intake. Am J Clin Nutr 54:678-83. View abstract.

5796               Braaten JT, Wood PJ, Scott FW, et al. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr 1994;48:465-74. View abstract.

5797               Foulke J. FDA Allows Whole Oat Foods To Make Health Claim on Reducing the Risk of Heart Disease. FDA Talk Paper. 1997. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00782.html.

6188               Maier SM, Turner ND, Lupton JR. Serum lipids in hypercholesterolemic men and women consuming oat bran and amaranth products. Cereal Chem 2000:77;297-302.

6266               Chandalia M, Garg A, Lutjohann D, et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000;342:1392-8. View abstract.

8521               Van Horn L, Liu K, Gerber J, et al. Oats and soy in lipid-lowering diets for women with hypercholesterolemia: is there synergy? J Am Diet Assoc 2001;101:1319-25. View abstract.

10145            Kerckhoffs DA, Hornstra G, Mensink RP. Cholesterol-lowering effect of beta-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when beta-glucan is incorporated into bread and cookies. Am J Clin Nutr 2003;78:221-7.. View abstract.

10435            Terry P, Lagergren J, Ye W, et al. Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology 2001;120:387-91.. View abstract.

11135            Jenkins DJ, Wesson V, Wolever TM, et al. Wholemeal versus wholegrain breads: proportion of whole or cracked grain and the glycaemic response. BMJ 1988;297:958-60.. View abstract.

12513            Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003;32:659-83.. View abstract.

12514            Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-8. . View abstract.

12515            De Paz Arranz S, Perez Montero A, Remon LZ, Molero MI. Allergic contact urticaria to oatmeal. Allergy 2002;57:1215. . View abstract.

12516            Storsrud S, Olsson M, Arvidsson Lenner R, et al. Adult coeliac patients do tolerate large amounts of oats. Eur J Clin Nutr 2003;57:163-9. . View abstract.

12517            Hendricks KM, Dong KR, Tang AM, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr 2003;78:790-5. View abstract.

12550            Cooper SG, Tracey EJ. Small-bowel obstruction caused by oat-bran bezoar. N Engl J Med 1989;320:1148-9. View abstract.

10250            Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-6.. View abstract.

10251            Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996;169:610-7.. View abstract.

10252            Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36.. View abstract.

10253            Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999;156:145-7.. View abstract.

10254            de Koning TJ, Duran M, Dorland L, et al. Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann Neurol 1998;44:261-5.. View abstract.

10255            Harvey SG, Gibson JR, Burke CA. L-cysteine, glycine and dl-threonine in the treatment of hypostatic leg ulceration: a placebo-controlled study. Pharmatherapeutica 1985;4:227-30.. View abstract.

10256            Fries MH, Rinaldo P, Schmidt-Sommerfeld E, et al. Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. J Pediatr 1996;129:449-52.. View abstract.

10257            Javitt DC, Balla A, Sershen H, Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 1999;45:668-79.. View abstract.

10258            Thurman RG, Zhong Z, von Frankenberg M, et al. Prevention of cyclosporine-induced nephrotoxicity with dietary glycine. Transplantation 1997;63:1661-7.. View abstract.

10259            Zhong Z, Arteel GE, Connor HD, et al. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Am J Physiol 1998;275:F595-604.. View abstract.

10260            Yin M, Ikejima K, Arteel GE, Seabra V, et al. Glycine accelerates recovery from alcohol-induced liver injury. J Pharmacol Exp Ther 1998;286:1014-9.. View abstract.

10261            Rose ML, Madren J, Bunzendahl H, Thurman RG. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis 1999;20:793-8.. View abstract.

10262            Rose ML, Cattley RC, Dunn C, et al. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis 1999;20:2075-81.. View abstract.

11320            Gusev EI, Skvortsova VI, Dambinova SA, et al. Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis 2000;10:49-60. View abstract.

11321            Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000;157:826-8.. View abstract.

11322            File SE, Fluck E, Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. J Clin Psychopharmacol 1999;19:506-12. . View abstract.

645                 Pye KG, Kelsey SM, House IM, et al. Severe dyserythropoeisis and autoimmune thrombocytopenia associated with ingestion of kelp supplement. Lancet 1992;339:1540. View abstract.

647                 Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed) 1981;282:186-7. View abstract.

7135               Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002. Available at: www.nap.edu/books/0309072794/html/.

12788            Baker DH. Iodine toxicity and its amelioration. Exp Biol Med (Maywood) 2004;229:473-8. View abstract.

12789            Phaneuf D, Cote I, Dumas P, et al. Evaluation of the contamination of marine algae (Seaweed) from the St. Lawrence River and likely to be consumed by humans. Environ Res 1999;80:S175-S182. View abstract.

12790            Skibola CF. The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report. BMC Complement Altern Med 2004;4:10. View abstract.

12791            Criado MT, Ferreiros CM. Toxicity of an algal mucopolysaccharide for Escherichia coli and Neisseria meningitidis strains. Rev Esp Fisiol 1984;40:227-30. View abstract.

12792            Beress A, Wassermann O, Tahhan S, et al. A new procedure for the isolation of anti-HIV compounds (polysaccharides and polyphenols) from the marine alga Fucus vesiculosus. J Nat Prod 1993;56:478-88. View abstract.

12793            Ruperez P, Ahrazem O, Leal JA. Potential antioxidant capacity of sulfated polysaccharides from the edible marine brown seaweed Fucus vesiculosus. J Agric Food Chem 2002;50:840-5. View abstract.

12794            Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988;32:1742-5. View abstract.

12795            Patankar MS, Oehninger S, Barnett T, et al. A revised structure for fucoidan may explain some of its biological activities. J Biol Chem 1993;268:21770-6. View abstract.

12796            O’Leary R, Rerek M, Wood EJ. Fucoidan modulates the effect of transforming growth factor (TGF)-beta1 on fibroblast proliferation and wound repopulation in in vitro models of dermal wound repair. Biol Pharm Bull 2004;27:266-70. View abstract.

12797            Durig J, Bruhn T, Zurborn KH, et al. Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb Res 1997;85:479-91. View abstract.

12798            Koyanagi S, Tanigawa N, Nakagawa H, et al. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol 2003;65:173-9. View abstract.

12799            Fujimura T, Tsukahara K, Moriwaki S, et al. Treatment of human skin with an extract of Fucus vesiculosus changes its thickness and mechanical properties. J Cosmet Sci 2002;53:1-9. View abstract.

12800            Conz PA, La Greca G, Benedetti P, et al. Fucus vesiculosus: a nephrotoxic alga? Nephrol Dial Transplant 1998;13:526-7. View abstract.

13061            Ohye H, Fukata S, Kanoh M, et al. Thyrotoxicosis caused by weight-reducing herbal medicines. Arch Intern Med 2005;165:831-4. View abstract.

13663            Bjorvell H, Rössner S. Long-term effects of commonly available weight reducing programmes in Sweden. Int J Obes 1987;11:67-71. . View abstract.

13664            Okamura K, Inoue K, Omae T. A case of Hashimoto’s thyroiditis with thyroid immunological abnormality manifested after habitual ingestion of seaweed. Acta Endocrinol (Copenh) 1978;88:703-12. View abstract.

14321            Agarwal SC, Crook JR, Pepper CB. Herbal remedies — how safe are they? A case report of polymorphic ventricular tachycardia/ventricular fibrillation induced by herbal medication used for obesity. Int J Cardiol 2006;106:260-1. View abstract.

14554            US Department of Health and Human Services, Public Health Service. Agency for Toxic Substances and Disease Registry. Toxicological profile for strontium. April 2004. Available at: www.atsdr.cdc.gov/toxprofiles/tp159.pdf. (Accessed 8 August 2006).

15588            Amster E, Tiwary A, Schenker MB. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environ Health Perspect 2007;115:606-8. View abstract.

17005            Kang K, Hwang HJ, Hong DH, et al. Antioxidant and antiinflammatory activities of ventol, a phlorotannin-rich natural agent derived from Ecklonia cava, and its effect on proteoglycan degradation in cartilage explant culture. Res Commun Mol Pathol Pharmacol 2004;115-116:77-95. View abstract.

33077            Burack, J. H., Cohen, M. R., Hahn, J. A., and Abrams, D. I. Pilot randomized controlled trial of Chinese herbal treatment for HIV- associated symptoms. J Acquir.Immune.Defic.Syndr.Hum.Retrovirol. 8-1-1996;12(4):386-393. View abstract.

33979            Colin, Slaughter J. The naturally occurring furanones: formation and function from pheromone to food. Biol Rev Camb.Philos.Soc 1999;74(3):259-276. View abstract.

40043            Dumelod, B. D., Ramirez, R. P., Tiangson, C. L., Barrios, E. B., and Panlasigui, L. N. Carbohydrate availability of arroz caldo with lambda-carrageenan. Int.J.Food Sci.Nutr. 1999;50(4):283-289. View abstract.

40044            Coggins, C., Blanchard, K., Alvarez, F., Brache, V., Weisberg, E., Kilmarx, P. H., Lacarra, M., Massai, R., Mishell, D., Jr., Salvatierra, A., Witwatwongwana, P., Elias, C., and Ellertson, C. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm.Infect. 2000;76(6):480-483. View abstract.

40058            Whitehead, S. J., Kilmarx, P. H., Blanchard, K., Manopaiboon, C., Chaikummao, S., Friedland, B., Achalapong, J., Wankrairoj, M., Mock, P., Thanprasertsuk, S., and Tappero, J. W. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 11-14-2006;20(17):2141-2148. View abstract.

41857            Bezpalov, V. G., Barash, N. I., Ivanova, O. A., Semenov, I. I., Aleksandrov, V. A., and Semiglazov, V. F. [Investigation of the drug “Mamoclam” for the treatment of patients with fibroadenomatosis of the breast]. Vopr.Onkol. 2005;51(2):236-241. View abstract.

46959            Catania, M. A., Oteri, A., Caiello, P., Russo, A., Salvo, F., Giustini, E. S., Caputi, A. P., and Polimeni, G. Hemorrhagic cystitis induced by an herbal mixture. South.Med.J. 2010;103(1):90-92. View abstract.

49176            Lis-Balchin, M. Parallel placebo-controlled clinical study of a mixture of herbs sold as a remedy for cellulite. Phytother.Res. 1999;13(7):627-629. View abstract.

55922            Aquaron, R., Delange, F., Marchal, P., Lognone, V., and Ninane, L. Bioavailability of seaweed iodine in human beings. Cell Mol.Biol.(Noisy.-le-grand) 2002;48(5):563-569. View abstract.

69257            Abidov, M., Ramazanov, Z., Seifulla, R., and Grachev, S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes.Metab 2010;12(1):72-81. View abstract.

74101            Barnaby, F. and Boeker, E. Is technetium-99 (Tc-99) radiologically significant? Med.Confl.Surviv. 1999;15(1):57-70. View abstract.

74102            Nagai, K., Hosaka, H., Kubo, S., Nakabayashi, T., Amagasaki, Y., and Nakamura, N. Vitamin A toxicity secondary to excessive intake of yellow-green vegetables, liver and laver. J.Hepatol. 1999;31(1):142-148. View abstract.

74103            Jimenez-Escrig, A. and Goni, Cambrodon, I. [Nutritional evaluation and physiological effects of edible seaweeds]. Arch.Latinoam.Nutr. 1999;49(2):114-120. View abstract.

74104            Nishino, T., Fukuda, A., Nagumo, T., Fujihara, M., and Kaji, E. Inhibition of the generation of thrombin and factor Xa by a fucoidan from the brown seaweed Ecklonia kurome. Thromb.Res. 10-1-1999;96(1):37-49. View abstract.

74105            Yamada, K., Yamada, Y., Fukuda, M., and Yamada, S. Bioavailability of dried asakusanori (porphyra tenera) as a source of Cobalamin (Vitamin B12). Int.J.Vitam.Nutr.Res. 1999;69(6):412-418. View abstract.

74106            Hou, X., Dahlgaard, H., Nielsen, S. P., and Ding, W. Iodine-129 in human thyroids and seaweed in China. Sci.Total Environ. 2-10-2000;246(2-3):285-291. View abstract.

74107            Funahashi, H. [Chemopreventive effect of tamoxifen on familial breast cancer]. Nihon Rinsho 2000;58(6):1267-1271. View abstract.

74108            Matsuse, H., Shimoda, T., Kawano, T., Fukushima, C., Mitsuta, K., Obase, Y., Tomari, S., Saeki, S., and Kohno, S. Airway foreign body with clinical features mimicking bronchial asthma. Respiration 2001;68(1):103-105. View abstract.

74109            Matsubayashi, S., Mukuta, T., Watanabe, H., Fuchigami, H., Taniguchi, J., Chinen, M., Ninomiya, H., and Sasaki, H. Iodine-induced hypothyroidism as a result of excessive intake of confectionery made with tangle weed, Kombu, used as a low calorie food during a bulimic period in a patient with anorexia nervosa. Eat.Weight.Disord. 1998;3(1):50-52. View abstract.

74110            Walkiw O and Douglas DE. Health food supplements prepared from kelp–a source of elevated urinary arsenic. Clin Toxicol 1975;8(3):325-331. View abstract.

74111            Knowles, S. R., Djordjevic, K., Binkley, K., and Weber, E. A. Allergic anaphylaxis to Laminaria. Allergy 2002;57(4):370. View abstract.

74112            Murakami, C., Takemura, M., Sugiyama, Y., Kamisuki, S., Asahara, H., Kawasaki, M., Ishidoh, T., Linn, S., Yoshida, S., Sugawara, F., Yoshida, H., Sakaguchi, K., and Mizushina, Y. Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases. Biochim.Biophys.Acta 2-20-2002;1574(1):85-92. View abstract.

74113            Salas, Coronas J., Cruz, Caparros G., Laynez, Bretones F., and Diez, Garcia F. [Hyperthyroidism secondary to kelp tablets ingestias]. Med.Clin.(Barc.) 6-1-2002;118(20):797-798. View abstract.

74114            Hsueh, Y. M., Hsu, M. K., Chiou, H. Y., Yang, M. H., Huang, C. C., and Chen, C. J. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol.Lett. 7-7-2002;133(1):83-91. View abstract.

74115            Cooper, R., Dragar, C., Elliot, K., Fitton, J. H., Godwin, J., and Thompson, K. GFS, a preparation of Tasmanian Undaria pinnatifida is associated with healing and inhibition of reactivation of Herpes. BMC.Complement Altern.Med. 11-20-2002;2:11. View abstract.

74116            Bell, J., Duhon, S., and Doctor, V. M. The effect of fucoidan, heparin and cyanogen bromide-fibrinogen on the activation of human glutamic-plasminogen by tissue plasminogen activator. Blood Coagul.Fibrinolysis 2003;14(3):229-234. View abstract.

74117            Harrell BL and Rudolph AH. Letter: kelp diet: a cause of acneiform eruption. Arch.Dermatol. 1976;112(4):560. View abstract.

74118            Teodoru, V. and Nicolau, G. Y. Iodine-enriched milk in goiter endemics. Rom.J.Endocrinol. 1992;30(3-4):165-167. View abstract.

74119            SPRINGER, G. F., WURZEL, H. A., and Mcneal, G. M. et al. Isolation of anticoagulant fractions from crude fucoidin. Proc.Soc.Exp.Biol.Med 1957;94(2):404-409. View abstract.

74120            Shibata, Y., Morita, M., and Fuwa, K. Selenium and arsenic in biology: their chemical forms and biological functions. Adv.Biophys. 1992;28:31-80. View abstract.

74121            Clark, C. D., Bassett, B., and Burge, M. R. Effects of kelp supplementation on thyroid function in euthyroid subjects. Endocr.Pract. 2003;9(5):363-369. View abstract.

74122            Chandrakumar, M. Could contact with seaweed cause skin blisters? Public Health 1992;106(6):482-485. View abstract.

74123            Vermeulen, H., Ubbink, D., Goossens, A., de, Vos R., and Legemate, D. Dressings and topical agents for surgical wounds healing by secondary intention. Cochrane.Database.Syst.Rev. 2004;(2):CD003554. View abstract.

74124            Soeda S, Sakaguchi S, Shimeno H, and et al. Fibrinolytic and anticoagulant activities of highly sulfated fucoidan. Biochem Pharmacol 4-15-1992;43(8):1853-1858. View abstract.

74125            Andrewes, P., Demarini, D. M., Funasaka, K., Wallace, K., Lai, V. W., Sun, H., Cullen, W. R., and Kitchin, K. T. Do arsenosugars pose a risk to human health? The comparative toxicities of a trivalent and pentavalent arsenosugar. Environ.Sci.Technol. 8-1-2004;38(15):4140-4148. View abstract.

74126            Damonte, E. B., Matulewicz, M. C., and Cerezo, A. S. Sulfated seaweed polysaccharides as antiviral agents. Curr.Med Chem. 2004;11(18):2399-2419. View abstract.

74127            Hoornstra, D., Andersson, M. A., Johansson, T., Pirhonen, T., Hatakka, M., and Salkinoja-Salonen, M. S. Mitochondrial toxicity detected in a health product with a boar spermatozoan bioassay. Altern.Lab Anim 2004;32(4):407-416. View abstract.

74128            Na, H. J., Moon, P. D., Ko, S. G., Lee, H. J., Jung, H. A., Hong, S. H., Seo, Y., Oh, J. M., Lee, B. H., Choi, B. W., and Kim, H. M. Sargassum hemiphyllum inhibits atopic allergic reaction via the regulation of inflammatory mediators. J.Pharmacol.Sci. 2005;97(2):219-226. View abstract.

74129            Sugimoto, K. and Ninomiya, Y. Introductory remarks on umami research: candidate receptors and signal transduction mechanisms on umami. Chem.Senses 2005;30 Suppl 1:i21-i22. View abstract.

74130            Maeda, H., Hosokawa, M., Sashima, T., Funayama, K., and Miyashita, K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem.Biophys.Res.Commun. 7-1-2005;332(2):392-397. View abstract.

74131            Silva, T. M., Alves, L. G., de Queiroz, K. C., Santos, M. G., Marques, C. T., Chavante, S. F., Rocha, H. A., and Leite, E. L. Partial characterization and anticoagulant activity of a heterofucan from the brown seaweed Padina gymnospora. Braz.J.Med.Biol.Res. 2005;38(4):523-533. View abstract.

74132            Heo, S. J., Park, E. J., Lee, K. W., and Jeon, Y. J. Antioxidant activities of enzymatic extracts from brown seaweeds. Bioresour.Technol. 2005;96(14):1613-1623. View abstract.

74133            Tokumine, J., Sugahara, K., Fuchigami, T., Teruya, K., Nitta, K., and Satou, K. Unanticipated full stomach at anesthesia induction in a type I diabetic patient with asymptomatic gastroparesis. J.Anesth. 2005;19(3):247-248. View abstract.

74134            Moriyama, K., Kanamoto, N., Hataya, Y., Nanbu, T., Hosoda, K., Arai, H., and Nakao, K. A case of type 2 diabetes mellitus developing hypothyroidism discovered as a result of a discrepancy between glycated hemoglobin and glycated albumin values. Diabetes Res.Clin.Pract. 2006;71(3):227-232. View abstract.

74135            Strand, J. and Jacobsen, J. A. Accumulation and trophic transfer of organotins in a marine food web from the Danish coastal waters. Sci.Total Environ. 11-1-2005;350(1-3):72-85. View abstract.

74136            Rudichenko, E. V., Gvozdenko, T. A., and Antoniuk, M. V. [Impact of dietotherapy with enterosorbent of marine origin on the indices of mineral and lipid metabolism for patients suffering from kidney diseases]. Vopr.Pitan. 2005;74(4):33-35. View abstract.

74137            Croft, M. T., Lawrence, A. D., Raux-Deery, E., Warren, M. J., and Smith, A. G. Algae acquire vitamin B12 through a symbiotic relationship with bacteria. Nature 11-3-2005;438(7064):90-93. View abstract.

74138            Tran, H. A. Inadvertent iodine excess causing thyrotoxic hypokalemic periodic paralysis. Arch.Intern.Med. 11-28-2005;165(21):2536. View abstract.

74139            Irhimeh, M. R., Fitton, J. H., Lowenthal, R. M., and Kongtawelert, P. A quantitative method to detect fucoidan in human plasma using a novel antibody. Methods Find.Exp.Clin.Pharmacol. 2005;27(10):705-710. View abstract.

74140            Maeda, H., Hosokawa, M., Sashima, T., Takahashi, N., Kawada, T., and Miyashita, K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int.J.Mol.Med. 2006;18(1):147-152. View abstract.

74141            Mussig, K., Thamer, C., Bares, R., Lipp, H. P., Haring, H. U., and Gallwitz, B. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. J Gen.Intern Med 2006;21(6):C11-C14. View abstract.

74142            Picco, G., Dios-Romero, A., Albanell, N., and Badia, J. [Regular intake of seaweed and hyperthyroidism]. Med Clin (Barc.) 7-1-2006;127(5):199. View abstract.

74143            Palfreyman, S. J., Nelson, E. A., Lochiel, R., and Michaels, J. A. Dressings for healing venous leg ulcers. Cochrane.Database.Syst.Rev. 2006;(3):CD001103. View abstract.

74144            Athukorala, Y., Lee, K. W., Kim, S. K., and Jeon, Y. J. Anticoagulant activity of marine green and brown algae collected from Jeju Island in Korea. Bioresour.Technol. 2007;98(9):1711-1716. View abstract.

74145            Yamaguchi, M. Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis. Yakugaku Zasshi 2006;126(11):1117-1137. View abstract.

74146            Lamberg, B. A. Endemic goitre–iodine deficiency disorders. Ann.Med. 1991;23(4):367-372. View abstract.

74147            Queiroz, K. C., Assis, C. F., Medeiros, V. P., Rocha, H. A., Aoyama, H., Ferreira, C. V., and Leite, E. L. Cytotoxicity effect of algal polysaccharides on HL60 cells. Biochemistry (Mosc.) 2006;71(12):1312-1315. View abstract.

74148            Nelson, E. A. and Bradley, M. D. Dressings and topical agents for arterial leg ulcers. Cochrane.Database.Syst.Rev. 2007;(1):CD001836. View abstract.

74149            Cumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D’Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., Usov, A. I., Ustyuzhanina, N. E., Grachev, A. A., Sanderson, C. J., Kelly, M., Rabinovich, G. A., Iacobelli, S., and Nifantiev, N. E. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007;17(5):541-552. View abstract.

74150            Bhattacharyya, S., Borthakur, A., Dudeja, P. K., and Tobacman, J. K. Carrageenan reduces bone morphogenetic protein-4 (BMP4) and activates the Wnt/beta-catenin pathway in normal human colonocytes. Dig.Dis.Sci. 2007;52(10):2766-2774. View abstract.

74151            Teas, J., Braverman, L. E., Kurzer, M. S., Pino, S., Hurley, T. G., and Hebert, J. R. Seaweed and soy: companion foods in Asian cuisine and their effects on thyroid function in American women. J Med Food 2007;10(1):90-100. View abstract.

74152            Freguin-Bouilland, C., Alkhatib, B., David, N., Lallemand, F., Henry, J. P., Godin, M., Thuillez, C., and Plissonnier, D. Low molecular weight fucoidan prevents neointimal hyperplasia after aortic allografting. Transplantation 5-15-2007;83(9):1234-1241. View abstract.

74153            Rowe, B. R., Bain, S. C., Pizzey, M., and Barnett, A. H. Rapid healing of ulcerated necrobiosis lipoidica with optimum glycaemic control and seaweed-based dressings. Br.J.Dermatol. 1991;125(6):603-604. View abstract.

74154            Watanabe, F. Vitamin B12 sources and bioavailability. Exp.Biol.Med.(Maywood.) 2007;232(10):1266-1274. View abstract.

74155            Heenan, A. Alginates: an effective primary dressing for exuding wounds. Nurs.Stand. 10-24-2007;22(7):53-4, 56, 58. View abstract.

74156            Colliec S, Fischer AM, Tapon-Bretaudiere J, and et al. Anticoagulant properties of a fucoidan fraction. Thromb Res 10-15-1991;64(2):143-154. View abstract.

74157            Hayashi, T. [Studies on evaluation of natural products for antiviral effects and their applications]. Yakugaku Zasshi 2008;128(1):61-79. View abstract.

74158            van de Wijgert, J. H., Braunstein, S. L., Morar, N. S., Jones, H. E., Madurai, L., Strickfaden, T. T., Moodley, M., Aboobaker, J., Ndlovu, G., Ferguson, T. M., Friedland, B. A., Hart, C. E., and Ramjee, G. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J.Acquir.Immune.Defic.Syndr. 12-15-2007;46(5):538-546. View abstract.

74159            MacArtain, P., Gill, C. I., Brooks, M., Campbell, R., and Rowland, I. R. Nutritional value of edible seaweeds. Nutr.Rev. 2007;65(12 Pt 1):535-543. View abstract.

74160            Frestedt, J. L., Walsh, M., Kuskowski, M. A., and Zenk, J. L. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J 2008;7:9. View abstract.

74161            Landa, N., Miller, L., Feinberg, M. S., Holbova, R., Shachar, M., Freeman, I., Cohen, S., and Leor, J. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 3-18-2008;117(11):1388-1396. View abstract.

74162            Novak, M. and Vetvicka, V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J.Immunotoxicol. 2008;5(1):47-57. View abstract.

74163            Dillehay, T. D., Ramirez, C., Pino, M., Collins, M. B., Rossen, J., and Pino-Navarro, J. D. Monte Verde: seaweed, food, medicine, and the peopling of South America. Science 5-9-2008;320(5877):784-786. View abstract.

74164            Kilmarx, P. H., Blanchard, K., Chaikummao, S., Friedland, B. A., Srivirojana, N., Connolly, C., Witwatwongwana, P., Supawitkul, S., Mock, P. A., Chaowanachan, T., and Tappero, J. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm.Dis. 2008;35(3):226-232. View abstract.

74165            Paxman, J. R., Richardson, J. C., Dettmar, P. W., and Corfe, B. M. Daily ingestion of alginate reduces energy intake in free-living subjects. Appetite 2008;51(3):713-719. View abstract.

74166            Miyai, K., Tokushige, T., and Kondo, M. Suppression of thyroid function during ingestion of seaweed “Kombu” (Laminaria japonoca) in normal Japanese adults. Endocr.J. 2008;55(6):1103-1108. View abstract.

74167            Asakawa, M. [Aquatic biotoxins in relation to food poisonings]. Chudoku.Kenkyu 2008;21(3):285-292. View abstract.

74168            Navas-Acien, A., Silbergeld, E. K., Pastor-Barriuso, R., and Guallar, E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 8-20-2008;300(7):814-822. View abstract.

74169            Kile, M. L. and Christiani, D. C. Environmental arsenic exposure and diabetes. JAMA 8-20-2008;300(7):845-846. View abstract.

74170            Fowler, E. and Papen, J. C. Evaluation of an alginate dressing for pressure ulcers. Decubitus. 1991;4(3):47-8, 50, 52. View abstract.

74171            Yang, C., Chung, D., Shin, I. S., Lee, H., Kim, J., Lee, Y., and You, S. Effects of molecular weight and hydrolysis conditions on anticancer activity of fucoidans from sporophyll of Undaria pinnatifida. Int.J.Biol.Macromol. 2008;43(5):433-437. View abstract.

74172            Wasiak, J., Cleland, H., and Campbell, F. Dressings for superficial and partial thickness burns. Cochrane.Database.Syst.Rev. 2008;(4):CD002106. View abstract.

74173            Miao, C., Du, J., Dang, H. T., Jeong, I. H., You, S., Park, J. S., Jung, J. H., and Kim, D. K. Apoptotic activity of fatty acid derivatives may correlate with their inhibition of DNA replication. Int.J.Oncol. 2008;33(6):1291-1298. View abstract.

74174            Tseng, C. H. A review on environmental factors regulating arsenic methylation in humans. Toxicol.Appl.Pharmacol. 3-15-2009;235(3):338-350. View abstract.

74175            Frestedt, J. L., Kuskowski, M. A., and Zenk, J. L. A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study. Nutr.J. 2009;8:7. View abstract.

74176            Holm, M., Johannesson, S., Toren, K., and Dahlman-Hoglund, A. Acute effects after occupational endotoxin exposure at a spa. Scand.J.Work Environ.Health 2009;35(2):153-155. View abstract.

74177            Novak, M. and Vetvicka, V. Glucans as biological response modifiers. Endocr.Metab Immune.Disord.Drug Targets. 2009;9(1):67-75. View abstract.

74178            Vasilevskaia, L. S., Pogozheva, A. V., Derbeneva, S. A., Zorin, S. N., Buchanova, A. V., Abramova, L. S., Petrukhanova, A. V., Gmoshinskii, I. V., and Mazo, V. K. [Clinical efficiency of using laminaria jam enriched with selenium]. Vopr.Pitan. 2009;78(1):79-83. View abstract.

74179            Bocanegra, A., Bastida, S., Benedi, J., Rodenas, S., and Sanchez-Muniz, F. J. Characteristics and nutritional and cardiovascular-health properties of seaweeds. J.Med.Food 2009;12(2):236-258. View abstract.

74180            Koetzner, L., Grover, G., Boulet, J., and Jacoby, H. I. Plant-derived polysaccharide supplements inhibit dextran sulfate sodium-induced colitis in the rat. Dig.Dis Sci 2010;55(5):1278-1285. View abstract.

74181            Fluhr, J. W., Breternitz, M., Kowatzki, D., Bauer, A., Bossert, J., Elsner, P., and Hipler, U. C. Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study. Exp.Dermatol. 2010;19(8):e9-15. View abstract.

74182            Steinmaus, C., Yuan, Y., Liaw, J., and Smith, A. H. Low-level population exposure to inorganic arsenic in the United States and diabetes mellitus: a reanalysis. Epidemiology 2009;20(6):807-815. View abstract.

74183            Irhimeh, M. R., Fitton, J. H., and Lowenthal, R. M. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul.Fibrinolysis 2009;20(7):607-610. View abstract.

74184            Teas, J., Baldeon, M. E., Chiriboga, D. E., Davis, J. R., Sarries, A. J., and Braverman, L. E. Could dietary seaweed reverse the metabolic syndrome? Asia Pac.J.Clin.Nutr. 2009;18(2):145-154. View abstract.

74185            Costa, L. S., Fidelis, G. P., Cordeiro, S. L., Oliveira, R. M., Sabry, D. A., Camara, R. B., Nobre, L. T., Costa, M. S., Almeida-Lima, J., Farias, E. H., Leite, E. L., and Rocha, H. A. Biological activities of sulfated polysaccharides from tropical seaweeds. Biomed.Pharmacother. 2010;64(1):21-28. View abstract.

74186            Odunsi, S. T., Vazquez-Roque, M. I., Camilleri, M., Papathanasopoulos, A., Clark, M. M., Wodrich, L., Lempke, M., McKinzie, S., Ryks, M., Burton, D., and Zinsmeister, A. R. Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity.(Silver.Spring) 2010;18(8):1579-1584. View abstract.

74187            Oh, J. K., Shin, Y. O., Yoon, J. H., Kim, S. H., Shin, H. C., and Hwang, H. J. Effect of supplementation with Ecklonia cava polyphenol on endurance performance of college students. Int.J.Sport Nutr.Exerc.Metab 2010;20(1):72-79. View abstract.

74188            Matanjun, P., Mohamed, S., Muhammad, K., and Mustapha, N. M. Comparison of cardiovascular protective effects of tropical seaweeds, Kappaphycus alvarezii, Caulerpa lentillifera, and Sargassum polycystum, on high-cholesterol/high-fat diet in rats. J.Med.Food 2010;13(4):792-800. View abstract.

74189            Ciancia, M., Quintana, I., and Cerezo, A. S. Overview of anticoagulant activity of sulfated polysaccharides from seaweeds in relation to their structures, focusing on those of green seaweeds. Curr.Med.Chem. 2010;17(23):2503-2529. View abstract.

74190            Almeida-Lima, J., Costa, L. S., Silva, N. B., Melo-Silveira, R. F., Silva, F. V., Felipe, M. B., Medeiros, S. R., Leite, E. L., and Rocha, H. A. Evaluating the possible genotoxic, mutagenic and tumor cell proliferation-inhibition effects of a non-anticoagulant, but antithrombotic algal heterofucan. J.Appl.Toxicol. 2010;30(7):708-715. View abstract.

74191            Miyashita, S. and Kaise, T. [Biological effects and metabolism of arsenic compounds present in seafood products]. Shokuhin Eiseigaku Zasshi 2010;51(3):71-91. View abstract.

74192            Wijesekara, I., Yoon, N. Y., and Kim, S. K. Phlorotannins from Ecklonia cava (Phaeophyceae): biological activities and potential health benefits. Biofactors 2010;36(6):408-414. View abstract.

74193            Jones, R. Unusual fucoidin-binding properties of chymotrypsinogen and trypsinogen. Biochim.Biophys.Acta 2-9-1990;1037(2):227-232. View abstract.

74194            Emder, P. J. and Jack, M. M. Iodine-induced neonatal hypothyroidism secondary to maternal seaweed consumption: a common practice in some Asian cultures to promote breast milk supply. J.Paediatr.Child Health 2011;47(10):750-752. View abstract.

74195            Araya, N., Takahashi, K., Sato, T., Nakamura, T., Sawa, C., Hasegawa, D., Ando, H., Aratani, S., Yagishita, N., Fujii, R., Oka, H., Nishioka, K., Nakajima, T., Mori, N., and Yamano, Y. Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease. Antivir.Ther. 2011;16(1):89-98. View abstract.

74196            Miyashita, K., Nishikawa, S., Beppu, F., Tsukui, T., Abe, M., and Hosokawa, M. The allenic carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. J.Sci.Food Agric. 2011;91(7):1166-1174. View abstract.

74197            Pangestuti, R. and Kim, S. K. Neuroprotective effects of marine algae. Mar.Drugs 2011;9(5):803-818. View abstract.

74198            Shin, H. C., Kim, S. H., Park, Y., Lee, B. H., and Hwang, H. J. Effects of 12-week oral supplementation of Ecklonia cava polyphenols on anthropometric and blood lipid parameters in overweight Korean individuals: a double-blind randomized clinical trial. Phytother.Res. 2012;26(3):363-368. View abstract.

74199            Hashimoto, T., Ozaki, Y., Mizuno, M., Yoshida, M., Nishitani, Y., Azuma, T., Komoto, A., Maoka, T., Tanino, Y., and Kanazawa, K. Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract. Br.J.Nutr. 2012;107(11):1566-1569. View abstract.

74200            Jeukendrup, A. E. and Randell, R. Fat burners: nutrition supplements that increase fat metabolism. Obes.Rev. 2011;12(10):841-851. View abstract.

74201            Thomas, N. V. and Kim, S. K. Potential pharmacological applications of polyphenolic derivatives from marine brown algae. Environ.Toxicol.Pharmacol. 2011;32(3):325-335. View abstract.

74202            Reilly, G. D., Reilly, C. A., Smith, E. G., and Baker-Austin, C. Vibrio alginolyticus-associated wound infection acquired in British waters, Guernsey, July 2011. Euro.Surveill 2011;16(42) View abstract.

74203            Rajapakse, N. and Kim, S. K. Nutritional and digestive health benefits of seaweed. Adv.Food Nutr.Res. 2011;64:17-28. View abstract.

74204            Kim, S. K., Pangestuti, R., and Rahmadi, P. Sea lettuces: culinary uses and nutritional value. Adv.Food Nutr.Res. 2011;64:57-70. View abstract.

74205            Shirosaki, M. and Koyama, T. Laminaria japonica as a food for the prevention of obesity and diabetes. Adv.Food Nutr.Res. 2011;64:199-212. View abstract.

74206            Kim, S. K. and Karadeniz, F. Anti-HIV activity of extracts and compounds from marine algae. Adv.Food Nutr.Res. 2011;64:255-265. View abstract.

74207            Senevirathne, M. and Kim, S. K. Marine macro- and microalgae as potential agents for the prevention of asthma: hyperresponsiveness and inflammatory subjects. Adv.Food Nutr.Res. 2011;64:277-286. View abstract.

74208            Pallela, R. and Kim, S. K. Impact of marine micro- and macroalgal consumption on photoprotection. Adv.Food Nutr.Res. 2011;64:287-295. View abstract.

74209            Cerna, M. Seaweed proteins and amino acids as nutraceuticals. Adv.Food Nutr.Res. 2011;64:297-312. View abstract.

74210            Jimenez-Escrig, A., Gomez-Ordonez, E., and Ruperez, P. Seaweed as a source of novel nutraceuticals: sulfated polysaccharides and peptides. Adv.Food Nutr.Res. 2011;64:325-337. View abstract.

74211            Misurcova, L., Ambrozova, J., and Samek, D. Seaweed lipids as nutraceuticals. Adv.Food Nutr.Res. 2011;64:339-355. View abstract.

74212            Skrovankova, S. Seaweed vitamins as nutraceuticals. Adv.Food Nutr.Res. 2011;64:357-369. View abstract.

74213            Misurcova, L., Machu, L., and Orsavova, J. Seaweed minerals as nutraceuticals. Adv.Food Nutr.Res. 2011;64:371-390. View abstract.

74214            Kim, S. K. and Li, Y. X. Medicinal benefits of sulfated polysaccharides from sea vegetables. Adv.Food Nutr.Res. 2011;64:391-402. View abstract.

74215            Paradis, M. E., Couture, P., and Lamarche, B. A randomised crossover placebo-controlled trial investigating the effect of brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) on postchallenge plasma glucose and insulin levels in men and women. Appl.Physiol Nutr.Metab 2011;36(6):913-919. View abstract.

74216            Hall, A. C., Fairclough, A. C., Mahadevan, K., and Paxman, J. R. Ascophyllum nodosum enriched bread reduces subsequent energy intake with no effect on post-prandial glucose and cholesterol in healthy, overweight males. A pilot study. Appetite 2012;58(1):379-386. View abstract.

74217            Arbaizar, B. and Llorca, J. [Fucus vesiculosus induced hyperthyroidism in a patient undergoing concomitant treatment with lithium]. Actas Esp.Psiquiatr. 2011;39(6):401-403. View abstract.

74218            Kang, Y. M., Lee, B. J., Kim, J. I., Nam, B. H., Cha, J. Y., Kim, Y. M., Ahn, C. B., Choi, J. S., Choi, I. S., and Je, J. Y. Antioxidant effects of fermented sea tangle (Laminaria japonica) by Lactobacillus brevis BJ20 in individuals with high level of gamma-GT: A randomized, double-blind, and placebo-controlled clinical study. Food Chem.Toxicol. 2012;50(3-4):1166-1169. View abstract.

74219            Cho, H. B., Lee, H. H., Lee, O. H., Choi, H. S., Choi, J. S., and Lee, B. Y. Clinical and microbial evaluation of the effects on gingivitis of a mouth rinse containing an Enteromorpha linza extract. J.Med.Food 2011;14(12):1670-1676. View abstract.

74220            Manzo-Silberman, S., Louedec, L., Meilhac, O., Letourneur, D., Michel, J. B., and Elmadbouh, I. Therapeutic potential of fucoidan in myocardial ischemia. J.Cardiovasc.Pharmacol. 2011;58(6):626-632. View abstract.

74221            Marais, D., Gawarecki, D., Allan, B., Ahmed, K., Altini, L., Cassim, N., Gopolang, F., Hoffman, M., Ramjee, G., and Williamson, A. L. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir.Ther. 2011;16(8):1219-1226. View abstract.

74222            Uenishi, K., Fujita, T., Ishida, H., Fujii, Y., Ohue, M., Kaji, H., Hirai, M., Kakumoto, M., and Abrams, S. A. Fractional absorption of active absorbable algal calcium (AAACa) and calcium carbonate measured by a dual stable-isotope method. Nutrients. 2010;2(7):752-761. View abstract.

74223            Mateu, C. G., Recalde, M. P., Artuso, M. C., Hermida, G., Linero, F. N., Scolaro, L. A., Damonte, E. B., Pujol, C. A., and Carlucci, M. J. Emergence of herpes simplex virus-1 syncytial variants with altered virulence for mice after selection with a natural carrageenan. Sex Transm.Dis. 2011;38(6):555-561. View abstract.

74224            Al-Bader, T., Byrne, A., Gillbro, J., Mitarotonda, A., Metois, A., Vial, F., Rawlings, A. V., and Laloeuf, A. Effect of cosmetic ingredients as anticellulite agents: synergistic action of actives with in vitro and in vivo efficacy. J.Cosmet.Dermatol. 2012;11(1):17-26. View abstract.

74225            Capitanio, B., Sinagra, J. L., Weller, R. B., Brown, C., and Berardesca, E. Randomized controlled study of a cosmetic treatment for mild acne. Clin.Exp.Dermatol. 2012;37(4):346-349. View abstract.

74226            Burger, J., Gochfeld, M., Jeitner, C., Donio, M., and Pittfield, T. Lead (Pb) in biota and perceptions of Pb exposure at a recently designated Superfund beach site in New Jersey. J.Toxicol.Environ.Health A 2012;75(5):272-287. View abstract.

74227            Michikawa, T., Inoue, M., Shimazu, T., Sawada, N., Iwasaki, M., Sasazuki, S., Yamaji, T., and Tsugane, S. Seaweed consumption and the risk of thyroid cancer in women: the Japan Public Health Center-based Prospective Study. Eur.J.Cancer Prev. 2012;21(3):254-260. View abstract.

74228            Park, K. Y., Jang, W. S., Yang, G. W., Rho, Y. H., Kim, B. J., Mun, S. K., Kim, C. W., and Kim, M. N. A pilot study of silver-loaded cellulose fabric with incorporated seaweed for the treatment of atopic dermatitis. Clin.Exp.Dermatol. 2012;37(5):512-515. View abstract.

74229            Silberstein, E. B. Radioiodine: the classic theranostic agent. Semin.Nucl.Med. 2012;42(3):164-170. View abstract.

74230            Min, S. K., Han, S. M., Kim, H. T., Kwon, O. C., Lee, S., and Kim, J. K. Algal fucoidan, unlike heparin, has thrombolytic activity in a murine arterial thrombosis model. Blood Coagul.Fibrinolysis 2012;23(5):359-366. View abstract.

74231            Obiero, J., Mwethera, P. G., and Wiysonge, C. S. Topical microbicides for prevention of sexually transmitted infections. Cochrane.Database.Syst.Rev. 2012;6:CD007961. View abstract.

74232            Fulton, J. A., Blasiole, K. N., Cottingham, T., Tornero, M., Graves, M., Smith, L. G., Mirza, S., and Mostow, E. N. Wound dressing absorption: a comparative study. Adv.Skin Wound.Care 2012;25(7):315-320. View abstract.

74233            Leung, A. M. and Braverman, L. E. Iodine-induced thyroid dysfunction. Curr.Opin.Endocrinol.Diabetes Obes. 2012;19(5):414-419. View abstract.

74234            de Smet, P. A., Stricker, B. H., Wilderink, F., and Wiersinga, W. M. [Hyperthyroidism during treatment with kelp tablets]. Ned.Tijdschr.Geneeskd. 5-26-1990;134(21):1058-1059. View abstract.

74235            Hartman AA. [Hyperthyroidism during administration of kelp tablets]. Ned Tijdschr Geneeskd 7-14-1990;134(28):1373. View abstract.

74236            Maruyama H, Nakajima J, and Yamamoto I. A study on the anticoagulant and fibrinolytic activities of a crude fucoidan from the edible brown seaweed Laminaria religiosa, with special reference to its inhibitory effect on the growth of sarcoma-180 ascites cells subcutaneously implanted into mice. Kitasato Arch Exp Med 1987;60(3):105-121. View abstract.

74237            Lamela M, Anca J, Villar R, and et al. Hypoglycemic activity of several seaweed extracts. J.Ethnopharmacol. 1989;27(1-2):35-43. View abstract.

74238            Ishizuki, Y., Yamauchi, K., and Miura, Y. [Transient thyrotoxicosis induced by Japanese kombu]. Nihon Naibunpi Gakkai Zasshi 2-20-1989;65(2):91-98. View abstract.

74239            Grauffel V, Kloareg B, Mabeau S, and et al. New natural polysaccharides with potent antithrombic activity: fucans from brown algae. Biomaterials 1989;10(6):363-368. View abstract.

74240            Church FC, Meade JB, Treanor RE, and et al. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 2-25-1989;264(6):3618-3623. View abstract.

74241            Jeanmougin, M., Lemarchand-Venencie, F., Hoang, X. D., D’Hondt, J. L., and Civatte, J. [Occupational eczema with photosensitivity caused by contact with Bryozoa]. Ann.Dermatol.Venereol. 1987;114(3):353-357. View abstract.

74242            van der Willigen, A. H., Habets, J. M., van, Joost T., Stolz, E., and Nienhuis, P. H. Contact allergy to iodine in Japanese sargassum. Contact Dermatitis 1988;18(4):250-252. View abstract.

74243            van der Willigen, A. H., Habets, J. M., van, Joost T., Nienhuis, P. H., and Stolz, E. [Allergic contact eczema caused by Sargassum muticum in professional fishermen on Lake Grevelingen]. Ned.Tijdschr.Geneeskd. 12-24-1988;132(52):2355-2356. View abstract.

74244            Shilo, S. and Hirsch, H. J. Iodine-induced hyperthyroidism in a patient with a normal thyroid gland. Postgrad Med J 1986;62(729):661-662. View abstract.

74245            Louekari, K. and Salminen, S. Intake of heavy metals from foods in Finland, West Germany and Japan. Food Addit.Contam 1986;3(4):355-362. View abstract.

74246            Caporiccio, B., Braun, M., Vignaud, M., Chalet, M., Teste, J., Codomier, L., and Catayee, G. [Characteristics of the action of an acidic sulfated polysaccharide on global blood coagulation in vitro. Preliminary study in various species of mammals and in man]. C.R.Seances Soc.Biol.Fil. 1983;177(4):412-420. View abstract.

74247            Criado, M. T. and Ferreiros, C. M. Selective interaction of a Fucus vesiculosus lectin-like mucopolysaccharide with several Candida species. Ann Microbiol (Paris) 1983;134A(2):149-154. View abstract.

74248            Teas, J. The dietary intake of Laminaria, a brown seaweed, and breast cancer prevention. Nutr Cancer 1983;4(3):217-222. View abstract.

74249            Fisher, A. A. Water-related dermatoses. Part I. Cutis 1980;25(2):132, 135-132, 140. View abstract.

74250            Yamaguchi, K., Fukushima, H., Uzawa, H., Iseki, T., Shiroozu, A., and Inoue, K. [A case of iodide myxedema observed for 3 years under a low iodide diet–especially on the restoration of the mechanism of escape from the Wolff-Chaikoff effect]. Nihon Naibunpi Gakkai Zasshi 1-20-1984;60(1):79-88. View abstract.

74251            Drnek, F., Prokes, B., and Rydlo, O. [Experiment in affecting cancer biologically with an intramuscular and local administration of the seaweed, Scenedesmus obliquus]. Cesk.Gynekol. 1981;46(6):463-465. View abstract.

74252            Leemhuis, M. P. and Quarles van Ufford, A. C. [Iodine goiter and hypothyroidism when using seaweed preparations]. Ned.Tijdschr.Geneeskd. 7-5-1980;124(27):1119. View abstract.

74253            Noguchi, T., Matsui, T., Miyazawa, K., Asakawa, M., Iijima, N., Shida, Y., Fuse, M., Hosaka, Y., Kirigaya, C., Watabe, K., and . Poisoning by the red alga ‘ogonori’ (Gracilaria verrucosa) on the Nojima Coast, Yokohama, Kanagawa Prefecture, Japan. Toxicon 1994;32(12):1533-1538. View abstract.

74254            Epstein, P. R. Algal blooms in the spread and persistence of cholera. Biosystems 1993;31(2-3):209-221. View abstract.

74255            Ellouali M, Boisson-Vidal C, Durand P, and et al. Antitumor activity of low molecular weight fucans extracted from brown seaweed Ascophyllum nodosum. Anticancer Res 1993;13(6A):2011-2020. View abstract.

74256            Sakata, T. A very-low-calorie conventional Japanese diet: its implications for prevention of obesity. Obes.Res. 1995;3 Suppl 2:233s-239s. View abstract.

74257            Riou D, Colliec-Jouault S, Pinczon du Sel D, and et al. Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Anticancer Res 1996;16(3A):1213-1218. View abstract.

74258            Vugia, D. J., Shefer, A. M., Douglas, J., Greene, K. D., Bryant, R. G., and Werner, S. B. Cholera from raw seaweed transported from the Philippines to California. J.Clin.Microbiol. 1997;35(1):284-285. View abstract.

74259            Monego, E. T., Peixoto, Mdo R., Jardim, P. C., Sousa, A. L., Braga, V. L., and Moura, M. F. [Different therapies in the treatment of obesity in hypertensive patients]. Arq Bras.Cardiol. 1996;66(6):343-347. View abstract.

74260            Yamamoto I, Nagumo T, Fujihara M, and et al. Antitumor effect of seaweeds. II. Fractionation and partial characterization of the polysaccharide with antitumor activity from Sargassum fulvellum. Jpn.J Exp Med 1977;47(3):133-140. View abstract.

74261            Burnett, J. W., Burnett, H. W., and Burnett, M. G. Sargassum dermatitis. Cutis 1997;59(6):303-304. View abstract.

74262            Drozhzhina, V. A., Fedorov, IuA, Blokhin, V. P., Soboleva, T. I., and Kazakova, O. V. [The use of dental elixirs based on natural biologically active substances in the treatment and prevention of periodontal diseases]. Stomatologiia (Mosk) 1996;Spec No:52-53. View abstract.

74263            Gaigi, S., Elati, J., Ben, Osman A., and Beji, C. [Experimental study of the effects of seaweed in the treatment of obesity]. Tunis Med. 1996;74(5):241-243. View abstract.

74264            Mauray, S., De, Raucourt E., Chaubet, F., Maiga-Revel, O., Sternberg, C., and Fischer, A. M. Comparative anticoagulant activity and influence on thrombin generation of dextran derivatives and of a fucoidan fraction. J.Biomater.Sci.Polym.Ed 1998;9(4):373-387. View abstract.

74265            Maguire, R. A., Zacharopoulos, V. R., and Phillips, D. M. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex Transm.Dis. 1998;25(9):494-500. View abstract.

74266            Nishimura, Y., Ishii, N., Sugita, Y., and Nakajima, H. A case of carotenodermia caused by a diet of the dried seaweed called Nori. J.Dermatol. 1998;25(10):685-687. View abstract.

74267            Moss, T. M. Herbal medicine in the emergency department: a primer for toxicities and treatment. J.Emerg.Nurs. 1998;24(6):509-513. View abstract.

74268            Wang, C. and Yang, G. [Comparison of effects of two kinds of soluble algae polysaccharide on blood lipid, liver lipid, platelet aggregation and growth in rats]. Zhonghua Yu Fang Yi.Xue.Za Zhi. 1997;31(6):342-345. View abstract.

74269            Eliason, B. C. Transient hyperthyroidism in a patient taking dietary supplements containing kelp. J Am Board Fam.Pract. 1998;11(6):478-480. View abstract.

74270            Taylor T., Czarnowski C. What caused this case of asymptomatic hyperthyroidism?: Everything pointed to an exogenous cause, but our patient denied taking anything. Only later did she mention a diet aid. Journal of Family Practice. 2009;58:203-206.

74271            Oguri T., Yoshinaga J. Tao H. Nakazato T. Cancer Risk Assessment of Inorganic Arsenic Among Japanese Population. Epidemiology. 2011;22(1):0.

74272            Iskandar, Fanny, Amiruddin, Muh Dali, Melati, Dewi, and Ilyas, Faridha S. The role of contact sensitization in contact dermatitis patients among the seaweed farmers in Bantaeng, South Sulawesi, Indonesia. World Allergy Organization Journal 2007;0:S56.

74273            Schornack, J. Ocular Side Effects of Herbal Supplements. Contact Lens Spectrum. 2003;18(8):0.

74274            Le Tutour B, Benslimane F, Gouleau MP, and et al. Antioxidant and pro-oxidant activities of the brown algae, Laminaria digitata, Himanthalia elongata, Fucus vesiculosus, Fucus serratus and Ascophyllum nodosum. J Applied Phycology 1998;10(2):121-129.

74275            Lindsey, H. Use of Botanicals for Cancer: Systematic Research Required to Determine Role. Oncology Times. 2005;27(6):52-55.

74276            Ewart, S Girouard G. Tiller C. et al. Antidiabetic Activities of a Seaweed Extract. Diabetes. 2004;53(Supplement 2):A509.

74277            Martyn-St James M., O’Meara S. Foam dressings for venous leg ulcers. Cochrane Library. 2012;0:0.

74278            Schreuder SM, Vermeulen H Qureshi MA Ubbink DT. Dressings and topical agents for donor sites of split-thickness skin grafts. JOURNAL 2009;0:0.

74279            Bradley MD, Nelson A Petticrew M Cullum N Sheldon T. Dressing for pressure sores. Cochrane Library 2011;0:0.

74280            Alraei, RG. Herbal and Dietary Supplements for Weight Loss. Topics in Clinical Nutrition. 2010;25(2):136-150.

Frequently Asked Questions

I am experiencing severe hair loss? Help !!

We understand that alopecia can have severe psychological implications on patients. After all, hair is complementary to appearance and regarded as our “crowning glory”.

During the last decade science has advanced significantly. Many forms of hair loss can now be reversed by correcting the underlying cause and subsequently improving follicle health and activity.

Trichotin contains a range of ingredients that are included to correct the various causes of hair damage, thus preventing hair loss and stimulating healthier regrowth.

Can Trichotin be used by both men and women?

Yes.

The product can be used by both males and females without interfering with endocrine metabolism.

Will it increase the growth of body hair?

No.

Trichotin promotes normal and regular scalp hair growth.

Does Trichotin have clinical research backing to support its claims?

Trichotin is supported by a team of clinical researchers and doctors. It is authenticated by clinical evidence and each of its ingredients has proven health benefits. All products developed by Fusion Laboratories conform to the stringent input, processing and quality control criteria of the legislative authorities within the countries in which they are marketed.

Is Trichotin safe and are there any side effects?

Trichotin is completely safe and does not have any known side effects. It has a well-established safety profile. To validate its safety, Fusion Laboratories have submitted the documentation for registration and manufactures the product under the Good Manufacturing Practices (GMP) standards in a fully controlled facility. This ensures purity, stability of its ingredients and accuracy of the final product. If, for any reason, Trichotin does not meet stringent pharmaceutical standards, the product is not approved for release from our facility.

Does Trichotin prevent the hair from greying?

Genetics and ageing play a crucial role in the premature greying of hair.

Melanocytes are responsible for generating the pigment melanin, which is responsible for hair colour. If the melanocytes produce decreased amounts of pigment, greying or whitening results.

Trichotin contains both PABA and Biotin which improve melanin distribution.

Could my hair loss be related to stress?

There is a direct link between stress and hair loss mediated by hormones and immune agents. Stress/trauma places greater strain on these systems which could induce increased hair fall. Stress also places an additional demand on the body for nutrients. If this is not catered for, nutrient deficiency will promote increased hair loss.

Interestingly the effects of stress usually occurs 1 – 4 months after the traumatic experience.

During stressful periods we recommend using Trichotin to prevent/minimise hair loss and also to provide the body with beneficial key nutrients.

Fusion Laboratories also encourages a lifestyle that nourishes the body. This includes a healthy diet, regular exercise, stress reduction techniques, adequate sleep, as well as technology free periods to ensure that we have time to connect with ourselves and each other. These simple yet vital practices are fundamental to protect our human capital.

Our goal is not only to treat alopecia, but also the lifestyle factors that contribute to it.

Can I use Trichotin in conjunction with my medication?

The use of many medications have been associated with alopecia.

Please consult your physician prior to use as he/she has access to your medical records and can provide the most accurate advice.

How long do I have to use Trichotin to see results?

Trichotin is formulated for both short and long-term effects. The initial benefits of Trichotin are evident within 14 days, but longer term use is recommended for ongoing benefits and to sustain the effect.

Note however that generally it takes a month initially to correct the body’s nutritional deficiency alone, which in most cases is the underlying cause. Once the essential nutrient balance in the body has been restored then only will the product’s full benefits become evident.

Results also depend on other variables which include underlying cause, severity of condition, diet, metabolic and genetic factors.

How does Trichotin provide healthier skin and minimise ageing?

The permutation of vitamins, minerals and Nettle Root extract acts synergistically with Glycine to encourage the growth of protein chains in collagen, while aiding in the removal of toxins from the skin. This stimulation and detoxification process, together with the proven benefits of Co-enzyme Q10, enhances aerobic cellular respiration, which radically minimises the process of ageing and gives the skin renewed radiance and clarity.

I don’t eat breakfast. Can I use Trichotin Hair Regenesis at lunchtime?

Yes. Trichotin can be taken 30 minutes before lunch. However, absorption is optimal in the morning.

Once my hair loss has been reduced do I still have to continue using Trichotin?

If you are satisfied with your hair condition and have rectified the underlying cause of hair loss, you can either discontinue use or reduce the dosage to a maintenance dose of one caplet every second day.

Can I use Trichotin as a multi-vitamin?

Trichotin can be used as a multi-nutrient supplement. It contains most of the essential vitamins and minerals. In addition, it also contains a herbal and amino acid blend that promotes healthier hair and skin. Supplements can be a useful link to extraordinary health.

Why doesn’t Fusion Laboratories offer topical applications for hair loss?

Fusion Laboratories specialises in designing and formulating nutritional and complementary medicines. We are of the opinion that it is best practice to treat most conditions systemically. Nourishment arises from within the body, not externally.

What is the difference between Trichotin Hair Regenesis and Trichotin DHT Inhibitor?

Trichotin Hair Regenesis is a unisex product specifically designed to prevent hair loss caused by hormonal imbalance, thyroid dysfunction, stress, nutrient deficiency, chemical damage, traction alopecia, poor circulation etc.

Trichotin Hair Regenesis also contains ingredients which improve follicle health and activity thereby stimulating regrowth.

Trichotin DHT Inhibitor is formulated to prevent hair loss by lowering levels of DHT, which is the enzyme primarily responsible for androgenic alopecia in men.

Only in exceptional cases of severe hair loss, with DHT excess being the confirmed cause, do we recommend the product for women.

Trichotin DHT Inhibitor also improves libido and prostate health.

Why should I use Trichotin Hair Regenesis?

Proven Benefits:

• Reduces hair loss
• Promotes healthier, stronger hair
• Stimulates hair growth
• Improves skin clarity
• Anti-greying

Why choose Trichotin over other hair supplements?

• Trichotin is the only Luxury, Premier Multi-Nutrient.
• Fusion Laboratories sources the highest quality ingredients and uses the most advanced technology and research to develop its products.
• Trichotin has superior product formulation. Its smart and balanced formula is specially designed to allow for optimal absorption and efficacy.
• None of the ingredients have been tested on animals.
• Fusion Laboratories does not use artificial flavourants or preservatives.